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Zusammenfassung  
Die Gene der T-cell leukemia/lymphoma 1 (TCL1) Familie wurden erstmals aufgrund ihrer 
Beteiligung an spezifischen Chromosomenaberrationen in reifen T-Zell-Erkrankungen 
identifiziert. Bei Menschen besteht diese Familie aus den drei Genen TCL1A, MTCP1 und 
TCL1B (auch TML1 genannt). Normalerweise werden diese Gene in Lymphozyten während 
der frühen B- und T-Zell Entwicklung und während der frühen Embryogenese exprimiert. 
Überexpression von TCL1A wird in vielen reifen B-Zell- und T-Zell-Tumoren detektiert, 
einschließlich der chronisch lymphatischen Leukämie (CLL) und der T-Zell 
Prolymphozyten-Leukämie (T-PLL). Expression von TCL1A oder MTCP1 in T Zellen 
transgener Mäuse führt zur Entwicklung T-PLL-ähnlicher Erkrankungen nach einer langen 
Latenzzeit (>15 Monate). In diesen Untersuchungen wurden zwei unterschiedliche 
Promotoren für die T-Zell-spezifische Expression verwendet, die keinen direkten Vergleich 
dieser zwei Onkogene zulassen. Studien zum Transformationspotenzial von TML1 wurden 
bislang nicht veröffentlicht. Im ersten Teil dieser Arbeit wurde deshalb das onkogene 
Potenzial der TCL1 Gene verglichen, indem gamma-retrovirale Vektoren für humanes 
TCL1A, MTCP1 und TML1 in hämatopoetische Stammzellen/hämatopoetische 
Vorläuferzellen (HSC/HPC) von Wildtyp-Mäusen eingebracht und in Wildtyp-Empfänger 
transplantiert wurden. TCL1A und MTCP1 Empfängermäuse entwickelten überwiegend B-
Zell-Tumore nach einer medianen Überlebenszeit von 388 Tagen, beziehungsweise 394 
Tagen. Somit beweisen diese Daten, dass TCL1A und MTCP1 Onkogene mit vergleichbarem 
onkogenen Potenzial sind und zeigen zum ersten Mal, dass MTCP1 nicht nur ein T-Zell- 
Onkogen ist, sondern auch in der Lage ist, B Zellen zu transformieren. Das dritte 
Familienmitglied TML1 induzierte die Entwicklung von unreifen T-Zell-Malignitäten in 
wenigen Mäusen. Obwohl TML1 ein schwächeres Onkogen zu sein scheint, liefert diese 
Studie erste Hinweise für dessen onkogene Funktion. Jedoch besteht in diesem Modell das 
Risiko der Insertionsmutagenese, die möglicherweise zur Induktion oder Beschleunigung der 
Tumorentwicklung beigetragen hat.   
Untersuchungen zur molekularen Funktion haben gezeigt, dass die Stimulierung des 
Antigenrezeptors (TCR) die Interaktion zwischen TCL1A und der Ser/Thr-Kinase AKT an 
der Zellmembran induziert, gefolgt von einer Kerntranslokalisation. Darauffolgende Studien 
zeigten, dass TCL1A auch mit anderen Signalmolekülen im Cytosol (p300, ATM) und im 
Kern (Jun, Fos) interagierte. Zusammen implizieren diese Daten, dass TCL1A 
Kompartiment-spezifische Funktionen hat. Aus diesem Grund wurde das 
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Transformationspotenzial von zwei Kompartiment-spezifischen TCL1A Varianten in dem 
zuvor beschriebenen Transplantationsmodell untersucht, indem eine myristoylierte 
(Membran-lokalisierende) Variante (myr-TCL1A) und eine Kern-lokalisierende Variante 
(nls-TCL1A) retroviral in HSC/HPC von Mäusen eingebracht wurden. Empfängermäuse von 
myr-TCL1A und nls-TCL1A transduzierten HSC/HPC entwickelten überwiegend B-Zell-
Tumore nach einer medianen Überlebenszeit von 360 Tagen beziehungsweise 349 Tagen. 
Demnach zeigte sich eine signifikant kürzere Latenzzeit für nls-TCL1A im Vergleich zum 
zuvor beschriebenen generischen TCL1A. Die Genexpressionsanalyse dieser Tumore 
offenbarte größere Ähnlichkeiten zwischen den Expressionsprofilen von Tumoren, die durch 
TCL1A und nls-TCL1A induziert wurden. Zusammen implizieren diese Daten, dass die 
überwiegend onkogene Funktion von TCL1A auf dessen Vorkommen im Kern beruhen 
könnte. 
Aufbauend auf publizierten in vitro Studien, die beschreiben, dass TCL1 die TCR-
Signalisierung verstärkt (z.B. via AKT), wurde im zweiten Teil dieser Arbeit untersucht, ob 
und wie sich TCR Stimulation auf das Transformationspotenzial von TCL1A auswirkt. 
Hierfür wurden reife OT-1 T Zellen, dessen monoklonaler TCR spezifisch Ovalbumin (OVA) 
erkennt, retroviral mit TCL1A und seinen myr/nls Varianten transduziert und wiederholt in 
vivo mit OVA-Peptide stimuliert. TCR stimulierte Empfängermäuse von TCL1A 
transduzierten T Zellen zeigten eine signifikante Beschleunigung der Leukämie-Entwicklung 
und eine verringerte mediane Überlebenszeit von 305 Tagen im Vergleich zu unstimulierten 
TCL1A Empfängern (417 Tage). Stimulierte und unstimulierte Empfängermäuse zeigten 
vergleichbare Unterschiede in der Überlebenszeit für die Kompartiment-spezifischen TCL1A 
Varianten und seine generische Form. Diese Daten implizieren eine pro-leukämogene 
Zusammenarbeit von TCL1A und TCR Signalen, die möglicherweise in zukünftigen 
Therapiekonzepten berücksichtigt werden kann.  
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Abstract 
The members of the T-cell leukemia/lymphoma 1 (TCL1) gene family were first identified 
through their involvement in specific chromosomal aberrations in mature T-cell malignancies. 
In humans this family consists of 3 genes: TCL1A, MTCP1, and TCL1B (also called TML1). 
Normally, these genes are expressed in lymphocytes during early B- and T-cell development 
and during initial embryogenesis. Overexpressed TCL1A is found in many mature B-cell and 
T-cell tumors, including chronic lymphocytic leukemia (CLL) and T-cell prolymphocytic 
leukemia (T-PLL). Transgenic mice expressing TCL1A or MTCP1 in T cells develop T-PLL-
like diseases after a long latency period (>15months). These transgenes employ two different 
promoters to drive T-cell specific expression, which does not allow a direct comparison of 
the two oncogenes. Studies on the transforming potential of TML1 have not been published 
yet. Therefore, in the first part of this thesis, the oncogenic potential of TCL1 genes was 
comparatively evaluated by using gamma-retroviral vectors to introduce human TCL1A, 
MTCP1, and TML1 into hematopoietic stem cells/hematopoietic progenitor cells (HSC/HPC) 
of wild type mice that were transplanted into wild type recipients. TCL1A and MTCP1 
recipient mice predominantly developed B-cell malignancies after a median survival of 388 
days and 394 days, respectively. The presented data indicates that TCL1A and MTCP1 are 
oncogenes with comparable oncogenic potential and shows for the first time that MTCP1 is 
not only a T-cell oncogene, but is able to transform B cells as well. The third family member 
TML1 induced the development of immature T-cell malignancies in only a few mice. 
Although TML1 appeared to be a weaker oncogene, this study provides first evidence for its 
oncogenic function. However, there is a risk for insertional mutagenesis in this model that 
might have contributed to induction or acceleration of tumor development.  
At the level of molecular function, it had been shown that engagement of the antigen receptor 
(TCR) induces the interaction of TCL1A with the ser/thr kinase AKT, initially at the cell 
membrane followed by nuclear translocalization. Subsequent studies described TCL1A to 
engage with other signaling molecules in the cytosol (p300, ATM) and in the nucleus (Jun, 
Fos). Together, these data suggest that TCL1A has compartment-specific functions. 
Consequently, the transforming potential of compartment-targeted TCL1A variants was 
evaluated in the above described transplantation model by retroviral expression of a 
membrane localizing myristoylated (myr-TCL1A) and a nuclear localizing (nls-TCL1A) 
variant in murine HSC/HPC. Recipients of HSC/HPC transduced with myr-TCL1A and nls-
TCL1A predominantly developed B-cell malignancies after a median survival of 360 days 
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and 349 days, respectively. There was a significantly shorter latency period for nls-TCL1A 
compared to the previously described generic TCL1A. Gene expression analysis of these 
tumors revealed higher similarities between expression profiles of tumors induced by TCL1A 
and nls-TCL1A. Together these data implicate that TCL1A’s predominant oncogenic 
function might rely on its nuclear presence.  
Expanding on previously reported in vitro observations of TCL1A to enhance TCR signaling 
(e.g. via AKT), the second part of this thesis aims to understand if and how TCR stimulation 
affects the transforming potential of TCL1A. Mature OT-1 T cells carrying monoclonal 
TCR’s that specifically recognize ovalbumin (OVA) were retrovirally transduced with 
TCL1A and its myr/nls variants and repeatedly stimulated in vivo with OVA-peptides. TCR 
stimulated recipient mice of TCL1A transduced T cells showed a significantly accelerated 
leukemic outgrowth and a reduced median survival of 305 days, when compared to 
unstimulated recipients (417 days). Stimulated vs unstimulated recipient mice showed 
comparable differences in survival across the compartment-targeted TCL1A variants and its 
generic form. These data strongly implicate a pro-leukemogenic cooperation of TCL1A and 
TCR signals that might be actionable in upcoming interventional designs.  
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1. Introduction 
1.1 T lymphocytes 
As part of the adaptive immune system, T lymphocytes are responsible for cell-mediated 
immune responses. They are able to recognize all kinds of foreign antigens through the 
expression of a highly variable antigen-receptor: the T-cell receptor (TCR). T cells cannot 
directly recognize pathogens. Their activation and function relies on other cells that display 
smaller fragments of processed proteins via a major histocompatibility complex (MHC) 
molecule. The majority of T cells have a TCR that consists of an α- and β-chain, whereas a 
minor population expresses γ/δ-TCRs. This thesis is focused on the more common α/β-T cells, 
which are generally referred to as T cells hereafter.   
 
1.1.1 T-cell development 
T lymphocytes originate from hematopoietic stem cells (HSC) in the bone marrow (BM). 
These stem cells differentiate into myeloid and lymphoid progenitors that give rise to the 
cellular components of the innate and adaptive immune system. For T-cell development 
(Figure 1-1), common lymphoid progenitors (CLPs) migrate to the thymus and pass through 
distinct developmental stages. As these progenitors still lack CD4 and CD8 co-receptor 
expression, they are referred to as double-negative (DN) thymocytes. Based on the expression 
of the adhesion molecule CD44 and the IL-2 receptor alpha-subunit CD25, DN thymocytes 
are subdivided into four stages: DN1 (CD44+, CD25-), DN2 (CD44+, CD25+), DN3 (CD44-, 
CD25+) and DN4 (CD44-, CD25-) (1). Expression of recombination-activating genes (RAG1 
and RAG2) during the DN2 stage initiates rearrangement of the TCR β-chain (2,3). The TCR 
β-chain is then paired with a pre-Tα-chain to form a pre-TCR at the DN3 stage (4). Only 
thymocytes that signal through the pre-TCR will be able to transition to the DN4 stage (5). 
Rearrangement of the TCR α-chain in DN4 thymocytes results in expression of a mature αβ-
TCR assembled with CD3/ζ proteins. These cells start to express CD4 and CD8, thereby 
forming a population of double-positive (DP) thymocytes. At this stage, different selection 
processes take place that only allow maturation of thymocytes that recognize presented 
MHC-bound self-peptides (spMHC) at the right strength: death by neglect, negative selection 
and positive selection.  
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Figure 1-1: T-cell development in the thymus 
HSCs give rise to CLPs that migrate to the thymus. There, they go through four different 
developmental stages as double-negative (CD4-/CD8-) thymocytes (DN1-4). Successful pre-TCR 
expression leads to transition into double positive (DP) (CD4+/CD8+) thymocytes and expression of a 
fully rearranged TCR. The fate of the DP thymocytes depends on their TCRs’ affinity to MHC-bound 
self-peptides presented by cortical epithelial cells. Cells that bind too weakly will not receive a 
survival signal and die by neglect. DP thymocytes that interact with MHC class II molecules at the 
right strength develop into CD4+ cells, whereas an appropriate interaction with MHC class I 
molecules leads to maturation into CD8+ cells. These cells will receive apoptotic signals, if the 
interaction with these molecules is too strong. After successful maturation, naïve T cells migrate to 
the periphery. Adapted from Germain et al (6). 
 
DP thymocytes that fail to interact with MHC-bound ligands will die by neglect, as they do 
not receive intracellular survival signals. A strong interaction between the TCR and the 
presented self-peptide on the other hand leads to induction of apoptosis (negative selection), 
thereby eliminating potentially self-reactive T cells. Only thymocytes that bind to self-peptide 
at low intensity receive signals that enable further maturation (positive selection). Depending 
on the recognition of MHC class I or MHC class II molecules, these cells develop into mature 
CD4 or CD8 single-positive (SP) T cells (7). Upon successful maturation and selection, 
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mature T cells leave the thymus and enter the peripheral blood to migrate to secondary 
lymphoid tissues. 
 
1.1.2 T-cell subsets 
Various mature T-cell subsets can be distinguished based on their function and expression of 
cell-surface markers. Co-receptor expression on these cells allows a broad division into two 
T-cell lineages: CD4 T-helper (Th) cells and cytotoxic CD8 T cells (CTL). CD4 T cells are 
mainly responsible for activating other immune cells through cytokine release. They 
recognize peptides presented by MHC class II molecules that are exclusively found on 
specialized antigen presenting cells (APCs), such as dendritic cells, macrophages and B cells 
(8). CD8 T cells are capable of killing infected cells and interact with MHC class I peptide 
complexes that are found on all nucleated cells (8). The functional status divides these 
lineages further into naïve, effector and memory cells (9). After their development in the 
thymus, naïve T cells circulate lymphoid tissue to screen for presented antigen. Upon antigen 
encounter, these cells proliferate and differentiate into effector T cells. Following the 
resolution of an immune response, most effector T cells die and only a small number of 
memory T cells remains that can quickly be reactivated at a second encounter with the same 
antigen (10). These basic functional groups can be distinguished based on specific marker 
expression. Differential isoform expression of the protein tyrosine phosphatase CD45 allows 
a general discrimination between naïve (CD45RA+) and effector/memory (CD45RO+) T cells 
in humans, but not in mice (11,12). In both species, the adhesion molecule CD62L and the 
chemokine receptor CCR7 are found on naïve and central memory T cells as these homing 
receptors enable migration within the lymphoid tissue (9). Effector T cells down-regulate 
these two markers and up-regulate E-selectin ligands, such as CD44, that enable migration to 
the site of infection (10). In addition, they up-regulate surface expression of CD69 and CD40 
ligand (CD40L). The role of CD69 in activated T cells is still unclear. It was thought to act as 
a co-stimulatory molecule, but more recent studies argue with that perception and suggest 
roles in negative regulation and T-cell polarization (13). CD40L interacts with CD40 on 
APCs and induces up-regulation of the co-stimulatory proteins CD80 and CD86. Although 
the interaction between CD40L and CD40 plays a major role in the effector functions of CD4 
T cells to activate APCs, it is also found on CD8 T cells (14). Moreover, activated CD8+ 
CTLs are characterized by the production of perforin and granzyme (10). These cytolytic 
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proteins are required for inducing cell death in their target cells. Effector CD4+ Th cells 
account for a heterogeneous group that can be further subdivided into Th1, Th2, Th9, Th17, 
Th22, Tfh (follicular Th) and Treg (regulatory T cells) based on their cytokine profile (15). 
Once an infection is cleared, most activation markers are down-regulated with exception of 
CD44. Subsequently, two populations of memory T cells remain: central memory (TCM) and 
effector memory (TEM) T cells. TCM are CCR7+ CD62L+ and CD44+, reside in the lymph 
node (LN), produce IL-2 and proliferate extensively (13). TEM lack CCR7 and CD62L 
expression and are found primarily in non-lymphoid tissue (16,17). They are less proliferative 
than TCM and produce a variety of effector cytokines, such as IL-4, IL-5 and interferon-γ 
(IFN-γ) (16).  
 
1.1.3  T-cell receptor engagement and signaling 
The TCR consists of the two polypeptide chains TCRα and TCRβ. Each cell expresses a 
unique TCR that is generated during their development in the thymus by rearrangement of 
TCR gene segments. This process is called V(D)J recombination according to the involved 
variable (V), diversity (D) and joining (J) gene segments and has the potential to 
generate >1015 different TCRs in mice and >1018 TCRs in humans (18). Fully rearranged 
TCR chains are composed of a constant region and a variable region (Figure 1-2A). 
Complementarity determining regions (CDRs) within the variable region are primarily 
responsible for antigen binding. TCR diversity allows recognition of a broad range of 
different antigens presented by MHC molecules. Typically, MHC class I molecules present 
protein fragments of endogenous pathogens to CD8 T cells, whereas MHC class II molecules 
present peptides of exogenous pathogens taken up by APCs to CD4 T cells. However, some 
APCs are also able to present extracellular antigens via MHC class I molecules through a 
process called cross-presentation. MHC class I molecules have a closed binding groove and 
therefore bind short peptides with a length between 8-15 amino acids (19). In contrast, MHC 
class II molecules have an open binding groove that presents larger peptides with a length 
between 11-30 amino acids (19). The TCR is expressed on the cell surface in a complex with 
accessory molecules. In addition to the TCRα- and TCRβ-chain, this complex consists of one 
CD3γ, one CD3δ and two CD3ε chains, as well as one intracytoplasmic ζ homodimer (Figure 
1-2B) (20).  
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Activation of naïve T cells requires two signals provided by APCs: a foreign antigen bound 
to a MHC molecule (signal one) and a co-stimulatory protein (CD80 or CD86) (signal two) 
(18). Signal one is recognized by the TCR and signal two by the co-receptor CD28 on T cells. 
Absence of either one of these signals leads to apoptosis or a state of anergy (18). In addition, 
the co-receptor CD4 or CD8 stabilizes the interaction between the TCR and MHC complex 
by binding to the respective MHC class (Figure 1-2B). 
 
Figure 1-2: TCR structure and engagement 
(A) The TCR consists of a TCRα- and TCRβ-chain. Each chain is composed of a variable and a 
constant region. Adapted from Murphy (21). (B) The TCR is expressed as a complex with CD3 and 
accessory chains on the cell surface. In association with the co-receptor, this complex is responsible 
for recognition of MHC-bound peptides and initiation of T-cell activation. Adapted from Gascoigne et 
al (22).   
 
Upon antigen recognition, the src-family kinases Lck and Fyn are activated and subsequently 
phosphorylate immunoreceptor tyrosine-based activation motifs (ITAMs) within the 
cytoplasmic domains of the CD3 and accessory ζ chains. Phosphorylation of the ITAMs leads 
to recruitment and activation of the tyrosine kinase ZAP-70, which propagates the TCR 
A B 
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signal by phosphorylating two critical adaptor molecules: SH2 domain-containing leukocyte 
protein of 76 kDa (SLP-76) and the linker for activation of T cells (LAT) (Figure 1-3) (23). 
Together they form a membrane-associated signaling complex that recruits various adapter 
and effector molecules, including phospholipase-γ (PLCγ). PLCγ is phosphorylated within 
this complex. Subsequently, PLCγ cleaves membrane-bound phosphatidylinositol 
biphosphate (PtdInsP2) into diacyl glycerol (DAG) and inositol trisphosphate (InsP3) (24).  
 
 
 
 
Figure 1-3: TCR signaling pathway 
Engagement of the TCR leads to activation of the kinases Lck and ZAP-70, followed by formation of a 
multimolecular signaling complex at the membrane involving the two adapter proteins SLP70 and 
LAT. The resulting activation of PLCγ induces cleaving of PtdInsP2 into DAG and InsP3, which in 
turn activates various downstream signaling pathways, such as calcium signaling, MAPK signaling 
and NFκB signaling pathways. At the same time, co-stimulation through CD28 induces the PI3K/AKT 
signaling pathway. Ultimately, all pathways activate transcription factors that induce transcription of 
IL-2 and other pro-inflammatory genes. Adapted from Pollizzi et al (25). 
RAF$
MEK$
$ERK$$
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InsP3 binds to calcium channels on the endoplasmic reticulum (ER) membrane, thereby 
releasing stored calcium into the cytosol. Calcium induces conformational changes in the 
messenger protein calmodulin that lead to recruitment of serine/threonine protein phosphatase 
calcineurin. Activated calcineurin desphosphorylates the transcription factor nuclear factor of 
activated T cells (NFAT), allowing NFAT to enter the nucleus (26). In the nucleus, NFAT 
cooperates with other transcription factors to induce transcription of IL-2 and other pro-
inflammatory genes. Parallel to calcium signaling, DAG recruits and activates the signaling 
molecules Ras and PKCΘ (27). Ras triggers the MAPK/ERK pathway, whereas PKCΘ 
activates the NF-κB pathway. The kinase cascade in the MAPK/ERK pathway follows 
successive activation of the mitogen-activated protein kinases (MAPK) Raf, MEK and ERK 
leading to activation of the transcription factor complex AP-1, which consists of Fos and Jun 
(28). The NF-κB pathway is blocked in resting T cells, as NF-κB transcription factors, such 
as p50 and p65, are associated with inhibitors of NF-κB (IκB) that prevent migration to the 
nucleus. Upon TCR stimulation, PKCΘ activates the IκB kinase (IKK), which induces 
degradation of IκB followed by translocation of NF-κB transcription factors to the nucleus 
(29,30). The MAPK/ERK and NF-κB pathways are also triggered through co-receptor CD28-
mediated signaling (31,32). Additionally, CD28 initiates the PI3K/AKT signaling pathway. 
The phosphoinositide 3-kinase (PI3K) binds to the phosphorylated cytoplasmic tail of CD28, 
followed by recruitment and phosphorylation of the serine/threonine kinase AKT (33). The 
relative contribution of the TCR vs its coreceptors in the initiation of the PI3K/AKT signaling 
pathway remains unresolved (34). AKT is best known for its role in cell survival and growth 
by binding various substrates. The anti-apoptotic effect of AKT is the result of binding pro-
apoptotic proteins directly, such as BAD, or the transcription factors that initiate transcription 
of pro-apoptotic genes, such as FOXO (35). AKT promotes cell growth through activation of 
the mammalian target of rapamycin (mTOR). Additionally, AKT directly interacts with the 
NF-κB pathway by phosphorylating IKK (36). Ultimately, all TCR- and CD28-initiated 
signaling pathways result in transcription of genes involved in cytokine production, 
differentiation and proliferation of effector T cells. One of these cytokines is IL-2, which 
plays an important role in enhancing activation of T cells. Activated T cells up-regulate 
expression of the IL-2 receptor and once IL-2 binds to this receptor, multiple signaling 
pathways are activated, including the MAPK/ERK pathway and the PI3K/AKT signaling 
pathway (37). 
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1.1.4 T-cell homeostasis 
Homeostatic mechanisms regulate size and composition of the peripheral T-cell pool and 
maintain total T-cell number throughout life. These mechanisms differ for naïve, effector and 
memory T-cell populations. Naïve T cells can survive for long periods of time without being 
exposed to an antigen. However, they require survival signals provided by interleukin-7 (IL-7) 
and TCR interaction with spMHC molecules on APCs (Figure 1-4) (38). Naïve T cells 
compete for these survival signals based on the limited availability of cytokines and specific 
spMHC molecules. Several models have been proposed that aim to explain how these 
survival signals regulate size and diversity of the naïve T-cell pool. Some studies suggested 
that T cells with TCRs of the same peptide specificity compete with each other for access to 
the same spMHC molecules (intraclonal competition), whereas T cells with a different 
specificity are unaffected (39,40). Others proposed competition between T cells of different 
specificities as a mechanism for maintaining T-cell diversity (interclonal competition) that is 
either based on TCR promiscuity, TCR affinity and/or the ability to respond to other survival 
signals, such as cytokines, upon TCR interaction with spMHC molecules (41–43). 
Additionally, it was shown that mature TCR polyclonal, but not TCR monoclonal T cells are 
resistant to oncogene-induced transformation, suggesting a role of clonal competition in 
suppression of malignant outgrowth (44,45).  
Upon activation, clonal expansion of antigen specific T cells is essential to generate a 
sufficient number of effector T cells to combat infection. Once a particular threat is 
eliminated, the large population of reactive T cells is not required any longer. Therefore, 
apoptosis is directly or indirectly induced in these cells through multiple mechanisms (Figure 
1-4). An indirect mechanism is the withdrawal of survival signals such as co-stimulators and 
cytokines, resulting in a loss of anti-apoptotic gene expression and death by neglect (46,47). 
Regulatory mechanisms and components that actively terminate T-cell responses include 
activation-induced cell death (AICD), expression of cytotoxic T lymphocyte antigen 4 
(CTLA-4) and the effect of Tregs. Repeated stimulation of the TCR triggers AICD by 
mediating the expression of the death receptor Fas (CD95) and its ligand FasL (48). 
Activated T cells also start to express CTLA-4, a second co-receptor besides CD28, that can 
bind the co-stimulatory molecules CD80 and CD86. Upon binding, CTLA-4 inhibits TCR 
downstream signaling, thereby blocking IL-2 production (49). Treg function is based on 
direct cell contact through binding of CTLA-4 on Tregs to CD80/CD86 on effector T cells, 
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the production of immunosuppressive cytokines, such as transforming growth factor–β1 
(TGF-β1) and IL-10, as well as granzyme- and perforin-mediated cytolysis (50). 
 
Figure 1-4: Homeostatic mechanisms during an immune response 
Naïve T cells require IL-7 and TCR interaction with spMHC molecules for survival. Upon antigen 
exposure, activated T cells differentiate and expand into a large population of effector T cells. After 
clearance of an immune response, loss of survival signals and regulatory mechanism, such as AICD, 
CTLA-4 expression and immunosuppressive Tregs, induce apoptosis in most effector T cells to turn 
the immune system back to a responsive state. The remaining memory T cells are kept alive through 
cytokine signaling induced by IL-7 and IL-15. Adapted from Parijs et al (51). 
 
The mechanisms that control survival and homeostasis of the remaining memory T cells in 
the absence of antigen stimulus are less well studied. Memory T cells seem to rely on 
survival signals mediated by the cytokines IL-7 and IL-15 (52–54). Thereby they compete 
with naïve T cells for the same resources. It remains controversial whether they require TCR-
MHC interactions for survival as well (55–58).  
Loss of survival signals 
Regulatory mechanisms 
IL-7 
IL-7 
IL-15 
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1.2 Leukemia and Lymphoma 
Malignant transformation of lymphocytes results in the development of leukemias and 
lymphomas. B- and T-cell malignancies can be divided into precursor B- and T-lymphoid 
neoplasms, mature neoplasms of B-, T-, and NK-cell lineage, and apart from these Non-
Hodgkin Lymphomas, the category of Hodgkin lymphoma (59). The vast majority of 
lymphomas arise from B cells, as they are more susceptible to accumulate secondary 
mutations during their development than do T cells. Error-prone mechanisms like somatic 
hypermutation and immunoglobulin class switch recombination are necessary to generate a 
diverse antibody repertoire in B cells, but contribute significantly to lymphomagenesis 
(60,61).   
 
1.2.1 Peripheral T-cell leukemia/lymphoma  
Peripheral or mature T-cell leukemias/lymphomas (PTCL/MTCL) account for 5-10% of all 
Non-Hodgkin lymphomas and are often associated with a very poor prognosis (62). The 
World Health Organization (WHO) classifies these neoplasms based on their clinical 
presentation into primarily nodal, extranodal, cutaneous, and leukemic malignancies (59). 
These entities are heterogeneous in their clinico-pathologic presentation. Given their 
infrequent incidence, they represent a considerable diagnostic challenge. Generally, there is a 
high demand for better treatments in PTCL, as standard therapies show poor responses in 
these patients (63).   
 
1.2.2 T-cell prolymphocytic leukemia (T-PLL) 
1.2.2.1 Characteristics of T-PLL 
T-cell prolymphocytic leukemia (T-PLL) represents the most frequent T-cell leukemia and 
incidences are estimated to be around 0.6 per million (64–66). Malignant T lymphocytes in 
T-PLL involve the peripheral blood (PB), LNs, BM, liver, spleen, and skin (59). 
Consequently, T-PLL patients commonly present with splenomegaly and elevated 
lymphocyte counts, and less frequently with lymphadenopathy, hepatomegaly, skin lesions, 
or serous effusions (67). T-PLL cells usually express the pan-T cell antigens CD2, CD3, CD5, 
and CD7 (68). The expression of CD4 and CD8 is variable. The most common 
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immunophenotype is CD4+/CD8- (60%), while cases with a CD4+/CD8+ (25%) and CD4-
/CD8+ (15%) phenotype occur less frequent (68). Most T-PLL cells are morphologically 
characterized as medium-sized pro-lymphocytes with a single prominent nucleoli, basophilic 
cytoplasm, and cytoplasmic blebs (68). The nuclei are usually round to oval, but an irregular 
cerebriform shape is observed in less common variants of T-PLL as well. Molecular studies 
revealed two characteristic genetic aberrations involving chromosome 14. Most T-PLL cells 
carry either chromosomal inversion inv(14)(q11;q32) or translocation t(14;14)(q11;q32) (69). 
This leads in both scenario to juxtaposition of the T-cell leukemia 1 (TCL1A) gene locus at 
14q32.1 to TCRα/δ regulatory elements (70). Consequently, overexpression of the TCL1A 
protein is observed in 70-80% T-PLL cases and is a hallmark of this entity (65,66,71–74). In 
20% of patients the TCL1 family member mature T-cell proliferation 1 (MTCP1) is activated 
due to translocation t(X;14)(q28;q11) (68). While genetic abnormalities involving the TCL1 
locus are regarded as initial transforming events, additional alterations, like those on 
chromosomes 11q (involving the tumor suppressor ataxia telangiectasia mutated (ATM)) or 
involving 8q are frequently observed as well (75,76).  
 
1.2.2.2 T-cell receptor expression in T-PLL 
The TCR is essential for normal T-cell survival and function. Transformed T cells of the 
different PTCL entities show diverse patterns of TCR expression and signaling activity, 
thereby suggesting a role in tumorigenesis (77). In T-PLL, most tumor cells express and 
signal through the TCR (65,74). TCR expression is associated with poorer patient survival 
compared to cases lacking TCR expression (Figure 1-5A) (74). TCL1A overexpression is a 
molecular hallmark for T-PLL and the result of chromosomal rearrangement involving 
TCRα/δ enhancer elements. Similar to TCR expression, TCL1A+ T-PLL cases correlate with 
poor outcome (Figure 1-5B). T-PLL cells with high expression of TCL1A have shown 
increased proliferation and AKT activation upon TCR engagement compared to tumor cells 
with low or absent TCL1A expression (74). A preferential usage of TCR-Vβ families, that 
would suggest an antigenic drive, has not been observed for this entity so far (78,79).   
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Figure 1-5: Correlation of TCR and TCL1A expression with patient survival in T-PLL 
In T-PLL patients, expression of a surface TCR (A) and TCL1A (B) correlate with poor survival 
compared to cases lacking respective expression. Adapted from Herling et al (74). 
 
1.2.2.3 Murine models for T-PLL 
Murine models are widely used to study human cancer. Given the limited availability of 
primary material of rare entities like T-PLL, murine models are especially valuable to gain a 
better understanding of their pathogenesis. As T-PLL is characterized by overexpression of 
TCL1A, transgenic mice expressing TCL1A under a T cell-specific Lck promoter developed 
a monoclonal T-PLL-like disease between 15 and 20 months of age (80). These mice showed 
enlarged spleens, LNs and thymi, and elevated white blood counts (WBCs) (Figure 1-6E). In 
contrast to human T-PLL, malignant cells in these mice had a CD4-CD8+ immunophenotype. 
Another T-PLL model is the MTCP1p13-transgenic mouse. The p13 oncogenic isoform of 
MTCP1 is expressed under a CD2 promoter in this model and induced a T-PLL-like disease 
to become clinically overt at 18-20 months of age (81). These mice frequently presented with 
enlarged spleens and lymphocytosis (Figure 1-6A-D). In most cases, leukemic cells showed a 
CD4-CD8+ immunophenotype.  
 
 
 
 
A B 
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 Figure 1-6: T-PLL-like disease in mice 
MTCP1 (A-D) and TCL1A (E) transgenic mice develop a T-PLL like disease with enlarged spleens (A, 
E).  T-cell prolymphocytes are found in the blood (B), spleen (C) and liver (D). Adapted from Virgilio 
et al and Gritti et al (80,81)  
 
1.3 The T-cell leukemia/lymphoma 1 (TCL1A) family 
The members of the T-cell leukemia/lymphoma 1 (TCL1A) family were first identified by 
their involvement in specific chromosomal rearrangements in mature T-cell malignancies. In 
humans this family consists of 3 genes: TCL1A, MTCP1, and TCL1B (also called TML1) 
(82–85). In mice, in addition to the 2 homologues of each TCL1A and MTCP1, there are five 
genes homologous to human TCL1B (Tcl1b1, Tcl1b2, Tcl1b3, Tcl1b4, Tcl1b5)(84).  
 
1.3.1 TCL1A 
1.3.1.1 Expression pattern of TCL1A in healthy tissues 
The TCL1A gene encodes a 14kDa non-enzymatic protein with a closed antiparallel β-barrel 
structure, consisting of eight β-strands with a hydrophobic core (86,87). Structural studies 
revealed that the TCL1A protein contains a homodimerization domain (87). 
In mice, TCL1A was shown to be expressed in embryonic stem cells and in fetal tissue, 
namely in liver, yolk sac, thymus and BM (88,89). In adult mouse tissue, TCL1A expression 
was found in spleen, thymus, BM, PB lymphocytes and testis, suggesting a functional role in 
lymphopoiesis (84,88,90). Murine TCL1A expression was detected in T cells at the DN4 and 
B A C 
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DP stage (see section 1.1.1) and in B cells during all developmental stages in the BM, as well 
as in all subpopulations of the spleen and LN (90).  
In human fetal tissues, TCL1A expression was detectable in liver, kidney, thymus and lung 
(91). In human adult tissues, it was found in spleen, LN, BM, thymus, and tonsil (91). Sorted 
B-cell populations from fetal BM showed TCL1A expression at the pro-B-cell, pre-B-cell 
and immature B-cell stage (70). High TCL1A transcript levels were also observed in naïve 
PB B cells and CD5+ B cells sorted from healthy adult donors (92), whereas others reported 
TCL1A expression in PB lymphocytes only upon stimulation (70). Sorted thymocyte 
populations expressed TCL1A at the DN stage, but not at the DP stage (70). Additionally, 
TCL1 expression was found in plasmacytoid dendritic cells in reactive human LNs (93). The 
expression pattern of TCL1A in humans showed high similarities with the one in mice. It is 
therefore most likely that TCL1A plays a similar role in human embryonic development and 
early T- and B-cell development. 
 
1.3.1.2 Oncogenic properties of TCL1A 
TCL1A was first described based on its aberrant expression in T-cell malignancies (85). In 
humans, TCL1A overexpression is detected in many mature B-cell lymphomas, in the 
majority of T-PLL, in T-cell leukemias arising in patients with the condition of ataxia 
telangiectasia (A-T), blastic plasmacytoid dendritic cell neoplasms, germ cell tumors, 
hepatocellular carcinoma, and adenocarcinoma of the esophagus (65,70,93–100). TCL1A 
expression has also been described for various human lymphoma/leukemia cell lines: 
Burkitt’s lymphoma cell lines Raji, Daudi, CA-46, P3HR-1 and AKUA; EBV transformed 
lymphoblastic cell lines Ado-1701 and Ado-2199; acute lymphoblastic cell lines 697, 
ALL380, ALL-1 and BV173; T-lymphoblastic leukemia/lymphoma cell line Sup-T11 
(70,84,91).  
In mice, the TCL1 locus is found on chromosome 12, whereas in humans the TCL1 locus is 
located on chromosome 14, band q32.1 (101). In humans, rearrangements involving the 
TCL1 locus are commonly found in T-PLL (see section 1.2.2.1) and lead to abnormal 
expression of TCL1A. The TCL1 locus rearranges either with the TCRα/δ locus on 
chromosome 14 by inversion inv(14)(q11;q32) or translocation t(14;14)(q11;q32) (Figure 
1-7), or with the TCRβ locus on chromosome 7 by translocation t(7;14)(q35;q32) (101). In all 
of these scenarios the TCL1 locus is juxtaposed to TCR enhancer elements, most likely 
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causing aberrant (prolonged) activation of TCL1A (101) as opposed to its physiological post-
thymic silencing.  
 
Figure 1-7: Chromosomal rearrangements involving the TCL1 locus 
The TCL1 locus is located on chromosome 14, band q32.1 (left). Chromosomal rearrangements that 
lead to overexpression in mature T-cell leukemias involve the TCRα/δ locus on chromosome 14, band 
q11. These rearrangements juxtapose TCL1A to the TCR locus either by translocation 
t(14;14)(q11;q32) (middle) or inversion inv(14)(q11;q32) (right). Adapted from Pekarsky et al (102). 
 
 
The majority of cases of human chronic lymphocytic leukemia (CLL) are associated with 
TCL1A expression as well (103). However, TCL1A expression levels vary between these 
patients. High TCL1A expression was associated with an unmutated IGHV gene status, high 
ZAP-70 expression, and chromosome 11q22–23 deletions in these patients (103). In contrast 
to T-PLL, CLL patient samples do not show rearrangements involving the TCL1 locus (104). 
Alternative mechanisms leading to abnormal expression of TCL1A in B-cell malignancies 
have been proposed, including those that involve transcriptional activation by Sp1, external 
signals provided by cells in the microenvironment that are either TCL1A suppressive (T cell-
mediated) or activating (stromal cell-mediated), and decreased levels of TCL1A-targeting 
micro-RNAs (103,105–109). Gene expression profiling revealed comparable TCL1A 
transcript levels in CLL cells and mature B-cell populations (naïve B cells and CD5+ B cells) 
from healthy donors, suggesting that CLL cells either inherited or adopted high TCL1 
expression from their histogenetically related healthy B-cell populations (92).  
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As described in section 1.2.2.3, overexpression of TCL1A in T cells of transgenic mice 
causes cellular transformation, thereby providing functional proof for its oncogenic potential 
(80). Although originally identified as an oncogene in T cells, TCL1A also plays a role in the 
transformation of mature B cells. Transgenic mice that expressed TCL1A in B and T cells 
predominantly developed Burkitt-like lymphoma (BLL) and diffuse large B-cell lymphoma 
(DLBCL) starting at the age of 4 months (110). These mice presented with variable 
splenomegaly, lymphadenopathy, and macroscopic lesions of the liver, lung, kidney, and 
intestines. Tumor cells in most cases were IgM+B220loCD5lo B cells. Splenocytes isolated 
from these transgenic mice before tumor development showed prolonged cell survival and 
increased proliferation compared to control mice. When TCL1A expression was driven by a 
B cell-specific IgH Eµ enhancer element, transgenic mice developed a CLL-like malignancy 
(111). These mice showed enlarged spleens, LNs and livers associated with elevated WBCs. 
Tumor cells were characterized as CD5+IgM+. This system has been widely used as a model 
for human CLL (112).  
 
1.3.1.3 Functional aspects of TCL1A 
The functional role of TCL1A as extrapolated by its expression patterns and as identified by 
its interaction partners and subcellular localization, is most likely determined in a cell and 
tissue specific manner. In embryonic stem cells, TCL1A enhanced proliferation and 
suppressed differentiation, implicating a functional role in self-renewal and maintenance of 
pluripotency (89,113–115). Its importance in embryonic development was also supported by 
studies of TCL1A deficient mice that showed reduced fertility in females caused by an 
impaired pre-implantation embryo development (95). TCL1A seems to function similarly in 
adult stem cells of the hair follicle as these cells showed reduced proliferation and loss of the 
stem-cell marker CD34 in TCL1A deficient mice (116). Loss of TCL1A also led to a 
significant decrease in the number of pre-B cells, immature B cells and thymocytes at the DN 
and DP stages, as well as splenic T-and B-cell populations (90).  
The first protein that was identified to co-precipitate and specifically (directly) interact with 
TCL1A in human B-cell lines is the serine/threonine kinase AKT (117). The PI3K/AKT 
signaling pathway has been described in section 1.1.3 as one of the major downstream 
signaling pathways involved in T-cell activation. TCL1A was described to interact with AKT 
at the membrane by binding to its N-terminal pleckstrin homology (PH) domain, a functional 
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domain that mediates protein-protein and protein-lipid interactions (117,118). Aberrant AKT 
activation by TCL1A resulted in augmented phosphorylation of downstream AKT target 
proteins promoting cellular survival and proliferation (117,119,120).  
Moreover, it was described that TCL1A activates the NF-κB pathway by interacting with the 
transcriptional activator p300, a known co-activator of NF-κB, in the Burkitt’s lymphoma cell 
line Daudi (121). In the same study, they showed that TCL1A also binds the AP-1 
components Jun and Fos in the nucleus, thereby inhibiting AP-1 transcriptional activity. In 
CLL cells, up-regulation of TCL1A was associated with down-modulation of Fos and Jun 
proteins (107). Although the AP-1 complex was described as an activator of proliferation in 
section 1.1.3, it is also known to be involved in induction of apoptosis in lymphoid cells after 
growth factor withdrawal (122). 
Another interaction partner of TCL1A is the serine/threonine protein kinase ATM that 
normally induces cell cycle arrest, DNA repair and/or apoptosis upon DNA damage 
(123,124). This interaction resulted in the activation of NF-κB by inducing degradation of 
IκB, allowing translocation of NF-κB transcription factors to the nucleus. Similar to AP-1, 
NF-κB transcription factors are required for T-cell activation (see section 1.1.3), but have 
been associated with initiation of apoptosis in response to cellular stress (125). 
AKT and ATM modulate important cellular signaling pathways and deregulation of these 
genes alone results in cellular transformation. Transgenic mice expressing myristoylated or 
constitutively active AKT developed lymphoblastic lymphomas (126). These tumors also 
arose in ATM-deficient mice (127). The oncogenic function of TCL1A is therefore mostly 
likely based on the combined deregulation of several different pathways, as it is associated 
with induction of mature T- and B-cell malignancies.  
As described before, the majority of T-PLL cells express a functional TCR (see 1.2.2.2). 
Engagement of the TCR in these cells led to TCL1A and AKT recruitment to the cell 
membrane (Figure 1-8A) and formation of TCR-signalosomes with other signaling kinases, 
such as Lck (Figure 1-8B) (74). Eventually TCL1A and AKT co-localized to the nucleus (74). 
Similarly, B-cell receptor (BCR) engagement in TCL1 expressing CLL cells led to 
recruitment of TCL1A and AKT to BCR membrane complexes (128). In mice, abnormal 
TCL1A expression enhanced cytokine secretion and proliferation of mature T cells upon 
TCR or pharmacologic activation through enhanced phosphorylation of PKCΘ and ERK (71). 
This is in contrast with a study of activated human T cells that showed impaired PKCΘ and 
ERK phosphorylation in the presence of TCL1A leading to an inhibition of AICD (129). 
However, it is unclear how TCL1A interferes with these signaling molecules.   
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The previously described interactions of TCL1A with other proteins were detected in the 
cytosol (AKT, p300, ATM) and the nucleus (AKT, Jun, Fos) (74,86,119,121,123). Thus, 
TCL1A protein localization is not restricted to a particular cellular compartment, but rather 
determines its function through compartment-specific interaction partners.   
  
Figure 1-8: TCL1A recruitment to the membrane upon TCR engagement in T-PLL cells 
(A) In unstimlulated T-PLL cells, TCL1A and AKT are found in the cytosol without co-localizing (ctr, 
top panel). However, upon TCR stimulation with CD3/28 beads, TCL1A and AKT co-localize at the 
cell membrane (middle panel). (B) Continuous TCR engagement leads to accumulation of TCL1A and 
AKT in distinct membrane complexes (top and middle panel) together with the signaling kinase Lck 
(bottom panel). Adapted from Herling et al (74). 
 
1.3.2 MTCP1 
MTCP1 was discovered by involvement in t(X;14) translocations in two mature T-cell 
proliferations (82). Normally, the gene is localized on Xq28 (82) and encodes two different 
proteins: the mitochondrial protein p8 (130) and the protein p13 (131). These proteins share 
no similarity with each other, but the p13 isoform shows 39% amino acid identity with 
TCL1A and 95% identity with murine p13Mtcp1 (131). As only the p13MTCP1 protein is 
part of the TCL1 family, it is generally referred to as MTCP1 in this thesis. Although this 
13kDA protein lacks a dimerization surface, it has been shown that it interacts with AKT (Kd 
of 537µM), however, with much lower affinity than TCL1A (Kd of 5.7µM) (87,117,132). 
A B 
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The fact that MTCP1 is oncogenic suggests other relevant executioners than / in addition to 
AKT or that it likely requires additional bridging molecules (132). Other interaction partners 
have not been described for this protein. In mice, normal Mtcp1 expression is found in early 
fetal tissues (liver, yolk sac); in liver, kidney and spleen in adult tissue (88) and in mature T 
cells after infection (133). The human MTCP1 oncoprotein showed low expression in most 
tissues (82) and was not detected in normal resting or activated lymphocytes (131). 
Therefore, MTCP1 expression was limited to mature T-cell proliferations with t(X;14) 
translocations in humans (82,131). Transgenic mice for human MTCP1 developed mature T-
cell leukemia similar to human T-PLL after a long latency period (>15months) (81), thereby 
directly demonstrating its oncogenic properties. Sick mice often presented with splenomegaly 
and elevated WBC. Further examination revealed infiltrations of lymphoid cells into all 
lymphoid organs, liver and lungs. In 23 cases tumor cells were phenotypically characterized 
as CD3+, CD8+, CD4-, CD25-, B220- and in one case as CD3+, CD4+, CD8-, CD25-, B220-. 
 
 
1.3.3 TCL1B/TML1 
Human TCL1B/TML1 (TCL1A/MTCP1-like 1) is the third member of the TCL1 family and 
was identified by screening the frequently rearranged region on chromosome 14q32.1 for 
affected genes other than TCL1A (83,91). The amino acid sequence of TML1 shows over 
30% identity and 60% similarity with TCL1A and MTCP1, and has a 14 amino acid insertion 
compared to human TCL1A (84,91). Similar to MTCP1, this 15kDA protein does not contain 
a dimerization domain and interacts with AKT with lower affinity than TCL1A (83,117). 
Human TML1 is normally expressed in fetal liver, kidney, heart, spleen and thymus (91). In 
adult tissue very low expression levels are found in placenta, testis, kidney, spleen, LNs, 
tonsil and PB lymphocytes (83,91). In human cancer cell lines, TML1 expression is detected 
in Burkitt’s lymphomas, EBV-transformed lymphoblastoid B-cell lines and T-cell leukemia 
with a translocation at 14q32.1 (83,91). In mice, five genes (Tcl1b1-Tcl1b5) were found in 
the TCL1 locus that are homologous to human TML1 (84). The five proteins showed a 30-
40% similarity to human TML1. Expression was high in mouse oocytes and two-cell 
embryos, but low in adult tissues and lymphoid cell lines (84). TML1 is the least studied 
family member and it is unknown whether it has oncogenic properties by itself.  
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1.4 Objectives 
Deregulated expression of the TCL1 family genes TCL1A, MTCP1 and TML1 was first 
described in T-cell malignancies. In transgenic mice, overexpression of TCL1A and MTCP1 
causes outgrowth of mature T- and B-cell tumors. Different promoters were used in these 
studies to target gene expression to T and/or B cells, making it difficult to compare oncogenic 
properties of the two family members directly. Studies describing the oncogenic potential of 
TML1 in vivo have not been described yet. Therefore, the first aim of this thesis is to 
determine and characterize tumorigenicity of the TCL1 family genes in vivo by using 
gamma-retroviral vectors to introduce human TCL1A, MTCP1 and TML1 into 
HSC/hematopoietic progenitor cells (HPC) of wild type mice that are transplanted into wild 
type recipients. TCL1A is expressed in the cytoplasm and the nucleus, thereby targeting 
different signaling molecules. To examine if enforced TCL1A localization influences its 
downstream effects, allowing inferences on a preferred/differential oncogenic potential, a 
myristoylated (membrane localizing) variant (myr-TCL1A) and a nuclear-site directed 
variant (nls-TCL1A) of the TCL1A construct are additionally used in the previously 
described mouse model. 
TCL1A overexpression is detected in the majority of T-PLL. These tumor cells usually 
express a TCR. The oncogenic function of TCL1A is based on the modulation of various 
signaling pathways by interacting with key signaling molecules, especially in the context of 
TCR activation. This suggests a cooperation of TCL1A and TCR signals in the development 
of T-PLL. However, it is unknown how and to what extend TCR signaling plays a role in 
TCL1-driven lymphomagenesis/leukemogenesis. The second part of this thesis aims to 
understand the combined action of TCR signals and TCL1A oncogenes in perturbation of T-
cell homeostasis and in cellular transformation. Therefore, TCR-transgenic monoclonal OT-1 
T cells are retrovirally transduced with vectors encoding TCL1A, myr-TCL1A, and nls-
TCL1A, and then transplanted into RAG1-deficient (RAG1-/-) mice. Recipient mice are 
injected with the OVA peptide SIINFEKL every two weeks to specifically stimulate the TCR 
of OT-1 donor cells and to study the impact of repeated TCR engagement on TCL1-driven 
transformation.  
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2. Materials and Methods 
2.1 Materials 
2.1.1 Antibodies 
Antibody 
Specificity Clone Conjugate Reactivity Manufacturer  Application 
CD3ε 145-2C11 Purified Mouse 
BD, Franklin Lakes, New 
Jersey, USA 
T-cell 
stimulation 
CD3ε 145-2C11 PE Mouse 
Miltenyi Biotec, Bergisch 
Gladbach, Germany 
FC 
CD4 GK1.5 APC Mouse 
Miltenyi Biotec, Bergisch 
Gladbach, Germany 
FC 
CD4 GK1.5 APC-Cy7 Mouse 
Biolegend San Diego, 
California, USA 
FC 
CD5 53-7.3 PE Mouse 
eBioscience, San Diego, 
California, USA 
FC 
CD8 53-6.7 VioBlue Mouse 
Miltenyi Biotec, Bergisch 
Gladbach, Germany 
FC 
CD19 6D5 APC Mouse 
Miltenyi Biotec, Bergisch 
Gladbach, Germany 
FC 
CD19 1D3 PE-Cy7 Mouse 
eBioscience, San Diego, 
California, USA 
FC 
CD28 37.51 Purified Mouse 
BD, Franklin Lakes, New 
Jersey, USA 
T-cell 
stimulation 
CD44 IM7.8.1 VioBlue Mouse 
Miltenyi Biotec, Bergisch 
Gladbach, Germany 
FC 
CD45.1 A20 PE Mouse 
BD, Franklin Lakes, New 
Jersey, USA 
FC 
CD45.2 104 V450 Mouse 
BD, Franklin Lakes, New 
Jersey, USA 
FC 
CD45R/B220 RA3-6B2 APC Human, Mouse 
Biolegend, San Diego, 
California, USA 
FC 
CD62L MEL-14 APC Mouse 
BD, Franklin Lakes, New 
Jersey, USA 
FC 
CD69 H1.2F3 PE-Cy7 Mouse 
BD, Franklin Lakes, New 
Jersey, USA 
FC 
CD117 (c-Kit) 3C11 PE, APC Mouse 
Miltenyi Biotec, Bergisch 
Gladbach, Germany 
FC 
CD197 (CCR7) 4B12 PE Mouse 
BD, Franklin Lakes, New 
Jersey, USA 
FC 
IgG2b, κ MPC-11 
Alexa Fluor 
647 
Human 
Biolegend San Diego, 
California, USA 
ICFC 
IgM Il/41 APC Mouse 
eBioscience, San Diego, 
California, USA 
FC 
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MTCP1  - - Human Abcam, Cambridge, UK WB 
Phospho- AKT 
(S473) 
M89-61 PE Mouse 
BD, Franklin Lakes, New 
Jersey, USA 
ICFC 
Phospho-ERK1/2 
(pT202/pY204) 
20A PE Mouse 
BD, Franklin Lakes, New 
Jersey, USA 
ICFC 
Phospho-STAT5 
(pY694) 
47 PE Mouse 
BD, Franklin Lakes, New 
Jersey, USA 
ICFC 
Sca-1 D7 PE Mouse 
Miltenyi Biotec, Bergisch 
Gladbach, Germany 
FC 
Streptavidin - APC Mouse 
BD, Franklin Lakes, New 
Jersey, USA 
FC 
TCL1A 1-21 
Alexa Fluor 
647 
Human 
Biolegend, San Diego, 
California, USA 
ICFC 
TCL1A  - - Human 
Provided by Dr. M. 
Herling 
WB 
TML1 - - Human 
Provided by Dr. M. 
Herling 
WB 
Vα2 TCR B20.1 APC Mouse 
eBioscience, San Diego, 
California, USA 
FC 
Vβ5 TCR MR9-4 PE Mouse 
BD, Franklin Lakes, New 
Jersey, USA 
FC 
Table 2-1: Antibodies 
FC: Flow Cytometry, ICFC: Intracellular Flow Cytometry, WB: Western Blot.  
 
2.1.2 Bacteria 
One Shot TOP10 chemically competent Escherichia coli (E.coli) (Invitrogen, Life 
Technologies, Darmstadt, Germany) 
Genotype: F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 Δ lacX74 recA1 araD139 
Δ( araleu)7697 galU galK rpsL (StrR) endA1 nupG 
 
2.1.3 Buffer and Solution Compositions 
Buffer Composition 
Annealing buffer (5x) 0.5 M Tris (pH 7.4-7.5), 0.35 M MgCl2 
Bovine serum albumine BSA (10%)  10% (m/v) BSA in ddH2O, sterile-filtered and stored at 4°C  
Bind and wash buffer (2x)  10mM Tris (pH 7.5), 1mM EDTA, 2M NaCl  
BSA/PBS 10% stock solution  10g BSA in 100ml PBS 
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Chloroquine 25µM in ddH2O, sterile-filtered and stored at 4°C  
FACS Fixation Solution 2% Paraformaldehyde in PBS  
FACS-buffer PBS, 2% FCS, 0.05% NaN3 stored at 4°C  
HEPES (2x)  
281mM NaCl, 100mM HEPES, 5mM Na2HPO4 in ddH2O, pH 7.0, 
stored at -20°C  
MSA blocking solution 0.1% 25mg MSA in 25ml PBS, sterile filtered and stored at 4°C 
PBS-T  0.05% Tween-20 in PBS 
SDS, 10% 25g SDS in 250ml ddH2O 
SDS loading buffer, 6x 
60% (v/v) glycerin, 18% (w/v) SDS, 0.3% (v/v) bromophenol blue, 
600mM Tris-HCl, 12% (v/v) β-mercaptoethanol 
Transfer/Blotting Buffer 20% (v/v) Methanol, 10% (v/v) TOWBIN Buffer 
TOWBIN Buffer 144g Glycin, 30.29g Tris, 250mg SDS 
Table 2-2: Buffer Compositions 
 
2.1.4 Chemicals and Reagents 
Chemical/Reagent Manufacturer  
4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic 
acid (HEPES)  
Sigma-Aldrich, St.Louis, Missouri, USA 
Ampicillin, sodium salt Roth, Karlsruhe, Germany 
Amplification buffer (10x) (Buffer A) Segenetic, Borken, Germany 
β-mercaptoethanol Gibco, Life Technologies, Darmstadt, Germany 
BSA (bovine serum albumin) Sigma-Aldrich, St.Louis, Missouri, USA 
Bromophenol Blue Sigma-Aldrich, St.Louis, Missouri, USA 
CaCl2 Merck, Darmstadt, Germany 
CellTrace Violet Cell Proliferation Kit Life Technologies, Darmstadt, Germany 
Chloroquine Sigma-Aldrich, St.Louis, Missouri, USA 
Dimethyl sulfoxide (DMSO) Serva, Heidelberg, Germany 
Distilled Water Gibco, Life Technologies, Darmstadt, Germany 
D-Luciferin PerkinElmer, Waltham, Massachusetts, USA 
DNA ExitusPlus IF AppliChem, Darmstadt, Germany 
DNA Ladder (100bp, 1kb) New England Biolabs, Ipswich, Massachusetts, USA 
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DNA loading dye (6x)  New England Biolabs, Ipswich, Massachusetts, USA 
dNTPs (10mM) 
Fermentas, Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
Dulbecco's Modified Eagle Medium (DMEM) Gibco, Life Technologies, Darmstadt, Germany 
Dulbecco’s Phosphate Buffered Saline (PBS)  PAA Laboratories, Pasching, Austria  
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich, St.Louis, Missouri, USA 
Ethanol  Roth, Karlsruhe, Germany 
Ethidium bromide Bio-Rad, Hercules, California, USA 
Extensor High Fidelity Master Mix 
ABgene, Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
FcR Blocking Reagent, mouse  Miltenyi Biotec, Bergisch Gladbach, Germany 
Fetal bovine serum (FBS) PAA Laboratories, Pasching, Austria 
Freund’s Adjuvant, Incomplete (IFA) Sigma-Aldrich, St.Louis, Missouri, USA 
Formaldehyde (37%) Roth, Karlsruhe, Germany 
Glycerol Roth, Karlsruhe, Germany 
Glycin Sigma-Aldrich, St.Louis, Missouri, USA 
Hanks balanced salt solution (HBSS) Sigma-Aldrich, St.Louis, Missouri, USA 
Human interleukin-2 (IL-2) (10000U/ml)  Novartis, Basel, Switzerland 
Hydrochloride (HCl) Merck, Darmstadt, Germany 
Isopropanol Merck, Darmstadt, Germany 
Iscove's Modified Dulbecco's Medium (IMDM) Gibco, Life Technologies, Darmstadt, Germany 
Isoflurane Abbvie, Ludwigshafen, Germany 
Kanamycin-sulfate Roth, Karlsruhe, Germany 
LB Broth Roth, Karlsruhe, Germany 
LE Agarose Bio-Rad, Hercules, California, USA 
L-Glutamine Gibco, Life Technologies, Darmstadt, Germany 
Lyse/Fix Buffer (5X) BD, Franklin Lakes, New Jersey, USA 
Lysing Buffer (10x)  BD, Franklin Lakes, New Jersey, USA 
Methanol Roth, Karlsruhe, Germany 
Magnesium Chloride MgCl2 Merck, Darmstadt, Germany 
Mouse Serum Albumin (MSA) EMD Millipore, Billerica, USA 
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Non-essential amino acids (NEAA) Gibco, Life Technologies, Darmstadt, Germany 
NuPAGE MES SDS Running Buffer (20X) Life Technologies, Darmstadt, Germany 
NuPAGE Novex 4-12% Bis-Tris Protein Gels, 1.0 
mm, 15 well 
Life Technologies, Darmstadt, Germany 
NuPAGE Novex 12% Bis-Tris Protein Gels, 1.0 
mm, 15 well 
Life Technologies, Darmstadt, Germany 
OVA (257-264) Eurogentec, Seraing, Belgium 
PCR Primers Eurofins MWG Operon, Ebersberg, Germany 
Penicillin/Streptavidin Gibco, Life Technologies, Darmstadt, Germany 
Perm Buffer III BD, Franklin Lakes, New Jersey, USA 
Phosphatase Inhibitor Cocktail Tablets, PhosSTOP Roche Diagnostics, Mannheim, Germany  
Phusion High-Fidelity DNA Polymerase 
Finnzymes, New England Biolabs, Ipswich, Massachusetts, 
USA 
Protease Inhibitor Cocktail Tablets, cOmplete Mini Roche Diagnostics, Mannheim, Germany 
Retronectin   Takara/Clontech, Mountain View, California, USA 
Restriction Endonucleases  New England Biolabs, Ipswich, Massachusetts, USA 
Roswell Park Memorial Institute (RPMI) 1640 Gibco, Life Technologies, Darmstadt, Germany 
Roti-Block Roth, Karlsruhe, Germany 
RNase (DNase free) Roche, Basel, Switzerland 
S.O.C. medium Invitrogen, Life Technologies, Darmstadt, Germany 
Sodium Chloride (NaCl) Roth, Karlsruhe, Germany 
Sodium Dodecyl Sulfate (SDS) AppliChem, Darmstadt, Germany 
Sodium Fluoride (NaF) Fluka, Sigma-Aldrich, St.Louis, Missouri, USA 
Sodium Hydroxide (NaOH) Merck, Darmstadt, Germany 
Sodium Orthovanadate (Na3VO4) Sigma-Aldrich, St.Louis, Missouri, USA 
Sodium Phosphate (Na3PO4) Sigma-Aldrich, St.Louis, Missouri, USA 
Sodium Pyruvate Gibco, Life Technologies, Darmstadt, Germany 
StemSpan SFEM STEMCELL Technologies, Vancouver, Canada 
T4 DNA Ligase New England Biolabs, Ipswich, Massachusetts, USA 
Taq Polymerase Segenetic, Borken, Germany 
Tris-(Hydroxymethyl)-Aminomethane (Tris) AppliChem, Darmstadt, Germany 
Tris-Hydrogen Chloride Buffer (Tris-HCl) Bio-Rad, Hercules, California, USA 
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Trypan Blue Sigma-Aldrich, St.Louis, Missouri, USA 
Trypsin-EDTA solution (0.05%)  Invitrogen, Life Technologies, Darmstadt, Germany 
Tween-20 Merck, Darmstadt; Germany 
Table 2-3: Chemicals and Reagents 
 
2.1.5 Commercial Kits 
Kit  Manufacturer 
Calcium Phosphat Transfektion Kit Sigma-Aldrich, St.Louis, Missouri, USA 
DNeasy Blood & Tissue Kit  Qiagen, Hilden, Germany 
Dynabeads M-280 Strepavidin Invitrogen, Life Technologies, Darmstadt, Germany 
Dynabeads M-450 Epoxy Invitrogen, Life Technologies, Darmstadt, Germany 
ECL-Plus Western Blot Kit 
Amersham, GE Healthcare Life Sciences, Freiburg, 
Germany 
Fix&Perm Cell Permeabilization Kit Life Technologies, Darmstadt, Germany 
Gel and PCR Clean-up NucleoSpin, Macherey-Nagel, Düren, Germany 
Lineage Cell Depletion Kit Miltenyi Biotec, Bergisch Gladbach, Germany 
MinElute Reaction Cleanup Kit Qiagen, Hilden, Germany 
peqGold Cycle Pure Kit peqLab, Erlangen, Germany 
Qiagen Plasmid Maxi Kit  Qiagen, Hilden, Germany  
QIAquick PCR Purification Kit  Qiagen, Hilden, Germany  
RNAlater Qiagen, Hilden, Germany  
RNeasy Mini Kit Qiagen, Hilden, Germany  
TOPO TA Cloning Kit Invitrogen, Life Technologies, Darmstadt, Germany 
Table 2-4: Commercial Kits 
 
2.1.6 Laboratory Equipment and Instruments 
Equipment / Instrument Manufacturer 
Analytical balance, BP61 Sartorius Stedim Biotec, Göttingen, Germany 
Autoclave, VX-95 Systec, Wettenberg, Germany 
Blotting system, Criterion Bio-Rad, Hercules, California, USA 
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Cell freezing container, Mr. Frosty  
Nalgene, Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
Cell Sorter, BD FACSAria II BD, Franklin Lakes, New Jersey, USA 
Centrifuge Heraeus Fresco 21, tabletop 
Heraeus, Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
Centrifuge, tabletop Hettich, Tuttlingen, Germany 
Centrifuge, Biofuge 15R, tabletop Thermo Fisher Scientific, Waltham, Massachusetts, USA 
Centrifuge, Minifuge RF 
Heraeus, Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
Centrifuge Megafuge 1.0R 
Heraeus, Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
Clean bench HERAsafe KS Thermo Fisher Scientific, Waltham, Massachusetts, USA 
CO2 Incubator HERAcell 150i Thermo Fisher Scientific, Waltham, Massachusetts, USA 
Flow Cytometer, MACS Quant Analyzer Miltenyi Biotec, Bergisch Gladbach, Germany 
Fluorescence Microscope, Axioskop 2 ZEISS, Oberkochen, Germany 
Horizontal Electrophoresis Systems Bio-Rad, Hercules, California, USA 
Hot Air Sterilizer, T12  
Heraeus, Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
Imaging System, Fusion-SL peqLab, Erlangen, Germany 
In Vivo Imaging System, IVIS Lumina Series II PerkinElmer, Waltham, Massachusetts, USA 
MACS MultiStand Miltenyi Biotec, Bergisch Gladbach, Germany 
MACS Separators Miltenyi Biotec, Bergisch Gladbach, Germany 
Magnetic Particle Concentrator, MPC-S Invitrogen, Life Technologies, Darmstadt, Germany 
Magnetic Stirrer, RCT basic IKA, Staufen, Germany 
Microplate Reader Infinite M200 Pro Tecan, Männedorf, Switzerland  
Microscope Olympus IX70 Olympus, Tokyo, Japan 
Mini-Cell Electrophoresis System, XCell SureLock Life Tehnologies, Darmstadt, Germany 
Nano-Drop ND 1000 spectrometer peqLab, Erlangen, Germany 
pH-Meter  Knick, Berlin, Germany 
Pipettes Eppendorf, Hamburg, Germany 
Pipetus Hirschmann, Eberstadt, Germany 
Pipet Stepper Eppendorf, Hamburg, Germany 
Power supply PowerPac Bio-Rad, Hercules, California, USA 
Scil Vet ABC (Animal Blood Counter) Scil animal care company, Viernheim, Germany  
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Shaking Incubator  Edmund Bühler LabTec, Hechingen, Germany 
Thermal Cycler Mastercycler Pro Eppendorf, Hamburg, Germany 
Thermomixer Eppendorf, Hamburg, Germany 
UV-Lamp Konrad Benda, Wiesloch, Germany 
Vacuum Pump Integra Biosciences, Fernwald, Germany 
Vortex Roth, Karlsruhe, Germany 
Water Bath GFL, Burgwedel, Germany 
XGI-8 anesthesia system PerkinElmer, Waltham, Massachusetts, USA 
Table 2-5: Laboratory Equipment and Instruments 
 
2.1.7 Laboratory Supplies and Consumables  
Supply / Consumable Manufacturer 
Blotting Sandwich Immobilon-P Merck Millipore, Billerica, Massachusetts, USA 
Combitips Advanced (1, 5 and 10ml) Eppendorf, Hamburg, Germany 
Conical Centrifuge Tubes (15 and 50ml) Greiner Bio-One, Frickenhausen, Germany 
C-Chip Disposable Hemocytometer, Neubauer 
improved 
NanoEnTek, Seoul, Korea 
Cryogenic Tubes (2ml) Thermo Fisher Scientific, Waltham, Massachusetts, USA 
Filter Cap Cell Culture flasks (25, 75 and 175cm2) Greiner Bio-One, Frickenhausen, Germany 
Microvette CB 300 µl, K2 EDTA Sarstedt, Nümbrecht, Germany 
Nitril Gloves Braun, Melsungen, Germany 
Non-tissue culture plates (6 and 24 well) Falcon, Corning, New York, USA 
Pasteur Pipettes Corning, New York, USA 
Petri Dishes Greiner Bio-One, Frickenhausen, Germany 
Pipette tips (10, 100, 200 and 1000µl) peqLab, Erlangen, Germany 
Pipette tips (10, 100, 200 and 1000µl) aerosol-
resistant 
peqLab, Erlangen, Germany 
Polystyrene Round-Bottom Tube (5ml) Falcon, Corning, New York, USA 
Reaction tubes (0.1, 0.2, 1.5 and 2ml) Eppendorf, Hamburg, Germany 
Scalpels mediware Servoprax, Wesel, Germany 
Serological pipettes (2, 5, 10 and 25ml) Costar, Corning, New York, USA 
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Sterile cell strainer BD, Franklin Lakes, New Jersey, USA 
Sterile filters (0.22 and 0.45µm) Merck Millipore, Billerica, Massachusetts, USA 
Syringes (5,10 and 20ml) Braun, Melsungen, Germany 
Tissue culture dishes (10cm) Greiner Bio-One, Frickenhausen, Germany 
Tissue culture plates (6, 12, 24 and 96 well) Costar, Corning, New York, USA 
Tube 5ml, 75x12mm, PS Sarstedt, Nümbrecht, Germany 
Table 2-6: Laboratory Supplies and Consumables 
 
2.1.8 Plasmids and Vectors 
Plasmid name  Description Reference 
Eco-env 
Expression plasmid for ecotropic envelope 
protein from MLV 
Stitz, J., et al (134)  
MP91-EGFP 
Retroviral vector with a modified leader 
region MP91 (MPSV-LTR and MESV-
leader), coding for IRES-EGFP with a 5' 
packaging signal 
Schambach, A., et al (135)  
MLV gag-pol 
Expression plasmid for MLV Gag-Pol with 
SV40-Promotor 
C.Baum (MHH) 
MP91-TCL1A-EGFP 
Retroviral vector containing human 
TCL1A-IRES-EGFP. 
Cloned for this study. 
MP91-myr-TCL1A- EGFP 
Retroviral vector coding for human 
myristoylated (myr) TCL1A-IRES-EGFP. 
Cloned for this study. 
MP91-nls-TCL1A-EGFP 
cDNA for human TCL1A, containing a 
nuclear localization sequence (nls), cloned 
into MP91-EGFP. 
Cloned for this study. 
MP91-MTCP1-EGFP 
Retroviral vector coding for human 
MTCP1-IRES-EGFP. 
Cloned for this study. 
MP91-TML1-EGFP 
Retroviral vector coding for human TML1-
IRES-EGFP. 
Cloned for this study. 
MP91-T-Sapphire-Luc 
Retroviral vector coding for T-Sapphire-
IRES-Luc. 
K.Cornils (University of 
Hamburg) 
MP91-TCL1A-Luc 
Retroviral vector coding for human 
TCL1A-IRES-Luc. 
K.Cornils (University of 
Hamburg) 
Table 2-7: Plasmids and Vectors 
 
The used retroviral vectors are flanked by 5’ and 3’ long terminal repeats (LTR), responsible 
for gene expression, reverse transcription and viral integration. Furthermore, the internal 
ribosome entry site (IRES) allows co-expression of multiple genes, e.g. a reporter gene and a 
gene of interest. In the presented model, enhanced green fluorescent protein (EGFP) or firefly 
luciferase (luc) were used as reporter genes and TCL1 oncogenes were genes of interest. The 
 43 
Woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) further enhances 
gene expression. For plasmid maps, see Figure 5-1 in section 5.2. 
 
2.1.9 Primary Cells and Cell Lines 
Cells Media Description 
Murine 
Splenocytes 
RPMI 1640 Mouse 
Special 
Isolated from spleen and LNs of OT-1 donor mice. 
Murine 
HSCs/HPCs 
StemSpan SFEM 
complete 
Isolated from femur and tibia of B6 SJL donor mice. 
HEK 293T DMEM complete 
Human embryonic kidney 293 cells containing the SV40 T-antigen 
(136). 
SC1 DMEM complete Mouse embryonic fibroblasts (137) 
CTLL-2 IMDM CTLL-2 Mouse cytotoxic T-lymphocyte (138)  
Table 2-8: Primary Cells and Cell Lines 
 
2.1.10 Primer Sequences   
Name Sequence 5' à  3' Application 
A1 RV Biotin (biotin) CTG GGG ACC ATC TGT TCT TGG CCC T LM-PCR 
A2 RV AAC CTT GAT CTG AAC TTC TC LM-PCR 
A3 RV CCA TGC CTT GCA AAA TGG C LM-PCR 
OC1 FW GTA ATA CGA CTC ACT ATA GGG C LM-PCR 
OC2 FW ACT ATA GGG CAG GCG TGG T LM-PCR 
Linker1 FW 
GTA ATA CGA CTC ACT ATA GGG CAC TAT AGG GCA CGC 
GTG GT 
LM-PCR 
Linker2 RV (phosphate) ACC ACG CGT GCC CTA TAG T LM-PCR 
M13_for (-40) GTT TTC CCA GTC ACG AC Colony PCR 
M13_for (-20) GTA AAA CGA CGG CCA G 
Sequencing after 
Colony PCR 
M13_rev CAG GAA ACA GCT ATG AC Colony PCR 
Clonecheck FW GTC TTG TCT GCT GCA GCA TC Control PCR 
Clonecheck RV GCT TCG GCC AGT AAC GTT AG Control PCR 
TCL1A FW ATC GGC GGC CGC ATC GCA TGG CCG AGT GCC CGA C Vector cloning 
TCL1A RV ATC GGA ATT CAT CGG GCC GCC ACT GTG CTG GA Vector cloning 
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myr-TCL1A 
FW 
TGC AGC GGC CGC TGC AGG AGA CCC AAG CTG GCT AGT T Vector cloning 
myr-TCL1A RV GCC ACT GTG CTG GAT ATC TGC Vector cloning 
nls-TCL1A FW GAC TGC GGC CGC GAC TGG GAG ACC CAA GCT GGC TAG Vector cloning 
nls-TCL1A RV GTC ATC TGG CAG CAG CTG GG Vector cloning 
Table 2-9: Primer Sequences 
 
2.1.11 Media 
Media Composition 
DMEM complete 
DMEM with 10% Fetal bovine serum (FBS), 2% L-glutamine, 1% 
Penicillin/Streptomycin 
RPMI 1640 complete 
RPMI 1640 with 10% Fetal bovine serum (FBS), 2% L-glutamine, 1% 
Penicillin/Streptomycin 
RPMI 1640 Mouse Special 
RPMI 1640 with 10% Fetal bovine serum (FBS), 2% L-glutamine, 1% 
Penicillin/Streptomycin, 1% Non-essential amino acids, 1% Sodium 
pyruvate, 0,1% β-mercaptoethanol 
StemSpan SFEM complete 
StemSpan SFEM with 10% Fetal bovine serum (FBS), 2% L-glutamine, 1% 
Penicillin/Streptomycin, 10ng/ mIL3, 50ng/ml mIL-6, 50ng/ml mSCF.   
IMDM CTLL-2 
IMDM with 10% Fetal bovine serum (FBS), 2% L-glutamine, 1% 
Penicillin/Streptomycin, 0,1% β-mercaptoethanol, 300U IL-2/ml. 
Table 2-10: Media 
 
2.1.12 Mouse Strains 
Name Common Name Distributor 
C57BL/6J Black 6 or B6 The Jackson Laboratory, Bar Harbor, Maine, USA 
B6.SJL-Ptprca Pepcb/BoyJ B6 CD45.1 or B6 SJL The Jackson Laboratory, Bar Harbor, Maine, USA 
B6.129S7-Rag1tm1Mom/J RAG1-/- The Jackson Laboratory, Bar Harbor, Maine, USA 
C57BL/6-Tg (TcraTcrb) 
1100Mjb/j 
OT-1 The Jackson Laboratory, Bar Harbor, Maine, USA 
Table 2-11: Mouse Strains 
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2.1.13 Tools and Software for Data Analysis 
Tool / Software Provider/Producer 
DNAstar Lasergene SeqMan / EditSeq / SeqBuilder DNASTAR, Inc., Madison, Wisconsin, USA 
Expression Console™ Software Affymetrix, Santa Clara, California, USA 
FlowJo TreeStar Inc, Ashland, Oregon, USA 
GraphPad Prism GraphPad Software Inc., La Jolla, California, USA 
Living Image Software 4.0 PerkinElmer, Waltham, Massachusetts, USA 
MACSQuantify Software Miltenyi Biotec, Bergisch Gladbach, Germany 
Mavric (Methods for analyzing viral integration 
clusters) 
Departments of Haematology and Bioinformatics, 
Erasmus MC  
PANTHER Classification System Thomas et al, 2003 (139) 
Transcriptome Analysis Console 3.0 Software Affymetrix, Santa Clara, California, USA 
Table 2-12: Tools and Software for Data Analysis 
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2.2 Methods 
2.2.1 Molecular Biology  
2.2.1.1 DNA digestion 
Digestion of DNA with endonucleases was performed according to the manufacturer’s 
protocol (New England Biolabs, Ipswich, Massachusetts, USA). Unless otherwise stated, 
reactions were incubated for 1 hour at 37°C in a total volume of 25µl.  
 
2.2.1.2 Agarose gel electrophoresis 
Standard agarose gel electrophoresis was carried out to separate DNA fragments. For 
preparation of the gel, agarose was dissolved in 1xTAE (Tris-acetate-EDTA) buffer by 
heating the agarose/buffer mixture in a microwave. Agarose concentration in the gel was 
typically between 1-2% (w/v). Afterwards, ethidium bromide (EtBr) was added to the 
mixture at a concentration of 2µg/ml to allow visualization of DNA under UV light exposure. 
The polymerized gel was then placed into an electrophoresis system with 1xTAE buffer, 
followed by loading of DNA samples mixed with 6x loading dye. DNA fragments were 
separated by running the gel at 100-120V for 30-60min, depending on the size of the desired 
fragments. These fragments were then visualized and documented in a Multi-Imaging System 
(Fusion-SL, peqLab, Erlangen, Germany).   
 
2.2.1.3 Isolation of DNA fragments from agarose gels 
Single DNA fragments were excised from agarose gels with a clean scalpel. DNA was 
isolated using a NucleoSpin Gel and PCR Clean-up Kit (Macherey-Nagel, Düren, Germany) 
by following the manufacturer’s instructions.    
 
2.2.1.4 Ligation of DNA-fragments with T4 DNA ligase  
Ligation of insert-DNA into vector-DNA was performed according to the manufacturer’s 
protocol using a molar ratio of 1:3 recipient vector to insert fragment. The reaction volume 
was increased to 25µl and incubated at 16°C overnight.  
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2.2.1.5 Baterial Transformation 
For amplification, plasmid DNA was transformed into chemically competent E.coli TOP10 
(Invitrogen). One vial of bacteria (50µl) was thawed and mixed with 100ng of plasmid DNA. 
The mix was kept on ice for 30min, followed by a short incubation at 42°C for 1min and 
another 2min on ice. Subsequently, 500µl LB medium was added to the bacteria and 
incubated at 37°C in a shaking incubator (200rpm) for 45min. Finally, 30-70µl of the bacteria 
mix were spread on LB plates supplemented with ampicillin and incubated at 37°C overnight. 
LB plates were examined for colony formation on the following day.  
 
2.2.1.6 Preparation of plasmid DNA from bacteria cultures 
After bacterial transformation, single colonies were picked from LB plates with a pipet tip 
and inoculated in 3ml LB medium supplemented with ampicillin. Bacterial cultures were kept 
in a shaking incubator (200rpm) at 37°C overnight. For small-scale DNA preparation, DNA 
was isolated from the overnight cultures using a JETquick Plasmid Miniprep Spin Kit 
(Genomed, Löhne, Germany) according to the manufacturer’s protocol. For large-scale DNA 
preparation, 200µl from the overnight cultures were added to 200ml LB medium 
supplemented with ampicillin. The cultures were kept in a shaking incubator (200rpm) at 
37°C overnight. DNA was isolated from these cultures using a Qiagen Plasmid Maxi Kit 
(Qiagen, Hilden, Germany) following the manufacturer’s instructions. Finally, DNA 
concentrations were determined using a NanoDrop (peqLab, Erlangen, Germany). 
 
2.2.1.7 DNA isolation from cell suspensions  
For DNA isolation from single cell suspensions, 1x106 to 5x106 cells were pelleted and 
processed using a DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s protocol. DNA was eluted with 50µl H2O and DNA concentration was 
determined using a NanoDrop (peqLab, Erlangen, Germany). 
 
2.2.1.8 DNA sequencing  
For DNA sequencing at an external sequencing facility (Eurofins Genomics, Ebersberg, 
Germany), a sequencing reaction mix was prepared using 50-100ng/µl plasmid DNA or 2-
10ng/µl purified PCR product in a total volume of 15µl and adding 2µl primer (10µM). This 
 48 
facility performs Sanger sequencing using an Applied Biosystems 3730xl DNA Analyzer 
(Life Technologies, Darmstadt, Germany). 
 
2.2.1.9 Polymerase chain reaction (PCR) 
For DNA amplification, PCR reactions were prepared using a Taq Polymerase (Table 2-13). 
The reaction tubes were transferred to a thermocycler. The used thermocycler program is 
shown in Table 2-14. Annealing temperature was adjusted to the melting temperatures of the 
forward and reverse primer. 
 
 
 
 
 
 
 
 
 
 
 
Table 2-13:  PCR Reaction 
 
 
 
 
 
 
Table 2-14: Thermocycling Conditions 
 
2.2.1.10 Ligation-mediated PCR (LM-PCR) 
Ligation-mediated PCR was performed to determine retroviral integration sites. Therefore, 
DNA was isolated from single cell suspensions of developed tumors (see section 2.2.1.7). 
The genomic DNA (250-1000ng) was then digested with the restriction enzyme Tsp5091 
(New England Biolabs, Ipswich, Massachusetts, USA) that cuts upstream from the LTR 
within the proviral sequence. Afterwards, the digestion mix was cleaned up using a MinElute 
 
Amplification buffer (10x) (Buffer A) 5µl 
Forward Primer (10µM) 1µl 
Reverse Primer (10µM) 1µl 
Taq Polymerase  0.4µl 
dNTPs (10mM) 1.5µl 
H2O 40.1µl 
DNA template (50-100ng/µl) 1µl 
 
95°C 3min Initial Denaturation  
95°C 30sec Denaturation  
30 
cycles 45-68°C 30sec Annealing          
72°C 1min Elongation  
72°C 3min Final Elongation   
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Reaction Cleanup Kit (Qiagen, Hilden, Germany). Next, the fragments containing LTR-
genomic DNA junctions were tagged with a biotinylated LTR-specific primer using a high 
fidelity DNA polymerase (Finnzymes, New England Biolabs, Ipswich, Massachusetts, USA). 
The product was cleaned up using a MinElute Reaction Cleanup Kit (Qiagen, Hilden, 
Germany), followed by incubation with streptavidin-coated beads (Invitrogen, Life 
Technologies, Darmstadt, Germany) at room temperature for 60min. Afterwards, the mix was 
washed several times using a magnetic particle concentrator to remove unbound DNA 
fragments. To be able to specifically amplify the isolated DNA fragments, an adapter 
oligonucleotide cassette of known sequence was ligated to the fragments using a T4 DNA 
ligase (New England Biolabs, Ipswich, Massachusetts, USA). After washing the reaction mix, 
a PCR and a nested PCR (Extensor Hi-Fidelity PCR Master Mix 1, Thermo Fisher Scientific, 
Waltham, Massachusetts, USA) were performed with oligonucleotides that specifically bind 
to the adaptor region. PCR products were analyzed by gel electrophoresis (see section 
2.2.1.2). Single bands were cut out of the gel and cleaned up (see section 2.2.1.3). The 
product was then subcloned into a pCR2.1 TOPO vector (Life Technologies, Darmstadt, 
Germany) following the manufacturer’s protocol. Finally, the product was transformed into 
TOP10 E.coli bacteria (see section 2.2.1.5). 
 
2.2.1.11 Colony PCR 
After LM-PCR and transformation of subcloned DNA fragments into bacteria, single 
colonies were picked and incubated in 50µl PCR reaction mix for 2min. During the following 
PCR, primers specifically bind to the TOPO plasmid and allow amplification of a single 
DNA fragment isolated during LM-PCR. Typically, 10 clones were picked per sample. 
Finally, the PCR reaction was cleaned up using NucleoSpin Gel and PCR Clean-up Kit 
(Macherey-Nagel, Düren, Germany) and send to an external sequencing facility for DNA 
sequencing (see section 2.2.1.8). 
 
2.2.1.12 Integration Site Analysis 
During the previously described LM-PCR and colony PCR, retroviral integration sites within 
the murine genome were isolated and amplified. The resulting DNA sequences contain parts 
of the proviral LTR on one side and the ligated adapter molecule on the other side. These 
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sequences were removed from the amplicon using Lasergene’s DNAStar SeqMan tool. The 
remaining sequence was then uploaded to the online tool Mavric (Departments of 
Haematology and Bioinformatics, Erasmus MC) to analyze the retroviral integration site in 
terms of exact integration locus, chromosomal location, surrounding genes, distance to 
surrounding genes and orientation. Thereby, genes 250kb up- and downstream of the 
integration site were included in this analysis. To further analyze these genes, ‘Entrez Gene’ 
IDs were entered into the online PANTHER Gene Ontology database (version 10.0) and 
characterized in terms of pathways, biological processes and molecular functions. As a 
reference dataset the ‘NCBI build 37 mouse genome’ was used.  
 
2.2.1.13 Western Blot 
For protein expression analysis by Western Blot, 1x106 cells were resuspended in 100µl cell 
lysis buffer (including protease inhibitors). The mix was kept at 99°C for 10min. Afterwards, 
samples were loaded onto 4-12% or 12% Bis-Tris Protein Gels (NuPage, Life Technologies, 
Darmstadt, Germany), depending on protein size. Gel electrophoresis was performed at 
40mA for 90min. Subsequently, proteins were eletrophoretically transferred from the 
polyacrylamide gel onto a polyvinylidene fluoride (PVDF) membrane (Immobilon, Merck 
Millipore, Billerica, Massachusetts, USA). The membrane was blocked with 1x Roti-Block 
(Roth, Karlsruhe, Germany) for one hour at room temperature to reduce nonspecific antibody 
binding. Afterwards, the membrane was incubated with the primary antibody at 4°C 
overnight. On the following day, the membrane was washed and then incubated with the 
secondary antibody for 2 hours. For chemiluminescent protein detection, the membrane was 
treated with the ECL-Plus Western Blot Kit (GE Healthcare Life Sciences, Freiburg, 
Germany) according to the manufacturer’s protocol and analyzed with a Multi-Imaging 
System (Fusion-SL, peqLab, Erlangen, Germany).   
 
2.2.1.14 Gene Expression Analysis 
For gene expression analysis, RNA was isolated from 2x105 cells using the RNeasy Mini Kit 
(Qiagen, Hilden, Germany). After transcription into cDNA, samples were hybridized onto 
Mouse Gene 1.0 ST Arrays (Affymetrix, Santa Clara, California, USA). Data normalization 
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and quality control was done using the Affymetrix Expression Console Software. The 
Affymetrix Transcriptome Analysis Console 3.0 Software was used for data analysis. 
 
2.2.2 Cell culture 
2.2.2.1 Cell line culture 
The adherent cells lines HEK 293T and SC-1 were cultured in DMEM complete medium (see 
section 2.1.11). HEK293T cells were passaged when 80% confluent to a ratio of 1:5, 
typically every 2-3 days. Similarly, SC-1 were subcultured at a 1:10 ratio. Both adherent cell 
lines were detached from the culture flask by using Trypsin-EDTA. The suspension cell line 
CTLL-2 was cultured in IMDM CTLL-2 medium (see section 2.1.11).  Cultures were 
maintained at a density of 1x105 to 1x106 cells/ml by replacement of medium every 2-3 days. 
All cell lines were kept in an incubator at 5.9% CO2 and 37°C.  
 
2.2.2.2 Primary single cell suspensions 
Primary cells were isolated from murine spleen, LN, BM, liver and thymus by squeezing the 
tissue through a 100µm cell strainer with a syringe plunger. Erythrocytes were removed from 
cell suspensions using 1x lysing buffer (BD, Franklin Lakes, New Jersey, USA). Cells were 
washed with PBS before further use.     
 
2.2.2.3 Primary murine HSC / HPC culture 
Primary hematopoietic stem cells (HSC)/hematopoietic progenitor cells (HPC) were isolated 
from tibias and femurs of B6 SJL mice (see section 2.2.2.2). After lysis and washing, BM 
cells were depleted of lineage-committed cells using a Lineage Cell Depletion Kit (Miltenyi 
Biotec, Bergisch Gladbach, Germany) according to the manufacturer’s instructions. Enriched 
lineage negative cells were resuspended in StemSpan SFEM complete at a density of 1x106 
cells per ml (see section 2.1.11). 
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2.2.2.4 Primary murine OT-1 T-cell culture 
Primary murine mononuclear cells were isolated from spleen and LNs of OT-1 mice as 
described before (see section 2.2.2.2). After washing with PBS, cells were resuspended in 
RPMI mouse special medium (see section 2.1.11) at a density of 2.5x106 cells per ml. 
Medium was additionally supplemented with ovalbumin (OVA) peptide (257-264) (10ng/ml) 
and IL-2 (10U/ml). 
  
2.2.2.5 Flow Cytometry 
Fluorescence activated cell sorting (FACS) was performed to either sort specific cell 
populations or analyze extra- and intracellular marker expression. Typically, 1-3x107 cells 
were used for cell sorting and 0.5-1x106 cells for flow cytometric analysis. For extracellular 
staining, 1x106 cells were resuspended in 100µl PBS with 1µl FcR Blocking Reagent and 
0.05-0.5ug antibody. Samples were incubated in the dark for 15min and washed twice with 
PBS. Cells were analyzed or sorted in PBS with 2% FCS and at a density of 1x107 per ml. 
For intracellular staining, 1x106 cells were treated with the Fix&Perm Cell Permeabilization 
Kit (Life Technologies, Darmstadt, Germany) following the manufacturer’s protocol.  
For intracellular staining of phosphorylated protein, 1-2x106 cells were resuspended in 1x 
pre-warmed lyse/fix buffer (BD, Franklin Lakes, New Jersey, USA) and incubated at 37°C 
for 10min. Afterwards cells were washed with stain buffer (500ml PBS, 2,2ml sodium azide, 
15ml FCS). Cells were then incubated with Perm Buffer III (BD, Franklin Lakes, New Jersey, 
USA) on ice for 30min. Subsequently cells were washed twice with stain buffer and then 
stained with 5µl phospho-antibody. After another 30min of incubation, cells were washed 
once with stain buffer before analysis.   
Antibodies used for FACS staining are shown in Table 2-1. Flow cytometric analysis was 
performed on a MACSQuant Analyzer (Miltenyi Biotec, Bergisch Gladbach, Germany) and 
cell sorting on a BD FACSAria II (BD, Franklin Lakes, New Jersey, USA).  
 
2.2.2.6 Retroviral vector production 
For production of replication-defective retroviral vectors, a split packaging approach was 
followed. Genes encoding for the gene of interest, envelope proteins (Env) and structural and 
enzymatic proteins (Gag/Pol) were kept on separate plasmids. Only the plasmid encoding the 
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gene of interest contained the packaging signal Ψ that allowed packaging into the viral capsid 
during replication. Consequently, the produced retroviral vectors lacked Env and Gag/Pol 
genes that are necessary for further replication.      
One day before transfection, 5x106 cells of the packaging cell line HEK293T were seeded in 
a 10cm tissue culture dish. The following day, 75µM chloroquine was added to the medium 
and cells were transfected using a Calcium Phosphate Transfection Kit (Sigma-Aldrich, 
St.Louis, Missouri, USA). Therefore, 7.5µg transfer vector, 12.5µg packaging plasmid 
(Gag/Pol) and 1µg envelope (Env) plasmid in 450µl H2O were mixed with 50µl CaCl2 (2.5M) 
and added dropwise to 500µl 2x HEPES buffer while bubbling. The DNA mix was kept at 
room temperature for 20min and then added to the cells. After 6 hours of incubation the 
medium was replaced with 5ml DMEM complete medium. Supernatant was collected 24, 36 
and 48 hours after transfection, filtered through a 0.45µm syringe filter and stored at 4°C 
(short-term) or -20°C (long-term).     
 
2.2.2.7 Retroviral vector titration 
For titration of retroviral supernatants, 5x104 SC1 cells were seeded in a 24-well tissue 
culture treated plate. The next day, supernatant was added to the cells using dilutions from 
1:1 to 1:100. The culture plate was centrifuged at 2000rpm and 31°C for 1hour. Transduction 
efficiencies were determined by flow cytometry 2 days later. The viral titer per ml was 
calculated as follows: (Percentage of fluorescent cells/100) x number of seeded cells x 
dilution factor.  
 
2.2.2.8 Retroviral transduction on retronectin-coated plates 
Transduction of cell lines and primary cells was performed on retronectin-coated 6- or 24-
well plates. Therefore, 1ml (6-well) or 0.4ml (24-well) retronectin (50µg/ml) were added to 
each well and incubated at room temperature for 2 hours or at 4°C overnight. Afterwards, 
plates were blocked with 2% BSA in PBS at room temperature for 30min. Plates were 
washed once with 1x HBSS and once with PBS. Subsequently, 1-5ml retroviral supernatant 
was added to the treated wells and centrifuged at 3100rpm and 31°C for 90min. Supernatant 
was removed before adding cells to the wells. For transduction of HSCs/HPCs (see section 
2.2.2.3), 1x106 cells were added to each 24-well the day after cell isolation. These cells were 
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only transduced once. OVA-stimulated OT-1 T cells (see section 2.2.2.4) were transduced in 
3ml medium on a retronectin-coated 6-well plate at a density of 1.5x106 cells per ml. 
Transduction was repeated 24 hours after the first transduction. For transduction of the 
murine cell line CTLL-2, 3ml cell suspension was added to a coated 6-well plate at a density 
of 2x105 cells per ml.  
 
2.2.3 Animals experiments 
2.2.3.1 Animal use 
Laboratory mice were kept in the animal facility of the Georg-Speyer-Haus (Frankfurt am 
Main) in individually ventilated cages (IVC). All animal use was approved by the regional 
authority (Regierungspräsidium, Darmstadt, Germany/Tierversuchsnummer: F21/03; 
FK/1050), and animals were maintained and killed in accordance with the guidelines of the 
Federation of European Laboratory Animal Science Associations (FELASA).  
 
2.2.3.2 Transplantation of HSCs/HPCs 
After isolation (see section 2.2.2.3) and transduction (see section 2.2.2.8) of HSCs/HPCs, 
cells were analyzed for transduction efficiency and HSC/HPC marker expression (Sca-1, c-
Kit) before transplantation into recipient mice. C57BL6 (CD45.2) recipient mice were 
irradiated with a split dose of 5.5Gy each, with 24 hours between doses, using a BIOBEAM 
2000 Cs-137 chloride gamma irradiator (Eckert & Ziegler, Berlin, Germany). One hour after 
the last dose, 1x106 cells were transplanted into each recipient mouse. 
 
2.2.3.3 Transplantation of OT-1 T cells  
After isolation (see section 2.2.2.4) and two rounds of transduction (see section 2.2.2.8), OT-
1 T cells were analyzed for transduction efficiency and lymphocyte marker expression (CD3, 
CD4, CD8, CD19, Vα2 TCR, Vβ5 TCR). Afterwards, 5x106 cells were injected intravenously 
into each RAG1-/- recipient.  
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2.2.3.4 Blood collection from mice 
Blood samples were taken from recipient mice of transduced HSCs/HPCs or OT-1 T cells to 
monitor for repopulation and lymphoma/leukemia development. Therefore, the lateral tail 
vein was gently nicked with a clean scalpel and 25-100µl blood were collected using EDTA-
coated microvettes (Sarstedt, Nümbrecht, Germany). Blood samples were prepared for flow 
cytometric analysis by lysing erythrocytes using 1x lysing buffer (BD, Franklin Lakes, New 
Jersey, USA).  
 
2.2.3.5 In vivo proliferation assay 
To analyze proliferation of OT-1 T cells upon OVA stimulation in vivo, freshly isolated OT-
1 splenocytes (CD45.2) were stained with CellTrace Violet (Life Technologies, Darmstadt, 
Germany) according to the manufacturer’s protocol and 1x106 cells transplanted into B6 SJL 
(CD45.1) mice. After transplantation, mice were injected with 25µg OVA/IFA or PBS/IFA 
(see section 2.2.3.6). Two and five days later mice were sacrificed. Single cell suspensions of 
the spleen were stained with CD3 and CD45.2 and analyzed by flow cytometry. 
 
2.2.3.6 Stimulation of OT-1 T-cell recipient mice 
For specific OT-1 T-cell stimulation, OT-1 T-cell recipient mice (see section 2.2.3.2) were 
injected intraperitoneally (i.p.) with 25µg OVA (257-264) in PBS mixed in a 1:1 ratio with 
incomplete Freund’s adjuvant (IFA) every two weeks. Control mice received PBS/IFA (1:1) 
injections.   
 
2.2.3.7 Necropsy of mice 
Mice were anesthetized with isoflurane prior to euthanasia by cervical dislocation. The 
thoracic cavity was opened immediately afterwards to allow blood collection via cardiac 
puncture. The mouse abdomen was opened through midline incisions of the skin and 
peritoneum. The organs were examined for macroscopic abnormalities. Spleen, liver, lung, 
LNs (inguinal, axillary, mesenteric), kidney, femur and tibia were isolated for flow 
cytometric and/or histological analysis.  
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2.2.3.8 Histological analysis 
For histological analysis, organs were fixed in 4% formaldehyde solution overnight. Fixed 
tissue was then placed into embedding cassettes, dehydrated and finally embedded in 
paraffin. Paraffin blocks were cut with a microtome into 5-10µm thick sections. Sections 
were stained with hematoxylin/eosin (HE) and TCL1A. Sample processing and staining was 
done in the Senckenberg Institute of Pathology, Frankfurt am Main, Germany.  Histological 
examination was performed by Prof. Dr. Dr. h.c. Martin-Leo Hansmann and Dr. Sylvia 
Hartmann. 
 
2.2.3.9 Bioluminescence Imaging  
In vivo imaging was performed for recipient mice of OT-1 T cells transduced with luciferase 
vectors four weeks after transplantation and repeated every four weeks. Therefore, mice were 
placed in a XGI-8 anesthesia system (PerkinElmer, Waltham, Massachusetts, USA) flooded 
with isoflurane gas. Anesthetized mice were shaved and injected i.p. with 150µl D-Luciferin 
(15mg/ml). Mice were then moved to the IVIS Imaging System Lumina II (PerkinElmer, 
Waltham, Massachusetts, USA) and imaged 10min after i.p. injection of D-Luciferin. Images 
were taken in ventro-dorsal and latero-lateral position and acquired after an exposure time of 
2 and 5 minutes using binning 4. Signal intensity was quantified as average radiance of 
photons emitted per second and area (p/s/cm²/sr) within a region of interest (ROI) using the 
Living Image Software 4.0 (PerkinElmer, Waltham, Massachusetts, USA).  
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3. Results 
Syngeneic mouse models using genetically manipulated grafts, offer a valuable method to 
study and compare cellular transformation in vivo. Therefore, a transplantation model 
established by Newrzela et al using gamma retroviral vectors to introduce oncogenes into 
HSCs/HPCs and T cells (44) was utilized in this thesis to study oncogenic properties of TCL1 
family members (section 3.2.2) and variants (sections 3.2.3-3.2.6) in HSCs/HPCs, and the 
cooperation of TCL1 and TCR signaling in monoclonal T cells (section 3.3).   
 
3.1 Cloning of retroviral vectors and validation 
For retroviral gene transfer of the different TCL1 family members and variants, gamma-
retroviral vectors encoding human TCL1A, TML1, MTCP1, myr-TCL1A and nls-TCL1A 
were generated (Figure 3-1). Therefore, all cDNAs were cloned in front of the IRES of the 
previously described gamma retroviral vector MP91-EGFP using the restriction sites EcoRI 
and NotI (44). The cDNA of human TCL1A and variants were obtained from Michael Teitell, 
MD (UCLA, USA). The cDNAs of human MTCP1 and human TML1 were purchased from 
Life Technologies (Darmstadt, Germany) and Source BioScience (Nottingham, UK), 
respectively. MP91-EGFP was used as a control vector and referred to as “EGFP only” 
hereafter. For in vivo imaging experiments, EGFP was replaced with a firefly luciferase 
reporter and either T-Sapphire or human TCL1A were cloned in front of the IRES. Luciferase 
vectors were cloned and provided by Kerstin Cornils, PhD (University of Hamburg). Figure 
3-1 shows the design of retroviral vectors used in this thesis.  
Successful cloning of retroviral vectors was verified by sequence analysis (data not shown). 
Additionally, protein expression of our genes of interest was confirmed by Western Blot 
analysis (Figure 3-2). Comparison of the protein expression level induced by the different 
TCL1A variants showed that myr-TCL1 was slightly higher expressed than generic TCL1A 
and nls-TCL1A (Figure 3-2C).    
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Figure 3-1: Design of retroviral vectors  
cDNAs of human TCL1A, myr-TCL1A, nls-TCL1A, MTCP1 and TML1 were cloned into the gamma 
retroviral vector MP91-EGFP / MP91-Luc. LTR: long terminal repeats. IRES: internal ribosomal 
entry site. wPRE: Woodchuck hepatitis virus posttranscriptional regulatory element. 
 
 
Figure 3-2: Protein expression of transgenes 
Western blot analysis of transgene expression in SC-1 cells transduced with MTCP1 (A), TML1 (B), 
TCL1A and its variants myr-TCL1A and nls-TCL1A (C). 
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3.2 Targeted expression of TCL1 family members and variants in 
HSCs/HPCs 
 
3.2.1 Transgene expression in mice 
To introduce TCL1 family members and variants into HSCs/HPCs, BM cells from C57BL/6 
mice (CD45.1) were depleted of lineage-committed cells (Lin- BM cells), transduced and 
1x106 cells were then transplanted into C57BL/6 (CD45.2) recipient mice (Figure 3-3).   
 
 
Figure 3-3: Experimental design of the HSC/HPC transplantation model 
C57BL/6 (CD45.1) mice were used as donors for Lin- depleted BM cells. These isolated cells were 
retrovirally transduced and kept in culture for 2 days followed by transplantation into lethally 
irradiated C57BL6 (CD45.2) mice. Mice were monitored by blood sampling and analyzed after 
lymphoma/leukemia development.  
 
Before transplantation into mice, cells were analyzed for transduction efficiency (Figure 
3-4A). For all constructs, the HSC/HPC culture showed comparable transduction efficiencies 
(52-65%). To monitor repopulation of donor HSC/HPC-derived lymphocytes, blood samples 
were taken from recipient mice six weeks after transplantation and analyzed by flow 
cytometry. Blood samples were stained with the T-cell marker CD3 and the B-cell marker 
CD19. Transgene (EGFP) expressing T and B cells were detectable in the PB of recipient 
mice as shown in Figure 3-4B. 
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Figure 3-4: Transduction efficiency and repopulation of HSCs/HPCs 
(A) Percentage of EGFP+ cells within HSC/HPC transplants transduced with TCL1 family members 
(TCL1A, MTCP1, TML1) and TCL1A variants (myr-TCL1A, nls-TCL1A). (B) Blood samples from 
HSC/HPC recipient mice were analyzed by flow cytometry for EGFP expressing CD3+ T cells and 
CD19+ B cells six weeks after transplantation. Error bars represent SD. 
 
 
 
3.2.2 TCL1A and MTCP1 are oncogenes with similar oncogenic potential 
After transplantation of TCL1A, MTCP1, and TML1 transduced HSCs/HPCs, recipient mice 
developed lymphoid malignancies after latencies between seven and 18 months (Figure 3-5, 
Table 3-1). 
TCL1A HSC/HPC recipient mice developed lymphoma / leukemia after a median latency of 
388 days (Figure 3-5). These mice showed an enlarged liver and spleen as well as enlarged 
mesenteric, inguinal, and/or axillary LNs (Table 3-1, Figure 3-7). All TCL1A mice displayed 
a leukemic WBC higher than 15x106 cells per µl peripheral blood (Table 3-1). 
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Figure 3-5: Survival of TCL1 family mice  
Animals that received human TCL1A (A), MTCP1 (B) and TML1 (C) transduced HSCs/HPCs 
developed lymphoma/leukemia after indicated latencies (black solid line, A-C). Control animals 
(EGFP only) did not show any signs of disease during the observation time (grey dotted line, A-C). 
 
The phenotype of these tumors was determined by flow cytometric analysis, staining for the 
basic lymphocyte markers CD3, CD4, CD8, and CD19. Additionally, the leukocyte markers 
CD45.1 and CD45.2 were analyzed to differentiate between recipient-derived (CD45.2) and 
donor-derived (CD45.1) cells. All tumor cells isolated from TCL1A recipient mice were 
positive for CD19 and CD45.1. This B-cell phenotype was further characterized using the 
following markers: CD5, IgM, CD21/35, B220, and CD138 (Table 3-2). The tumor cells did 
not express the plasma cell marker CD138 and the splenic marginal zone B-cell markers 
CD21/35. Positive staining was observed for B220 and surface IgM. Tumor cells in most 
mice expressed CD5 as well (Table 3-2).   
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Table 3-1: Phenotypes and WBC of tumors induced by TCL1 family genes 
DP=double positive.  
 
 
Figure 3-6: Flow cytometric analysis of tumors induced by TCL1 family genes 
Representative FACS plots of analyzed B-cell tumors (A) and T-cell tumors (B) gated on EGFP 
positive cells. 
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MTCP1 HSC/HPC recipient mice developed lymphoma/leukemia after a median latency of 
394 days (Figure 3-5). Similar to TCL1A recipient mice, mice developed mostly B-cell 
malignancies (CD19+, B220+, IgM+, CD5-) with elevated WBC and enlarged liver, spleen and 
LNs (Table 3-1). Only one recipient showed an enlarged thymus with a CD3+ and CD4/CD8 
DP phenotype.   
Only two out of 14 TML1 recipient mice developed lymphoma/leukemia, becoming overt 
at223 and 371 days after transplantation (Figure 3-5). Therefore, no median survival was 
reached. The diseased mice displayed enlarged thymi with a CD4/8 DP phenotype, and 
varying CD3+ and TCRαβ+ expression  (Table 3-1, Figure 3-6B). 
 
Table 3-2: Phenotype of B-cell tumors induced by TCL1 family members 
 
Sick mice with B-cell malignancies presented with variable hepatomegaly, splenomegaly and 
lymphadenopathy. Round lymphoblasts with scant cytoplasm were visible in spleen, LN, and 
liver (Figure 3-7A,B), and were also abundant in blood (Figure 3-8A). Additionally, 
macroscopic lesions and microscopic infiltrations were often visible in lung and kidney of 
mice with B-cell malignancies (not shown). Mice with immature T-cell malignancies showed 
enlarged thymi and mostly no other macroscopic visible abnormalities (Figure 3-7C). Tumor 
cells had a round lymphoblastoid morphology in thymus (Figure 3-7C) and blood (Figure 
3-8B), similar to the one seen in B-cell tumors. 
TCL1A-induced tumors were further analyzed for expression of TCL1A by flow cytometry 
(Figure 3-9A) and by immunohistochemical stainings (Figure 3-9B). All tumors expressed 
TCL1A and signals were observed in the cytoplasmic and nuclear compartments (Figure 
3-9B). A representative plot/image is shown in Figure 3-10.  
Oncogene CD19 B220 IgM CD5 CD138 CD21/35 
TCL1A 5/5 5/5 5/5 4/5 0/5 0/5 
MTCP1 4/4 4/4 3/4 0/4 0/4 0/4 
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Figure 3-7: Gross-anatomic and histological features of B-cell and immature T-cell malignancies 
induced by TCL1 family genes  
Representative macroscopic images and H&E stained histological sections of animals with B-cell 
malignancies showing enlarged spleens, LNs (A) (original magnification 20x) and livers (B) (original 
magnification 10x); and animals with immature T-cell malignancies showing enlarged thymi (C) 
(original magnification 20x). Scale bar: 20µm.  
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Figure 3-8: Cytological features in blood smears of TCL1A recipient mice upon tumor development 
Representative blood smears of animals with B-cell malignancies (A) and with immature T-cell 
malignancies (B). Original magnification: 40x. Scale bar: 20µm.  
 
 
 
Figure 3-9: TCL1A expression in TCL1A-induced tumors  
Intracellular TCL1A staining of the blood gated on EGFP+ cells (black line) and EGFP- cells (grey 
line) (A). Representative immunohistochemical staining for TCL1A of tumor bearing LN (original 
magnification: 20x, scale bar: 20µm) (B). 
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3.2.3 Targeted expression of TCL1A to the membrane and the nucleus 
Engagement of the TCR in T-PLL cells leads to TCL1A recruitment to the cell membrane 
and later to the nucleus (22). The changing localization of TCL1A during TCR signaling 
suggests that the protein participates in this process by interacting with different proteins 
along the signaling cascade. To address the functional impact of TCL1A localization on its 
oncogenic potential, retroviral vectors containing modified TCL1A transgenes were used to 
target protein expression to the membrane (myr-TCL1A) or the nucleus (nls-TCL1A).  
 
Figure 3-10: TCL1A protein localization in HEK293T cells after transduction with different 
TCL1A variants  
Fluorescence microscopy on TCL1A (second row), myr-TCL1A (third row) and nls-TCL1A (fourth 
row) transduced HEK293T cells. Non-transduced HEK293T cells were used as a negative control 
(first row). Staining was done using DAPI (blue, left column) and anti-TCL1A (green, middle column). 
Merged pictures are shown in the right column. 
           nls-TCL1A 
DAPI TCL1 TCL1 DAPI 
    TCL1A 
DAPI TCL1 DAPI TCL1 
DAPI TCL1 DAPI TCL1 
      myr-TCL1A 
Untransduced 
DAPI TCL1 DAPI TCL1 
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For membrane localization, a DNA sequence for an N-terminal myristoylation signal was 
added to the transgene sequence. This signal allows cotranslational modification resulting in 
the attachment of a myristic acid to the N-terminus of TCL1A (myr-TCL1A). Myristic acid is 
hydrophobic and anchors the protein into the lipid bilayer of the cell’s membrane. For nuclear 
localization, a DNA sequence for an N-terminal nuclear localization signal (nls) was added to 
the transgene sequence. This peptide motif tags the protein for traffic through nuclear pores 
into the nucleus. To validate targeted TCL1A expression, HEK293T cells were transduced 
with retroviral vectors for TCL1A, myr-TCL1A and nls-TCL1A, and analyzed by 
fluorescence microscopy for TCL1A expression (Figure 3-10). For this analysis, HEK293T 
cells were chosen as their larger size allowed studying protein distribution in cellular 
compartments. HEK293T cells expressing the generic TCL1A showed an even distribution of 
the protein in the cytoplasm and nucleus (Figure 3-10, second row). Myr-TCL1A expressing 
cells showed condensed protein localization at the membrane (Figure 3-10, third row). A 
nuclear accumulation of TCL1A was observed for nls-TCL1A transduced HEK293T cells 
(Figure 3-10, fourth row). Therefore, targeted expression of TCL1A to the membrane and 
nucleus with myr-TCL1A and nls-TCL1A was validated.  
 
3.2.4 Localization of TCL1A influences its oncogenic potential 
Transplantation of myr-TCL1A and nls-TCL1A transduced HSCs/HPCs resulted in 
lymphoma/leukemia development in recipient mice after latencies between five and 20 
months. Survival was compared to the previously described cohort of generic TCL1A 
recipient mice (see section 3.2.2). TCL1A HSC/HPC recipient mice developed 
lymphoma/leukemia after a median latency of 388 days. Similarly, myr-TCL1A recipient 
mice had a median survival of 372 days (Figure 3-11A). However, survival was significantly 
reduced in nls-TCL1A recipients compared to recipient mice of TCL1A HSCs/HPCs with a 
median latency of 349 days (Figure 3-11B). Despite a reduced latency in nls-TCL1A mice, 
no striking difference in phenotype was observed between tumors induced by the generic 
TCL1A and its variants. Similar to TCL1A-induced tumors, most myr-TCL1A and nls-
TCL1A mice developed tumors with a B-cell phenotype and presented with enlarged liver, 
spleen and LNs (Table 3-3). The remaining mice, showed enlarged thymi with a DP or DN T-
cell phenotype (Table 3-3). An elevated WBC (>15x106 cells/µl blood) was detected in the 
majority of myr-TCL1A and nls-TCL1A recipient mice upon tumor development (Table 3-3). 
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Flow cytometric analysis of B-cell tumors induced by myr-TCL1A and nls-TCL1A showed 
expression of CD19, surface IgM, and B220, except for one nls-TCL1A tumor that lacked 
surface IgM expression (Table 3-4). None of the B-cell tumors expressed CD138 or CD21/35 
(Table 3-4). CD5 expression was only detected in half of the tumors induced by myr-TCL1A 
tumors and nls-TCL1A, whereas most tumors derived from overexpression of generic 
TCL1A expressed this marker (Table 3-4). A representative flow cytometric analysis is 
shown in Figure 3-6A. 
 
Figure 3-11: Survival of TCL1A variants mice 
Animals that received TCL1A variants myr-TCLA (A) and nls-TCL1A (B) transduced HSCs/HPCs 
developed lymphoma/leukemia after indicated latencies (blue solid line, A-B). Survival of the 
previously described recipient mice of generic TCL1A is shown as black solid line in each graph. 
Control animals (EGFP only) did not show any signs of disease during the observation time (grey 
dotted line, A-B). 
 
Myr-TCL1A and nls-TCL1A HSC/HPC recipient mice that developed T-cell malignancies 
displayed enlarged thymi with a CD4/8 DP phenotype and varying expression of CD3 and 
TCRαβ. A representative flow-cytometric analyses is shown in Figure 3-6B. Only one T-cell 
tumor induced by myr-TCL1A was negative for CD4 and CD8 expression (CD4/8 DN) 
(Table 3-3), but showed TCRαβ+ expression (data not shown).  
Representative images of macroscopic and histological/cytological analyses of B- and T-cell 
malignancies are shown in Figure 3-7 and Figure 3-8, as they had the same cytomorphologic 
features as tumors induced by non-compartment targeted TCL1A overexpression.  
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Table 3-3: Phenotype of tumors induced by TCL1A variants 
 
 
Table 3-4: Phenotype of B-cell tumors induced by TCL1A variants 
 
 
Oncogene Gross-anatomic features 
Elevated PB 
leukocyte count 
(15x106 cells/µl) 
CD4/8 
DP 
CD4/8 
DN 
CD19 
TCL1A 
Hepatomegaly, 
Splenomegaly, 
Lymphadenopathy. 
5/5 0/5 0/5 5/5 
myr-TCL1A 
Thymoma (CD4/8DP). 
Hepatomegaly, 
Splenomegaly, 
Lymphadenopathy (CD19). 
13/16 3/16 1/16 12/16 
nls-TCL1A 
Thymoma (CD4/8DP). 
Hepatomegaly, 
Splenomegaly, 
Lymphadenopathy (CD19). 
12/15 2/15 0/15 13/15 
 
Oncogene CD19 B220 IgM CD5 CD138 CD21/35 
TCL1A 5/5 5/5 5/5 4/5 0/5 0/5 
myr-TCL1A 12/12 12/12 12/12 6/12 0/12 0/12 
nls-TCL1A 13/13 13/13 12/13 5/13 0/13 0/13 
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3.2.5 The primary oncogenic function of TCL1A depends on its nuclear presence 
A comparative gene expression analysis of the TCL1A variants was performed to identify 
differently expressed genes in target cells at overt leukemic phases. These analyses were 
performed on an Affymetrix Mouse Gene 1.0 ST Array, whose 764885 probes cover a total 
of murine 28869 genes. Differently expressed genes were filtered using a fold-change of 2 
(up and down) and an ANOVA p-value lower than 0.05.  
For tumor cell analysis, cell suspensions from spleens of mice with B-cell malignancies were 
used with at least 70% tumor cell content. Gene expression profiles of tumor samples from 
TCL1A, myr-TCL1A and nls-TCL1A recipient mice were compared to CD19+EGFP+ B cells 
sorted from spleen and LNs of EGFP only control mice 100 days after transplantation (Figure 
3-12).  
Figure 3-12: Differently expressed genes in TCL1A-, myr-TCL1A- and nls-TCL1A-induced tumors 
compared to control B cells 
Volcano plots of up-regulated (red) and down-regulated (green) genes with a fold change (FCh) of 2. 
Genes in grey did not match the filter criteria (FCh>2, P<0.05) and were excluded from further 
analysis.  
 
A pathway enrichment analysis was performed to characterize the functional role of 
differently expressed genes. There was a large overlap within the ten most affected pathways 
in TCL1A-, myr-TCL1A-, and nls-TCL1A-induced tumors including chemokine, cell cycle, 
PI3K/AKT, p53, and MAPK signaling pathways (Figure 3-13). Interestingly, a lot of 
receptor-induced signaling pathways were deregulated in these tumors involving the BCR, 
cytokine receptors, chemokine, and other G protein–coupled receptors (GPCRs). A list of 
genes that are up-regulated or down-regulated in at least two of three cohorts are shown in 
Table 5-1 in the supplementary section 5.3.  
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Figure 3-13: Top 10 pathways affected in TCL1A-, myr-TCL1A- and nls-TCL1A-induced tumors 
compared to control B cells 
Pathway enrichment analysis of differently expressed genes in TCL1A- (A), myr-TCL1A- (B), and nls-
TCL1A-induced (C) tumors compared to control B cells. 
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Next, the relation of compartment-targeting variants of TCL1A to unmodified TCL1A was 
characterized. The numbers of overlapping genes that are differently expressed in the three 
TCL1A cohorts are shown in Figure 3-14. The largest overlap was observed between the 
generic TCL1A and its nuclear variant nls-TCL1A. 
 
 
 
Figure 3-14: Overlap of differently expressed genes in TCL1A-, myr-TCL1A- and nls-TCL1A- 
induced tumors 
Venn diagram showing the number of differently expressed genes in B-cell tumors induced by TCL1A, 
myr-TCL1A and nls-TCL1A. 
 
This overlap was further supported by a pathway enrichment analysis of deregulated genes in 
TCL1A-induced tumors compared to tumors induced by myr-TCL1A and nls-TCL1A (Figure 
3-15). There was no significant enrichment within the top ten pathways between tumors of 
TCL1A and nls-TCL1A recipient mice.  
Noteworthy is also the more than 2-fold down-regulation of the TCL1 family gene Mtcp1 in 
TCL1A-induced tumors (data not shown). Expression of the murine TML1 isoforms was not 
affected. 
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Figure 3-15: Top 10 pathways affected in tumors induced by TCL1A compared to tumors induced 
by compartment-targeting TCL1A variants 
Pathway enrichment analysis of differently expressed genes in TCL1A-induced tumors compared to 
myr-TCL1A-induced tumors (A) and nls-TCL1A-induced tumors (B). 
 
3.2.6 TCL1A-induced changes in gene expression are more prominent in B cells than 
in T cells at pre-leukemic stages  
To characterize TCL1A-induced changes in gene expression of lymphocytes at pre-leukemic 
phases, CD19+ EGFP+ B and CD3+ EGFP+ T cells were sorted from spleen and LNs of EGFP 
only, TCL1A, myr-TCL1A and nls-TCL1A HSC/HPC mice 100 days after transplantation. 
This time point was chosen based on tumor latencies that showed that the earliest tumor arose 
131 days after transplantation (Figure 3-11). Analyses were performed on the previously 
described Affymetrix Mouse Gene 1.0 ST Array. Due to the low number of differently 
expressed genes in T cells, results were filtered using a fold-change of 1.5 (up and down) and 
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an ANOVA p-value lower than 0.05. Gene expression in sorted B and T cells from TCL1A, 
myr-TCL1A and nls-TCL1A recipient mice, was compared to sorted B and T cells from 
EGFP only control mice (Figure 3-16). Interestingly, a significant higher number of genes 
were differently expressed in B cells (more than 400 genes per cohort) than in T cells (less 
than 400 genes per cohort) at the pre-leukemic phase (Figure 3-16).  
 
Figure 3-16: Differently expressed genes in TCL1A, myr-TCL1A and nls-TCL1A expressing B and 
T cells compared to control cells 
Volcano plots of up-regulated (red) and down-regulated (green) genes with a fold change (FCh) of 
1.5. Genes in grey did not match the filter criteria (FCh>1.5, P<0.05) and were excluded from 
further analysis.  
 
To further classify the functional role of differently expressed genes, a pathway enrichment 
analysis was performed. Genes involved in chemokine, PI3K/AKT, and MAPK signaling 
pathways were differently expressed in pre-leukemic B and T cells (Figure 3-17, Figure 3-18). 
Additionally, pre-leukemic B cells showed a deregulation of genes involved in cell cycle and 
p53 signaling. A list of genes that are up-regulated or down-regulated in pre-leukemic B and 
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T cells from at least two of three cohorts are shown in Table 5-2 and Table 5-3 in the 
supplementary section 5.3. 
 
Figure 3-17: Top 10 pathways affected in TCL1A, myr-TCL1A and nls-TCL1A pre-leukemic B 
cells compared to control B cells 
Pathway Enrichment Analysis of differently expressed genes in TCL1A (A), myr-TCL1A (B) and nls-
TCL1A (C) B cells 100 days after transplantation compared to control B cells. 
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Figure 3-18: Top 10 pathways affected in TCL1A, myr-TCL1A and nls-TCL1A pre-leukemic T 
cells compared to control T cells 
Pathway Enrichment Analysis of differently expressed genes in TCL1A (A), myr-TCL1A (B) and nls-
TCL1A (C) T cells 100 days after transplantation compared to control T cells. 
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The numbers of overlapping genes that are differently expressed in pre-leukemic B and T 
cells of the three TCL1A cohorts are shown in Figure 3-19 to study the relation of different 
TCL1A variants. In pre-leukemic B cells, the biggest overlap was observed between B cells 
expressing the generic TCL1A and B cells expressing myr-TCL1A (Figure 3-19A). In T cells, 
the biggest overlap was found in T cells expressing myr-TCL1A and T cells expressing nls-
TCL1A (Figure 3-19B).  
Similar to the gene expression in TCL1A B cells at the tumor stage, day 100 B cells showed a 
1.5-fold down-regulation of a TCL1 family member, in this case Tcl1b4 (data not shown).  
 
 
Figure 3-19: Overlap of differently expressed genes in TCL1A, myr-TCL1A and nls-TCL1A B and 
T cells 
Venn diagrams showing the number of differently expressed genes in pre-leukemic B cells (A) and T 
cells (B) of TCL1A, myr-TCL1A and nls-TCL1A HSC/HPC recipient mice. 
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3.3 Targeted expression of TCL1A variants in monoclonal T cells 
 
3.3.1 Specific TCR stimulation in vivo 
For the second aim of this thesis, the chimeric model was modified using transplanted T cells 
as target cells instead of reconstitution by HSCs/HPCs. Single cell suspensions from spleens 
and LNs of OT-1 transgenic TCR mice were retrovirally transduced with TCL1A and its 
variants myr-TCL1A and nls-TCL1A. Subsequently, 5x106 transduced cells were 
transplanted into RAG1-/- recipient mice (no irradiation) that lack mature T and B cells 
(Figure 3-20). CD8 T cells from OT-1 mice exclusively express a monoclonal TCR that 
specifically recognizes the OVA peptide (amino acids 257-264) and is composed of a 
Valpha2 (Vα2) and a Vbeta5 (Vβ5) chain. Therefore, the TCR of transgenic OT-1 T cells can 
be stimulated specifically, which allows to study the impact of chronic TCR engagement on 
TCL1A-driven transformation. In the presented model, TCR stimulation was initiated by 
injecting recipient mice i.p. with OVA (257-264) in PBS mixed with the adjuvant IFA every 
two weeks. This mix was prepared to generate water-in-oil emulsions that serve as antigen 
depots at the injections site. Control mice were injected with a PBS/IFA mix.  
 
Figure 3-20: Experimental design of the T-cell transplantation model 
TCR transgenic (tg) OT-1 mice were used as donors for mature T cells. These cells were retrovirally 
transduced and kept in culture for 3 days followed by transplantation into RAG1-/- recipient mice. 
Every two weeks, mice were injected with an OVA/IFA or PBS/IFA mix. Mice were monitored by 
blood sampling and analyzed after lymphoma/leukemia development.  
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Before using OVA/IFA injections in the described transplantation model, the responsiveness 
of OT-1 T cells to OVA stimulation was first analyzed in vivo. For that, OT-1 splenocytes 
(CD45.2) were stained with the proliferation marker CellTrace Violet and transplanted into 
B6 SJL WT (CD45.1) mice. WT mice were used as recipients for this experiment instead of 
RAG1-/- mice, as T cells undergo spontaneous proliferation in lymphopenic mice without the 
presence of a TCR stimulus, thereby not allowing to study the effect induced by the injection 
of OVA. After transplantation, mice were injected with OVA/IFA or PBS/IFA. Spleen 
suspensions were analyzed two and five days after transplantation for proliferation within the 
donor cell population (CD45.2+, CD3+) (Figure 3-21). Donor splenocytes in OVA/IFA-
injected mice showed distinct inductions of proliferation after two days, whereas donor 
splenocytes in PBS/IFA-injected mice did not show any proliferative activity at this time 
point (Figure 3-21, left panel). After five days, the CellTrace Violet fluorescent signal had 
mostly disappeared within the high proliferating donor cell population of OVA stimulated 
mice, but was still detectable in slow proliferating donor cells of PBS control mice (Figure 
3-21, right panel). OT-1 T cells responded to OVA/IFA injections and were thus applicable 
for chronic TCR engagement in the T-cell transplantation model. 
 
Figure 3-21: Proliferation of OT-1 T cells in vivo 
B6 SJL WT mice were injected with PBS/IFA (w/o stim) or PBS/OVA (OVA stim) after transplantation 
of CellTrace Violet stained OT-1 splenocytes. Mice were sacrificed two and five days later. Spleen 
suspensions were analyzed by flow cytometry for CellTrace labeled generations of proliferating, 
donor derived (CD45.2, CD3) OT-1 T cells.  
w/o stim  
OVA stim 
Cell Trace Violet 
(gated on CD45.2 and CD3) 
Ev
en
ts
 
2 days after injection 5 days after injection 
 80 
Next, the transplantation model as shown in Figure 3-20 was set up. Phenotype and 
transduction efficiency of OT-1 T-cell cultures were analyzed by flow cytometry before 
transplantation into recipient mice (Figure 3-22A). All retrovirally transferred constructs 
showed comparable transduction efficiencies (35-50%). Phenotypically, transgenic CD8+ 
Vα2/Vβ5 DP T cells made up >95% of the cells in this culture. The remaining cells were 
comprised of CD19+ B cells (<4%) and CD4+ T cells (<1%). 
Figure 3-22: Transduction efficiency and repopulation of OT-1 T cells 
(A) Percentage of EGFP+ T cells transduced with TCL1A variants (TCL1A, myr-TCL1A, nls-TCL1A). 
(B) Blood samples from OT-1 T cells recipient mice were analyzed by flow cytometry for EGFP 
expressing T cell populations (CD3+, CD4+, CD8+ and Vα2/Vβ5 DP) and CD19+ B cells two weeks 
after transplantation. Error bars represent SD. 
 
To monitor repopulation of OT-1 T cells, blood samples were drawn from recipient mice two 
weeks after transplantation and analyzed by flow cytometry. Blood samples were stained 
with the B-cell marker CD19, transgenic TCR markers Vα2 and Vβ5, as well as the T-cell 
markers CD3, CD4, and CD8. CD8 and Vα2/Vβ5 DP T cells accounted for around 98% of 
the transgenic (EGFP+) lymphocytes in PB (Figure 3-22B). CD19+ B cells and CD4+ T cells 
made up less than 2% of the EGFP+ population. Blood analysis was repeated every four 
weeks until mice developed lymphoma/leukemia (Figure 3-23).  
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Figure 3-23: Monitoring of transduced OT-1 T cells in the PB over time   
Blood samples were taken from unstimulated (green, w/o stim) and stimulated (red, OVA stim) EGFP 
only (circle) and TCL1A (triangle) OT-1 T-cell recipient mice every four weeks and analyzed by flow 
cytometry. Mean percentage of CD3+ cells gated on live cells (top left), EGFP+ cells gated on CD3+ 
cells (top right), CD8+ (middle left), CD4+ (middle right) and CD4/8 DP (bottom left) cells gated on 
CD3+ and EGFP+ cells was compared between different cohorts throughout the whole observation 
time. Experiment was started with five mice per group. Symbols represent mean values and error bars 
represent SD.  
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In OVA stimulated EGFP and TCL1A cohorts, the percentage of CD3+ T cells dropped 
within the first 12 weeks after the first injection (Figure 3-23). Interestingly, stimulated 
TCL1A mice showed an increase of CD3 percentage after the initial decline, whereas in 
stimulated EGFP only mice this percentage remained low until the end of the experiment.  
The percentage of transgene/EGFP expressing cells within the CD3+ population of these two 
cohorts rose almost to up to 100% in TCL1A recipients and to 80% in EGFP control mice. 
Surprisingly, unstimulated TCL1A showed a comparable increase in EGFP percentage as 
OVA stimulated EGFP mice. Although the initial transplant mainly consisted out of 
transgenic CD8 T cells, TCL1A cohorts also showed a significant decline of EGFP+ CD8 T 
cells and an increase of EGFP+ CD4 T cells instead (Figure 3-23). The percentage of CD19+ 
B cells in the PB was less than 5% throughout the entire observation time in all cohorts (data 
not shown). The blood analysis of TCL1A mice shown in Figure 3-23 is representative for its 
two variants myr-TCL1A and nls-TCL1A, as these groups show similar expression patterns 
in the PB during the experiment.  
To characterize the functional phenotype of OT-1 T cells in recipient mice, blood samples 
were further analyzed for the T-cell markers CD69, CCR7, CD62L and CD44 (see section 
1.1.2). Most TCL1A transduced T cells in OVA stimulated recipient mice showed a typical 
TEM profile as they expressed CD44, but lacked expression of CD69, CCR7, and CD62L 
(Figure 3-24). Only small subpopulations showed expression of CCR7, CD62L and CD69. 
Stimulated EGFP only transduced T cells showed the same expression pattern with the 
exception to CD62L, which was detected on almost half of the cells (Figure 3-24). The T 
cells of unstimulated EGFP only and TCL1A cohorts showed mostly a high expression of 
CD62L and CD44, while only a small population expressed CCR7 and CD69 expression was 
completely absent. Again, myr-TCL1A and nls-TCL1A expressing T cells showed a similar 
functional phenotype as TCL1A+ T cells shown in Figure 3-24. 
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Figure 3-24: Functional phenotype of transduced OT-1 T cells in the PB 
Flow cytometric analysis of EGFP+ cells in the PB of PBS/IFA (w/o stim) and OVA/IFA (OVA stim) 
injected OT-1 T-cell recipient mice 36 weeks after transplantation. Cells were gated on EGFP+ cells 
and analyzed for the expression of CCR7 and CD62L (left panel), and CD69 and CD44 (right panel) 
in EGFP only (top row) and TCL1A (bottom row) cohorts. FACS plots show mean percentage and SD 
of sub-gates of five analyzed animals.  
 
 
3.3.2 Stimulated TCL1A T cells accumulate in spleen and other abdominal regions 
Analysis of the PB showed that the percentage of CD3+ cells decreased upon TCR 
stimulation with OVA. Without sacrificing the mice, it was not possible to determine the 
localization of the transplanted T cells in other organs. Thus, a retroviral vector with a 
luciferase reporter was utilized to visualize T-cell localization by in vivo imaging (Figure 
3-1). The control vector contained a T-Sapphire reporter gene in addition to the luciferase 
reporter. The control vector and TCL1A vector were both transduced into OT-1 T cells with a 
comparable transduction efficiency of around 20% (data not shown). Twelve weeks after the 
first PBS or OVA injection, mice were analyzed by bioluminescence imaging (Figure 3-25). 
This analysis was done 10 days after the last injection. 
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Figure 3-25: Bioluminescence imaging of OT-1 T-cell mice 
Bioluminescence imaging of unstimulated (w/o stim) and stimulated (OVA stim) control and TCL1A 
OT-1 T-cell recipient mice. (A) For all images shown, the color scale for bioluminescence displayed 
as average radiance ranges from 5x104 (blue) to 1x106 (red) photons/s/cm2/sr. (B) For each group of 
mice, whole body bioluminescence signals were determined and shown as mean values of average 
radiance relative to the unstimulated control group. Error bars represent RSD. 
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The strongest whole body bioluminescence signals, expressed as average radiance, were 
detected in OVA stimulated mice (Figure 3-25). Relative to unstimulated control mice, this 
signal was approximately 60 times higher for stimulated TCL1A mice, 10 times higher for 
stimulated control mice, and 5 times higher for unstimulated TCL1A mice (Figure 3-25B). 
To narrow down the localization of transplanted cells, signals were determined for selected 
regions of interest (ROI) (Figure 3-26A). Average radiance for each ROI relative to the 
cervical LN of each cohort is shown in Figure 3-26B. In unstimulated control and TCL1A 
mice, the strongest signal was found in the abdominal regions and the spleen (Figure 3-26B). 
Based on the strong signal in the abdominal regions, it was not possible to narrow down the 
exact tissues involved; and an intestinal origin is a rather speculated site. Cervival, axillary, 
and inguinal LN showed an evenly distributed signal in these mice. In OVA stimulated 
cohorts, the signal was low in cervical and axillary LNs, but high in regions of the inguinal 
LNs, abdominal regions, and spleen (Figure 3-26B).  
 
Figure 3-26: Bioluminescence signals in selected regions of interest 
Bioluminescence imaging of unstimulated (w/o stim) and stimulated (OVA stim) control and TCL1A 
OT-1 T-cell recipient mice. (A) In ventro-dorsal position of the mouse, regions of interest (ROI) were 
drawn for the abdominal regions and cervical, axillary and inguinal LNs (left). In latero-lateral 
position, a ROI was drawn for the spleen (right). (B) For each group of mice, bioluminescence signals 
were determined for each ROI and shown as mean values of average radiance relative to its own 
cervival LN ROI. Error bars represent RSD. 
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3.3.3 Constant TCR stimulation facilitates TCL1A-driven transformation 
After transplantation of TCL1A, myr-TCL1A and nls-TCL1A transduced OT-1 T cells, 
PBS/IFA injected recipients developed lymphoid malignancies after latencies between 7 and 
20 months, whereas mice receiving OVA/IFA injections showed a significantly reduced 
survival between 6.5 and 13.5 months (Figure 3-27).  
 
Figure 3-27: Survival of OT-1 T-cell recipient mice 
Recipient mice of TCL1A (A), myr-TCL1A (B) and nls-TCL1A (C) transduced OT-1 T cells were 
injected with IFA/PBS (w/o stim, red dotted line) or IFA/OVA (OVA stim, red solid line) every two 
weeks and developed lymphoma/leukemia after significant different latencies. Control animals (EGFP 
only) that were treated with IFA/PBS (w/o stim, green dotted line) or IFA/OVA (OVA stim, green 
solid line) did not show any signs of disease during the observation time (A-C). 
 
Recipient mice of TCL1A transduced OT-1 T cells that were injected with PBS had a median 
survival of 417 days. Repeated stimulation of the OT-1 TCR through OVA injections, led to 
a significant reduction of the median survival to 305 days (Figure 3-27). The same was 
observed for stimulated and unstimulated recipient mice of myr-TCL1A and nls-TCL1A 
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variants. All groups presented with splenomegaly, variable enlargement of mesenteric, 
inguinal and/or axillary LNs, as well as leukemic WBC higher than 15x106 cells per µl blood 
(Table 3-5). The phenotype of these tumors was determined by flow cytometric analysis, 
staining for CD3, CD4, CD8, and CD19 (Table 3-5). Recipient mice of OT-1 T cells 
transduced with TCL1A variants developed mostly T-cell malignancies. Interestingly, a few 
mice of the unstimulated cohorts developed B-cell tumors.  
 
Table 3-5: Phenotype of tumors induced by TCL1A variants in OT-1 transplantation model 
+ = OVA stimulation, - = w/o stimulation 
 
 
 
 
 
Oncogene 
Gross-anatomic 
features 
Elevated PB 
leukocyte count 
(15x106 cells/µl) 
CD4/8 
DP 
CD4 
SP 
CD8 
SP 
CD19 
TCL1A 
+ 
Splenomegaly, 
Lymphadenopathy 
7/7 0/7 3/7 4/7 0/7 
- 
Splenomegaly, 
Lymphadenopathy 
6/6 1/6 3/6 0/6 2/6 
myr-
TCL1A 
+ 
Splenomegaly, 
Lymphadenopathy 
3/5 0/5 4/5 1/5 0/5 
- 
Splenomegaly, 
Lymphadenopathy 
3/9 1/9 4/9 2/9 2/9 
nls- 
TCL1A 
+ Splenomegaly, 
Lymphadenopathy 
2/3 0/3 3/3 0/3 0/3 
- 
Splenomegaly, 
Lymphadenopathy 
5/6 1/6 3/6 0/6 2/6 
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Figure 3-28: Histological and cytomorphological features of T- and B-cell malignancies induced 
by TCL1 family genes in OT-1 transplantation model 
Representative H&E stained histological sections of animals with T-cell (A) and B-cell (B) 
malignancies showing enlarged spleens and LNs (original magnification 20x), infiltrations in the liver 
(original magnification 10x) and PB. Scale bar: 20µm.  
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Liver 
PB 
Spleen LN 
Liver 
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Clinically apparent mice with T- and B-cell malignancies presented with variable 
splenomegaly and lymphadenopathy. Cytological analysis showed medium-sized lymphoid 
cells with scant basophilic cytoplasm in the blood of mice that developed tumors with a T-
cell phenotype (Figure 3-28A). These tumor cells also infiltrated the spleen, LNs, and liver 
(Figure 3-28A). B-cell tumors in this model showed round medium-sized lymphoid cells with 
a high nucleo-cytoplasmic ratio in the blood that appeared more mature than the ones seen in 
the HSC/HPC model (Figure 3-28B). These cells were also found in spleen, LNs, and liver 
(Figure 3-28B). Infiltrations in lung and kidney were often observed for both T- and B-cell 
tumor types (data not shown) 
LM-PCR analyses were performed using genomic DNA from tumor tissue to determine 
clonality of the T-cell tumors and to identify integration sites of retroviral vectors within the 
host cell genome. Tumors were classified based on the number of identified clones into 
monoclonal, oligoclonal, and polyclonal tumors. Figure 3-29 shows a typical pattern of 
monoclonal (1 band), oligoclonal (more than 1 band), and polyclonal samples (smear). The 
internal control for gammaretroviral vectors is visible as a 200bp band. Tumors of all cohorts 
showed a monoclonal or oligoclonal pattern, summarized in Table 3-6. 
 
Figure 3-29: LM-PCR Analysis of tumors 
Representative gel image for monoclonal (Lane 1 and 2), oligoclonal (Lane 3) and polyclonal (Lane 4, 
“smear”) band patterns. Tissue from EGFP control mice was used as an example for a polyclonal 
pattern. The 200bp band represents internal control (ç).     
 
Retroviral integration sites were further analyzed based on the genes that are found within a 
250kb distance up- and downstream of the integration site. Affected genes in tumors of 
unstimulated mice (Table 3-7) and OVA stimulated mice (Table 3-8) were functionally 
characterized using the PANTHER pathway classification system. Generally, there was no 
statistical overrepresentation of flanking genes involved in signaling pathways. However, 
similar signaling pathways were affected in the different tumor cohorts, e.g. CCKR signaling, 
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inflammation mediated by chemokine and cytokine signaling pathway, PI3 Kinase pathway, 
etc. A complete list of identified genes can be found in section 5.4. 
Table 3-6: Number of identified clones in T-cell tumors induced by TCL1 variants 
OVA stim: OVA/IFA injection, w/o stim: PBS/IFA injection. 
 
w/o stim TCL1 myr-TCL1A nls-TCL1A 
Distance to integration site 250kb (n=115) 
C 
(n=7) 
250kb 
(n=83) 
C 
(n=8) 
250kb 
(n=59) 
C 
(n=5) 
Alzheimer disease-presenilin 
pathway - - 1 (1.2) - - - 
Angiogenesis 2 (1.7) - 1 (1.2) - - - 
Blood coagulation 3 (2.6) - - - - - 
Cadherin signaling pathway - - 1 (1.2) - - - 
Cell cycle - - 1 (1.2) 1 (12.5) - - 
CCKR signaling map 3 (2.6) - 1 (1.2) - 1 (1.7) - 
Cortocotropin signaling 
pathway 1 (0.9) - - - - - 
Cytoskeletal regulation by Rho 
GTPase 1 (0.9) - 2 (2.4) - 1 (1.7) - 
EGF receptor signaling pathway 2 (1.7) - 1 (1.2) - - - 
FAS signaling pathway 1 (0.9) - - - - - 
FGF signaling pathway 1 (0.9) - 1 (1.2) - - - 
Gonadotropin releasing 
hormone receptor pathway 2 (1.7) 1 (14.3) - - - - 
 
 Monoclonal Oligoclonal 
TCL1A 
OVA 
stim 
3/7 4/7 
w/o 
OVA 2/6 4/6 
myr-TCL1A 
OVA 
stim 
2/5 3/5 
w/o 
OVA 
4/9 5/9 
nls-TCL1A 
OVA 
stim 1/3 2/3 
w/o 
OVA 
3/6 3/6 
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Table 3-7: PANTHER pathway classification of retroviral integrations sites in T-cell tumors 
induced by TCL1A variants in unstimulated mice 
N=Number of genes within a 250kb distance up- and downstream of the integration site, recognized 
by PANTHER. C= closest genes to integration site. In brackets: %-ages of genes within gene set. 
Heterotrimeric G-protein 
signaling pathway 7 (6.3) - - - 6 (10.2) - 
Huntington disease - - 1 (1.2) - 1 (1.7) - 
MAPK pathway 1 (0.9) - - - - - 
Inflammation mediated by 
chemokine and cytokine 
signaling pathway 
3 (2.6) - 9 (10.8) 1 (12.5) 1 (1.7) - 
Insulin/IGF pathway - - 1 (1.2) - 1 (1.7) - 
Integrin signaling pathway 1 (0.9) - - - 1 (1.7) - 
Interleukin signaling pathway 2 (1.7) - - - - - 
Ionotropic glutamate receptor 
pathway - - - - 1 (1.7) - 
JAK/STAT signaling pathway - 1 (14.3) - - - - 
Metabotropic glutamate 
receptor pathway - - - - 2 (3.4) - 
Methylmalonyl pathway - - 1 (1.2) - - - 
Muscarinic acetylcholine 
receptor 1 and 3 signaling 
pathway 
- - - - 1 (1.7) - 
Nicotinic acetylcholine receptor 
signaling pathways - 1 (14.3) 1 (1.2) - 1 (1.7) - 
Nicotine pharmacodyn. pathway 1 (0.9) - - - - - 
Notch signaling pathway - - 1 (1.2) - - - 
Parkinson disease 2 (1.7) - 1 (1.2) - - - 
PDGF signaling pathway 2 (1.7) - - - 1 (1.7) - 
PI3 kinase pathway 1 (0.9) - 1 (1.2) 1 (12.5) 1 (1.7) - 
p53 pathway 1 (0.9) - 3 (3.6) - 2 (3.4) - 
Ras Pathway 1 (0.9) - - - - - 
TGF-beta signaling pathway 1 (0.9) - - - - - 
Toll receptor signaling pathway 1 (0.9) - - - 1 (1.7) - 
Transcription regulation - - - - - 2 (40) 
Ubiquitin proteasome pathway - - 2 (2.4) - - - 
VEGF signaling pathway 1 (0.9) - - - - - 
Wnt signaling pathway 1 (0.9) - 1 (1.2) - - - 
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OVA stim TCL1 myr-TCL1A nls-TCL1A 
Distance to integration site 250kb (n=71) 
C 
(n=7) 
250kb 
(n=43) 
C 
(n=4) 
250kb 
(n=50) 
C 
(n=2) 
Alzheimer disease-amyloid 
secretase pathway 1 (1.4) - - - - - 
Alzheimer disease-presenilin 
pathway 1 (1.4) - - - - - 
Angiogenesis - - 1 (2.0) - 1 (2.0) - 
Angiotensin II-stimulated 
signaling - - 1 (2.0) - - - 
Apoptosis signaling pathway 1 (1.4) - - - - - 
Axon guidance mediated by 
netrin 1 (1.4) - - - - - 
Cadherin signaling pathway 1 (1.4) - - - - - 
CCKR signaling map 1 (1.4) - 1 (2.0) - 1 (2.0) - 
Cell cycle - - - - - - 
Cholesterol biosynthesis - - - - 1 (2.0) - 
Cortocotropin signaling 
pathway - - 1 (2.0) - - - 
Cytoskeletal regulation by Rho 
GTPase 1 (1.4) - - - 1 (2.0) - 
De novo purine biosynthesis 1 (1.4) - - - - - 
Dopamine receptor mediated 
signaling pathway - - 1 (2.0) - - - 
EGF receptor signaling pathway - - 2 (4.1) - 1 (2.0) - 
Endogenous cannabinoid 
signaling - - 1 (2.0) - - - 
5HT2 type receptor mediated 
signaling pathway 1 (1.4) - - - - - 
Flavin biosynthesis - - - - 1 (2.0) - 
FGF signaling pathway 1 (1.4) - 1 (2.0) - 1 (2.0) - 
GABA-B receptor II signaling - - 1 (2.0) - - - 
Glycolysis - - - - 1 (2.0) - 
Gonadotropin releasing 
hormone receptor pathway 2 (2.8) - 1 (2.0) - - - 
Heterotrimeric G-protein 
signaling pathway - - 3 (6.2) - - - 
Histamine H1 receptor mediated 
signaling pathway 1 (1.4) - - - - - 
Inflammation mediated by 
chemokine and cytokine 
signaling pathway 
4 (5.6) 1 (14.3) 1 (2.0) - 2 (4.0) - 
Integrin signaling pathway 1 (1.4) - - - 1 (2.0) - 
Interleukin signaling pathway - - 1 (2.0) - 1 (2.0) - 
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Table 3-8: PANTHER pathway classification of retroviral integrations sites in T-cell tumors 
induced by TCL1A variants in stimulated mice 
N=Number of genes within a 250kb distance up- and downstream of the integration site, recognized 
by PANTHER. C= closest genes to integration site. In brackets: %-ages of genes within gene set.  
 
 
3.3.4 TCL1A functions as a signaling enhancer in vitro 
In vitro studies with OT-1 T cells are challenging, as these primary cells do not survive long 
enough in culture to study the effect of TCL1A expression on cellular properties. Thus, the 
murine IL-2 dependent T-cell line CTLL-2 was used instead (138). Although this cell line 
showed TCR expression, it did not respond to stimulation with CD3/28 beads (data not 
shown). Instead, these cells responded well to activation through IL-2. As this cytokine 
activates similar downstream pathways as the TCR (see section 1.1.3), it was used to analyze 
the cooperation of TCL1A and downstream signaling.  
First, survival and proliferation of EGFP only or TCL1A expressing CTLL-2 cells at different 
IL-2 concentrations was analyzed. CTLL-2 cells were normally maintained at an IL-2 
concentration of 300 units (U) per ml. Cell numbers were determined every two days in 
Methylmalonyl pathway - - 1 (2.0) - - - 
N-acetylglucosamine 
metabolism - - - - 1 (2.0) - 
Oxytocin receptor mediated 
signaling pathway 1 (1.4) - - - - - 
PDGF signaling pathway 1 (1.4) - - - 1 (2.0) - 
PI3 kinase pathway - - - - - - 
p53 pathway - - 3 (6.2) - - - 
Pyruvate metabolism - - - - 1 (2.0) - 
Ras Pathway - - - - 1 (2.0) - 
Serine glycine biosynthesis - - - - 1 (2.0) - 
Thyrotropin receptor signaling 
pathway 1 (1.4) - - - - - 
Toll receptor signaling pathway - - - - 2 (4.0) - 
Ubiquitin proteasome pathway - - 1 (2.0) - - - 
VEGF signaling pathway - - 1 (2.0) - - - 
Wnt signaling pathway 2 (2.8) - 2 (4.1) 1 (25.0) 1 (2.0) - 
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cultures with IL-2 concentrations ranging from 0 to 300U per ml over a period of 16 days 
(Figure 3-30A). Cell numbers dropped with decreasing IL-2 concentrations in both groups 
and did not show a significant difference. Next, cell numbers were determined in cultures 
with IL-2 concentrations ranging from 300 to 1000U per ml after two days in culture. Higher 
IL-2 concentrations showed an effect on cell number in TCL1A transduced CTLL-2 (Figure 
3-30B). While the EGFP only group maintained the same cell number at different 
concentrations, cell numbers of TCL1A expressing CTLL-2 increased with rising IL-2 
concentrations. 
 
Figure 3-30: Cell numbers of TCL1A transduced CTLL-2 at different IL-2 concentrations 
CTLL-2 cells were transduced with EGFP only and TCL1A and maintained at different IL-2 
concentrations. CTLL-2 cells are normally cultured at a concentration of 300U IL-2 per ml. (A) At 
lower IL-2 concentrations, cell numbers of CTLL-2 decreased over a period of 16 days. (B) At higher 
IL-2 concentrations, cell numbers increased in TCL1A transduced over a period of two days.    
 
 
Next, protein phosphorylation of downstream signaling molecules was evaluated in these 
cells by PhosFlow analysis of pSTAT5, pAKT and pERK1/2, 24 hours after adding fresh IL-
2 to the cultures (Figure 3-31). TCL1A CTLL-2 cells showed increased phosphorylation of 
AKT (Figure 3-31A) and ERK1/2 (Figure 3-31B) compared to EGFP control cells, whereas 
no difference was observed in phosphorylation of the key IL-2 signaling protein STAT5 
(Figure 3-31C).   
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Figure 3-31: Protein phosphorylation in TCL1A transduced CTLL-2 at high IL-2 concentrations 
CTLL-2 cells transduced with EGFP only and TCL1A were cultured with 300U and 1000U IL-2 for 
24hours and then analyzed for phosphorylation of AKT (S473)(A), ERK1/2 (B) and STAT5 (C). Serum 
starved CTLL-2 cells were used as negative control and CTLL-2 stimulated with H2O2 served as 
positive control. 
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4. Discussion 
In this thesis, the oncogenic mechanisms of the TCL1 family have been studied using two 
murine transplantation models. These genes were introduced into HSCs/HPCs for 
comparative analyses of their oncogenic potential in general (see section 4.1) or upon 
targeted expression to cellular compartments (see section 4.2). Additionally, TCL1A variants 
were introduced into monoclonal T cells to study the cooperation of TCR signaling and 
TCL1A in mature T-cell transformation (see section 4.3). Both transplantation systems 
proved to be useful to study different aspects of the TCL1 family and its role in B- and T-cell 
malignization (see section 4.4).   
 
4.1 Comparative analysis of TCL1 family members 
The oncogenic potential of the TCL1 family members TCL1A and MTCP1 in lymphocytes 
has been described in different transgenic mouse models (see section 1.2.2.3). However, the 
use of different promoters that drive TCL1 family gene expression in these models, does not 
allow a direct comparison of the different family members in their oncogenic potential. 
Additionally, no transgenic model has been described for the third TCL1 family member 
TML1. The establishment of transgenic mouse models is laborious and hardly feasible for the 
three family members at once. As syngeneic mouse models offer a good alternative, retroviral 
vectors were used in this thesis to introduce the TCL1 family genes TCL1A, MTCP1, and 
TML1 into HSCs/HPCs that were then transplanted into lethally irradiated WT mice (see 
section 3.2.2). Transduced HSCs/HPCs were not sorted before transplantation to recapitulate 
a more ‘natural’ pathogenesis, where not all cells carry the same genetic hit. TCL1A and 
MTCP1 mice predominantly developed B-cell lymphomas after comparable latencies (Figure 
3-5). Based on the expression of the mature B-cell markers B220, CD19, and IgM (Table 3-2), 
a lymphoblastoid morphology (Figure 3-7) and leukemic presentation (Figure 3-8), these 
tumors were classified as Burkitt-like lymphomas according to the proposed classification of 
lymphoid neoplasms in mice (140). Thus, TCL1A and MTCP1 are oncogenes with 
comparable oncogenic potential. Although the exact oncogenic mechanisms of TCL1A 
remain incompletely resolved, it is known to interact with various key signaling molecules 
(see section 1.3.1.3). Less is known about the functional aspects of MTCP1, except that it 
binds AKT. This interaction is approximately 100-fold weaker than the interaction between 
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TCL1A and AKT (132). TCL1 is thought to enhance AKT activity by dimerization and 
oligomerization, thereby facilitating AKT transphosphorylation (141). The low affinity for 
AKT and the lack of a MTCP1 dimerization domain suggests that MTCP1 has a distinct 
mechanism for AKT activation and/or induces transformation of lymphocytes through 
separate mechanisms.  
Although originally described as T-cell oncogenes, most TCL1A and MTCP1 recipient mice 
developed B-cell malignancies in the presented model. For TCL1A, this is in accordance with 
a study of transgenic mice expressing TCL1A in T- and B-cell populations at equal levels 
that predominantly developed Burkitt-like lymphomas as well (110). However, the only 
published MTCP1 transgenic model was T cell-specific (81). Therefore, the presented data 
showed for the first time that MTCP1 is capable of B-cell transformation. The predominant 
transformation of B cells by TCL1A and MTCP1 is most likely due to accumulation of 
secondary mutations during B cell-specific diversification processes. Upon activation, 
peripheral B cells undergo secondary diversification processes, such as somatic 
hypermutation and class switch recombination, to further enhance antigen binding (60). 
Somatic hypermutation is achieved by introducing point mutations into the variable regions 
of immunoglobins resulting in the expression of mutant BCRs. During immunoglobulin class 
switching the constant region of the immunoglobulin heavy chain is replaced with an 
alternate region through a process called class switch recombination, a intrachromosomal 
deletional recombination event requiring double strand breaks. Both processes are known to 
contribute of deregulated gene expression resulting in transformation of B cells (61). Mature 
T cells lack similar error-prone mechanisms. It is therefore likely that TCL1/MTCP1-induced 
T-cell transformation requires more time and is outcompeted by transformation of B cells in 
the presented model.  
The third TCL1 family member TML1 is activated in human T-PLL together with TCL1A. 
However, it is unknown whether TML1 itself has oncogenic properties. Although TML1 
appears to be a weaker oncogene than its two other family members, the presented data 
provided the first proof for the oncogenic function of TML1 (Figure 3-5). Moreover, it’s 
oncogenic function was restricted to T cells (Table 3-1). There is little information on the 
functional aspects of TML1. Unlike TCL1A, it lacks a dimerization domain and binds AKT 
with low affinity (141). As it has a weak T cell-specific oncogenic function, TML1 most 
likely has mechanisms that are different from TCL1A and MTCP1. Interesting is also a 14aa 
stretch insertion in TML1 as compared to TCL1A, which may point to a phylogenetic 
evolution from TML1 to the proto-oncogene TCL1 after duplication and deletion of the14aa 
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stretch in higher mammals, where TCL1A expression is restricted to. Moreover, retroviral 
vector-mediated gene transfer bears the risk for insertional mutagenesis that might have 
contributed to induction or acceleration of tumor development in this model. 
 
4.2 Targeting TCL1A to cellular compartments 
In the next part of this thesis, the focus was laid on one of the family members, namely 
TCL1A, to learn more about the molecular basis of its oncogenic properties. It has been 
described that TCL1A interacts with different signaling molecules in different cellular 
compartments (see section 1.3.1.3). However, these studies did not reveal how localization of 
TCL1A relates to its oncogenic potential. Therefore, expression of TCL1A was targeted to 
the membrane and the nucleus using a myristoylated variant of TCL1A (myr-TCL1A) and a 
variant containing a nuclear localization signal (nls-TCL1A), respectively (see section 3.2.4). 
Interestingly, restricted localization of TCL1A did not impair its oncogenic potential. Similar 
to the generic TCL1A and MTCP1, both variants predominantly induced Burkitt-like 
lymphomas (Table 3-4). Survival of myr-TCL1A mice was comparable to the generic 
TCL1A cohort, whereas nls-TCL1A mice showed a significant reduction in survival (Figure 
3-11). Gene expression analyses of these tumors revealed higher similarities between TCL1A 
and its nuclear variant (Figure 3-14, Figure 3-15). Together this data implicates that TCL1A’s 
predominant oncogenic function relies on its nuclear presence.  
Nevertheless, the oncogenic properties of the membrane-bound variant of TCL1A are not 
impaired compared to the generic TCL1A. Gene expression analyses of TCL1A-, myr-
TCL1A- and nls-TCL1-induced tumors also showed that several signaling pathways are 
always affected in these tumors, including PI3K/AKT signaling, cell cycle, MAPK signaling, 
p53 signaling and GPCR signaling pathways (Figure 3-13). These pathways either share 
pathway components (Table 5-1) or are known to regulate each other. Together these data 
suggest, that TCL1A has a wide range of molecular mechanisms and is able to ultimately 
deregulate the same pathways regardless of its cellular localization.     
Tumor cells usually show highly deregulated gene expression making it impossible to 
pinpoint the genetic alteration leading to deregulation of these pathways and ultimately to 
cellular transformation. Therefore, pre-leukemic B and T cells were sorted from TCL1A, 
myr-TCL1A and nls-TCL1A HSC/HPC recipient mice 100 days after transplantation to 
identify early changes in gene expression. Generally, B cells expressing TCL1A variants 
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showed a significant higher number of deregulated genes than the respective T cells at this 
time point (Figure 3-16). Moreover, similar pathways were affected in B and T cells (Figure 
3-17, Figure 3-18), suggesting that transformation of both cell types is due to deregulation of 
the same signaling pathways. This data supports the hypothesis that predominant 
transformation of B cells is due to accumulation of secondary mutations during error-prone, 
B cell-specific diversification processes, thereby leading to earlier deregulation of cellular 
pathways. 
Interestingly, cell cycle and p53-signaling pathway genes were both affected in B cells and 
B-cell tumors (Figure 3-13, Figure 3-17), but not in T cells. These pathways might therefore 
play an important role in the transformation of B cells in the presented model. DNA damage 
induces the p53-signaling pathway resulting in cell cycle checkpoint activation, thereby 
promoting either cell survival or death. Deregulation of these pathways has been associated 
with cellular transformation in general, but has also been detected specifically in B-cell 
lymphomas as a common feature (142). Cell cycle/p53 pathway genes up-regulated in 
analyzed B cells and B-cell tumors are Bub1b, Ccna2, Ccnb1, Ccnb2, Mpeg1 and Rrm2 
(Table 5-1, Table 5-2). The cyclin genes Ccna2, Ccnb1 and Ccnb2 play an essential role in 
G2/M cell cycle transition. Overexpression is associated with chromosomal instability and 
double-strand breaks (143,144). The mitotic checkpoint gene Bub1b normally inhibits cell 
cycle progression and is more associated with tumor suppressive properties as heterozygous 
mice display chromosome instability and increased tumor susceptibility (145,146). The 
observed up-regulation might therefore be a compensatory effect for deregulation of other 
cell cycle components. The ribonucleotide reductase Rrm2 is important for DNA synthesis in 
dividing cells and overexpression in mice induces tumor development (147). There is no 
information on Mpeg1 and its role in cell cycle regulation. Based on this data it is not 
possible to determine which gene is responsible for cell cycle/p53 signaling deregulation as 
most of the up-regulated genes have been associated with cellular transformation. TCL1A has 
been associated with cell cycle interaction through ATM (see section 1.3.1.3). However, this 
gene is only down-regulated in TCL1A B cells and TCL1A tumors, but not in other cohorts 
(data not shown). This suggests that TCL1A might interfere with the cell cycle through other 
components besides ATM. The presented data does not allow drawing similar conclusions 
about the role of this pathway in the transformation of T cells, as this pathway is not affected 
in pre-leukemic T cells at the selected time point. This is most likely due to the general lack 
of early changes in T cells and analyses at later time points might reveal more about the 
involvement of this pathway. Nevertheless, a few genes were already deregulated in these 
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cells and they affect the same pathways as the ones seen in pre-leukemic and leukemic B 
cells, including PI3K/AKT signaling, MAPK signaling pathways and chemokine signaling 
(Figure 3-13, Figure 3-17, Figure 3-18). Remarkably, one gene is found in five out of the six 
affected pathways in pre-leukemic T cells, namely AKT1 (Table 5-3). It has been described 
that TCL1A enhances the kinase activity of AKT by forming hetero-oligomers at the plasma 
membrane (141). AKT has numerous substrates, thereby regulating survival, growth, cell 
cycle, proliferation, migration, etc (148). It is therefore likely that it plays a central role in 
deregulating these pathways in pre-leukemic T cells. However, it seems that the TCL1A-
induced activation of AKT is not solely based on the interaction at the plasma membrane, as 
nls-TCL1A expressing T cells show the same up-regulation of AKT1 (Table 5-3). So far, it 
has only been described that TCL1A mediates nuclear translocation of AKT (74,119). This 
data suggests that TCL1A has additional mechanisms for activation of AKT besides 
oligomerization at the plasma membrane.  
Interestingly, the murine TCL1 family members Mtcp1 and Tcl1b4 were down-regulated in 
TCL1A tumors and pre-leukemic TCL1A B-cells, respectively. This might be due cellular 
compensation of TCL1A overexpression by reducing endogenous expression of TCL1 family 
members that does not affect expression of the transgene.   
 
4.3 Cooperation of TCL1A and TCR signaling 
In a previously described HSC/HPC transplantation model, overexpression of TCL1A 
variants resulted predominantly in the transformation of B cells, which makes this model 
unsuitable to study the role of TCL1A in T cells. TCL1A interacts with different signaling 
molecules along the TCR signaling cascade, suggesting a role of TCR signaling in TCL1A-
induced T-cell transformation (see section 1.3.1.3). Newrzela et al showed that T cells can be 
transformed in a TCR mono-/oligoclonal setting by certain T-cell oncogenes (45), but not in a 
TCR polyclonal environment (44). This OT-1 TCR monoclonal T-cell model was utilized to 
study the cooperation between TCL1A and TCR signaling by specifically stimulating the 
TCR of TCL1A transduced OT-1 T cells in vivo with an OVA peptide. Therefore, mice 
received transplants of TCL1A transduced OT-1 T cells and were then repeatedly injected 
with OVA peptide every two weeks. Blood sampling revealed early differences between 
OVA stimulated TCL1A mice and control mice. In stimulated control mice, the percentage of 
transplanted T cells decreased in the PB, whereas in TCL1A mice this percentage increased 
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after an initial decline (Figure 3-23). In vivo imaging showed that these cells are not lost in 
control mice and rather accumulate in inguinal LNs, abdominal regions and spleen, which 
was the same for stimulated TCL1A recipient mice (Figure 3-25, Figure 3-26). Thus, this 
data suggests that T cells retreat to secondary lymphoid organs in a ‘chronically’ stimulated 
environment. These organs provide pro-survival signals, including cytokines and spMHC 
peptides that might be essential for maintenance of repeatedly stimulated memory T cells.  
The higher percentage of TCL1A expressing T cells in the PB was most likely due to 
enhanced accumulation of T cells in the presence of TCL1. This is supported by several 
observations: 1.) Generally higher bioluminescence signals in TCL1A cohorts compared to 
their unstimulated/stimulated control counterparts (Figure 3-25), 2.) Enrichment of 
transgene/EGFP expressing T cells in unstimulated TCL1 recipient mice, but not in 
unstimulated EGFP control mice (Figure 3-23), and 3.) Accelerated enrichment of TCL1A+ T 
cells in OVA stimulated TCL1 recipient mice (Figure 3-23). Together this data implicates 
that enhanced accumulation of TCL1A+ T cells in these mice is due to increased proliferative 
activity of these T cells, which is further enhanced by TCR stimulation. More importantly, 
the presence of TCL1A seemed to be enough to compensate for a TCR signal, as a similar 
enrichment of EGFP+ T cells was only observed in stimulated and not unstimulated EGFP 
only control mice (Figure 3-23). In stimulated control EGFP recipient mice, this enrichment 
is most likely due to the viral integration that gives these cells an advantage over non-
transduced cells, but only in the presence of a TCR stimulus.  
The primary aim of this model was to establish, if chronic TCR stimulation has an effect on 
TCL1A’s oncogenic potential. A significant reduction of survival of stimulated TCL1A mice 
compared to their unstimulated counterpart clearly demonstrated that chronic TCR 
engagement facilitated TCL1A-driven transformation (Figure 3-27). The same was observed 
for the two variants of TCL1A, namely myr-TCL1A and nls-TCL1A (Figure 3-27). This data 
provides functional proof for the role of TCR stimulation in augmenting the oncogenic 
properties of TCL1A, most likely by enhancing proliferation of TCL1A expressing T cells. 
Notable is also the difference in tumor phenotype between unstimulated and stimulated 
TCL1A mice (Table 3-5). Although a T-cell based transplantation model was used, B-cell 
tumors arose in a few unstimulated mice. This can be explained by a low percentage of B-cell 
contamination in the initial transplant (Figure 3-22). However, these tumors did not develop 
in stimulated mice, thereby suggesting that TCR stimulation drives specific transformation of 
T cells (or helps in outcompeting the B-cell tumors that would develop at a “basal” rate).  
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T-cell tumors in these mice often had a CD4 phenotype. This was unexpected as the initial 
transplant mainly consisted out CD8+ T cells that specifically recognize the injected OVA 
peptide. The transgenic OT-1 TCR is MHC class I-restricted thereby limiting OT-1 TCR 
expression to CD8 T cells. The transgenic TCR is primarily selected in these mice, which 
leads to preferential outgrowth of transgenic OT-1 TCR expressing CD8 T cells. However, it 
has been shown that OT-1 thymocytes contain endogenous α chains that are able to undergo 
rearrangement and pair with the transgenic β chain, thereby producing CD4 and CD8 T cells 
with a chimeric TCR (149). These cells usually remain at a very low percentage in the initial 
transplant, but are not able to recognize the injected OVA peptide (Figure 3-22). A different 
explanation for the outgrowth of CD4 T-cell malignancies in the presented model is offered 
by a recent study that has shown that CD8 T cells in OT-1 mice have the capability of 
differentiating into CD4 T cells that express a functional OT-1 TCR (150). These cells were 
mostly detected in the large-intestine lamina propria of RAG1-/- OT-1 TCR transgenic mice 
that lack T cells with chimeric TCRs. Adoptively transferred CD4 T cells into WT mice 
responded to stimulation with OVA peptide. Interestingly, the CD4 tumor phenotype 
observed in the presented mouse model resembles the T-PLL phenotype in humans (see 
section 1.2.2.1). Cytologically, these cells resemble medium-sized T lymphocytes seen in T-
PLL as well.  
Studying OT-1 stimulation in vitro over a long period of time was not feasible. Therefore, for 
in vitro studies an IL-2 dependent murine T-cell line was used instead. These cells did not 
respond to TCR stimulation, but to IL-2 stimulation. The IL-2 pathway initiates the same 
downstream pathways as TCR engagement. In accordance with the data collected in vivo, 
TCL1A enhanced proliferation of T cells upon activation (Figure 3-30B). At low IL-2 
concentrations, TCL1A did not have an anti-apoptotic effect that conferred a survival 
advantage (Figure 3-30A). The phosphorylation status of the two key signaling molecules 
AKT1 and ERK1/2 increased with higher IL-2 concentrations in stimulated TCL1A-carrying 
cells (Figure 3-31). STAT5 is one of the key mediators of IL-2-induced signaling and did not 
show any difference in its phosphorylation status. Thus, augmented proliferation of TCL1A 
expressing cells was associated with an enhanced activation of specific signaling molecules. 
TCL1A enhanced signaling pathways involved in activation and proliferation of T cells in the 
presented study, but only in the presence of an external stimulus. IL-2 or any other cytokine 
or co-stimulus would not be sufficient to induce a functional immune response in vivo. 
Therefore, the TCR plays most likely an important role in mediating / enhancing TCL1A’s 
oncogenic properties by initiating downstream signaling pathways.  
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The involvement of the TCR in TCL1-driven transformation of T cells suggests the presence 
of a specific (auto)antigenic drive in T-PLL patients. For some PTCL entities, it has been 
shown that chronic inflammations often precede lymphoma / leukemia development, e.g. 
dermatitis prior to cutaneous T-cell lymphomas or expansions of autoimmune cytotoxic T 
cells prior to T-cell large granular lymphocyte leukemia (77). Inflammatory lesions or a bias 
in TCR gene usage has not been observed for T-PLL (78,79). This might hint at alternative 
mechanisms of TCR activation, such as intrinsically autonomous activation.    
Retroviral vectors are commonly used for stable integration of genes into the genome of 
target cells. Despite the initial success in gene therapy, the further use of these vectors in 
clinical trials has been limited by severe side effects caused by insertional mutagenesis. In 
our studies, this clinical disadvantage is used to recapitulate secondary genetic hits that often 
drive the development of cancer. Integration of viral vectors into the host’s genome can alter 
expression of genes around the site of integration that might favor malignant outgrowth. 
Control mice in these studies did not develop tumors, proving that this side effect is rare. 
Additionally, integration site analysis of tumors showed that only low numbers of genes are 
affected and classified in pathways, indicating that the introduced oncogene alone is 
responsible for cellular transformation (Table 3-7, Table 3-8). Although similar pathways are 
affected, there is no statistical overrepresentation that would allow drawing sound 
conclusions.    
Besides the generic TCL1A, its variants myr-TCL1A and nls-TCL1A were also used in the 
described T-cell model. The effect of stimulation on survival was comparable to the generic 
TCL1A (Figure 3-27). There was no significant difference in survival between the different 
variants in the T-cell model, although nls-TCL1A showed reduced survival in the HSC/HPC 
model compared to the other variants (Figure 3-11). This suggests that TCL1A’s nuclear 
presence might be more important for transformation of B cells than for T cells.   
It should be noted that mice often developed ascites in this model as a side effect of repeated 
i.p. injections over a long period of time and had to be sacrificed before tumor development. 
This was not cohort-related as it was observed for stimulated and unstimulated control and 
TCL1A mice. To prevent this side effect and improve the system, it might be necessary to 
lower the frequency of injections.    
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4.4 General considerations for the use of HSCs/HPCs or TCR 
monoclonal T cells as target cells in syngeneic mouse models for 
lymphoma/leukemia studies 
 
In the presented syngeneic mouse models, grafts from mice with the same genetic 
background were genetically manipulated using retroviral vectors. Most studies that work 
with these models use BM-derived HSCs/HPCs as donor cells. Retroviral transduction and 
transplantation of HSCs/HPCs is an efficient method to introduce transgenes into 
lymphocytes without altering these cells directly. Additionally, this has the advantage that the 
hematopoietic system is fully developed and functional, recapitulating a more “natural” 
tumorigenesis in immunocompetent hosts. This model is highly suitable for comparative 
analyses of oncogenic properties. In the case of TCL1A and its family members, B cells are 
predominantly transformed, making this a useful model for B-cell studies, but not for 
studying T-cell transformation. Interestingly, histological and cytological analysis showed 
that B-cell tumors induced in the HSC/HPC model had a larger and more immature 
morphology than the ones that developed in the T-cell model. This difference was not 
observed based on the flow cytometric analysis alone. Thus, using HSCs/HPCs or mature 
lymphocytes made a difference for the phenotype of the induced B-cell tumors.  
Studying mature T-cell malignancies in mice has been challenging, as there is no promoter 
available that targets transgene expression specifically to mature T cells (151). In the 
presented HSC/HPC model, only immature T-cell tumors developed and were mostly 
outcompeted by the outgrowth of B-cell malignancies. Using mature T cells as target cells for 
retroviral transduction has been limited by their resistance to transformation by oncogenes, 
including TCL1A (44). However, using TCR monoclonal instead of TCR polyclonal T cells 
circumvented this effect (45). The TCR monoclonal system offers the possibility to study the 
role of the TCR in cellular transformation. There are several different transgenic TCR models 
that allow specific stimulation of CD4 and CD8 T cells, such as OT-1, OT-2 or P14. 
Similarly, this could be done for B cells and BCR stimulation, e.g. using MD4 transgenic B 
cells that specifically recognize hen egg lysozyme. However, these models represent rather 
simplified approaches to study the pathogenesis of mature T- or B-cell tumors. 
Immunodeficient hosts and TCR monoclonal lymphocytes do not represent a “natural” 
environment, but they offer a good starting point to dissect the complex course of cellular 
transformation. Next, this model can be further adapted by mixing TCR polyclonal T cells to 
 105 
the TCR monoclonal transplant or by using Nude mice as recipients that have functional B 
cells and only lack T cells.  
 
4.5 Conclusions and Outlook 
The presented study covers different aspects on the function of TCL1 oncogene family 
members. First, it was shown that TCL1A and MTCP1 share a similar oncogenic capacity, 
whereas TML1 is a weak oncogene with low penetrance in our systems. Currently, primary 
T-PLL cases are analyzed for expression frequency of these three oncogenes in our 
laboratory.  
Next, it was shown that nuclear localization of TCL1A reduced survival of recipient mice 
compared to the generic TCL1A protein and a membrane-localizing variant. Gene expression 
data revealed an important role of p53 signaling and cell cycle genes in the transformation of 
B cells. Gene expression data collected from this study is currently compared to gene 
expression data from TCL1A transgenic mice at different time points before tumor 
development.  
In the last part of this thesis a new in vivo model was established to specifically stimulate the 
TCR of TCR monoclonal T cells in vivo. The data clearly show that TCL1A-driven 
transformation is facilitated by repeated TCR stimulation, thereby demonstrating that there 
likely is a pro-leukemogenic cooperation between TCL1A and TCR signaling. To further 
analyze this synergy, signaling dosages of TCL1A and TCR are currently analyzed in human 
CTCL cell lines by titrating TCL1A levels in a Tet-ON TCL1A-inducible system and by 
titrating TCR activation through blocking antibodies (OKT3 or 15E8). The aim of this 
experiment is to determine how these signals compensate for each other, e.g. if a higher 
expression of TCL1A can compensate for high-avidity TCR engagement. For further in vivo 
studies polyclonal T cells are added to the OT-1 T cell transplant to test if the additional TCR 
stimulus allows TCL1A transduced T cells to overcome clonal competition. Furthermore, 
TCL1 transgenic mice are crossbred with CD3-deficient and MHC-deficient mice to address 
the requirement of TCR signaling input in TCL1-mediated oncogenesis.   
The antigen receptor plays a central role in T- and B-cell development, function and survival. 
The clinical and therapeutic importance of the BCR has been well described for B-cell 
malignancies (152). In the recent years, specific inhibitors of BCR signaling molecules, such 
as PI3K or Bruton's tyrosine kinase (BTK), have been approved for the treatment of B-cell 
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lymphomas / leukemias and have shown promising clinical results (153,154). For the 
treatment of PTCL, an inhibitor of the TCR signaling kinase mTOR showed successful 
results in ongoing clinical trials as well (155). The suitability of interleukin-2-inducible T-cell 
Kinase (ITK) as an effective drug target for PTCL is currently investigated, but likely its role 
in T cells is not congruently reflected by BTK in B-cells and the derived tumors (156). These 
studies emphasize the potential of treatment approaches targeting antigen receptor signaling 
and the demand for a detailed understanding of TCR involvement in PTCL pathobiology. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 107 
References 
1.  Godfrey DI, Kennedy J, Suda T, Zlotnik A. A developmental pathway involving four 
phenotypically and functionally distinct subsets of CD3-CD4-CD8- triple-negative 
adult mouse thymocytes defined by CD44 and CD25 expression. J Immunol. 
1993;150(10):4244–52.  
2.  Oettinger MA, Schatz DG, Gorka C, Baltimore D. RAG-1 and RAG-2, adjacent genes 
that synergistically activate V(D)J recombination. Science (80). 
1990;248(4962):1517–23.  
3.  Capone M, Hockett RD, Zlotnik A. Kinetics of T cell receptor beta, gamma, and delta 
rearrangements during adult thymic development: T cell receptor rearrangements are 
present in CD44(+)CD25(+) Pro-T thymocytes. Proc Natl Acad Sci U S A. 
1998;95(21):12522–7.  
4.  von Boehmer H, Fehling HJ. Structure and function of the pre-T cell receptor. Annu 
Rev Immunol. 1997;15:433–52.  
5.  Falk I, Nerz G, Haidl I, Krotkova A, Eichmann K. Immature thymocytes that fail to 
express TCRbeta and/or TCRgamma delta proteins die by apoptotic cell death in the 
CD44-CD25- (DN4) subset. Eur J Immunol. 2001;31(11):3308–17.  
6.  Germain RN. T-cell development and the CD4-CD8 lineage decision. Nat Rev 
Immunol. 2002;2(5):309–22.  
7.  Teh HS, Kisielow P, Scott B, Kishi H, Uematsu Y, Blüthmann H, et al. Thymic major 
histocompatibility complex antigens and the alpha beta T-cell receptor determine the 
CD4/CD8 phenotype of T cells. Nature. 1988;335(6187):229–33.  
8.  Singer A, Adoro S, Park J-H. Lineage fate and intense debate: myths, models and 
mechanisms of CD4- versus CD8-lineage choice. Nat Rev Immunol. 2008;8(10):788–
801.  
9.  Broere F, Apasov SG, Sitkovsky M V., van Eden W. T cell subsets and T cell-
mediated immunity. Principles of Immunopharmacology. Basel: Birkhäuser Basel; 
2011. p. 15–27.  
10.  Mueller SN, Gebhardt T, Carbone FR, Heath WR. Memory T Cell Subsets, Migration 
Patterns, and Tissue Residence. Annu Rev Immunol. 2013 Mar 21;31(1):137–61.  
11.  Appay V, Van Lier RAW, Sallusto F, Roederer M. Phenotype and function of human 
T lymphocyte subsets: Consensus and issues. Cytom A. 2008;73(11):975–83.  
12.  Hamann D, Baars PA, Rep MH, Hooibrink B, Kerkhof-Garde SR, Klein MR, et al. 
Phenotypic and functional separation of memory and effector human CD8+ T cells. J 
Exp Med. 1997;186(9):1407–18.  
 108 
13.  Alari-Pahissa E, Notario L, Lorente E, Vega-Ramos J, Justel A, López D, et al. CD69 
Does Not Affect the Extent of T Cell Priming. Hasenkrug KJ, editor. PLoS One. 2012 
Oct 30;7(10):e48593.  
14.  Hernandez MGH, Shen L, Rock KL. CD40-CD40 Ligand Interaction between 
Dendritic Cells and CD8+ T Cells Is Needed to Stimulate Maximal T Cell Responses 
in the Absence of CD4+ T Cell Help. J Immunol. 2007 Mar 1;178(5):2844–52.  
15.  Wambre E, James EA, Kwok WW. Characterization of CD4+ T cell subsets in allergy. 
Curr Opin Immunol. 2012;24(6):700–6.  
16.  Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T 
lymphocytes with distinct homing potentials and effector functions. Nature. 
1999;401(6754):708–12.  
17.  Masopust D, Vezys V, Marzo AL, Lefrançois L. Preferential localization of effector 
memory cells in nonlymphoid tissue. Science (80- ). 2001;291(5512):2413–7.  
18.  Venturi V, Price DA, Douek DC, Davenport MP. The molecular basis for public T-cell 
responses? Nat Rev Immunol. 2008 Mar;8(3):231–8.  
19.  Meydan C, Otu HH, Sezerman O. Prediction of peptides binding to MHC class I and II 
alleles by temporal motif mining. BMC Bioinformatics. 2013;14(Suppl 2):S13.  
20.  Weiss A. Molecular and genetic insights into T cell antigen receptor structure and 
function. Annu Rev Genet. 1991;25:487–510.  
21.  Murphy K. Antigen Recognition by B-cell and T-cell Receptors. Janeway’s 
Immunobiology. 8th ed. New York: Garland Science; 2011. p. 127–56.  
22.  Gascoigne NRJ. Do T cells need endogenous peptides for activation? Nat Rev 
Immunol. 2008 Nov;8(11):895–900.  
23.  Zhang W, Sloan-Lancaster J, Kitchen J, Trible RP, Samelson LE. LAT: The ZAP-70 
Tyrosine Kinase Substrate that Links T Cell Receptor to Cellular Activation. Cell. 
1998 Jan;92(1):83–92.  
24.  Sue Goo Rhee, Choi KD. Regulation of inositol phospholipid-specific phospholipase 
C isozymes. J Biol Chem. 1992;267(18):12393–6.  
25.  Pollizzi KN, Powell JD. Integrating canonical and metabolic signalling programmes in 
the regulation of T cell responses. Nat Rev Immunol. 2014 Jun 25;14(7):435–46.  
26.  Masuda ES, Imamura R, Amasaki Y, Arai K, Arai N. Signalling into the T-Cell 
Nucleus: NFAT regulation. Cell Signal. 1998 Oct;10(9):599–611.  
27.  Teixeira C, Stang SL, Zheng Y, Beswick NS, Stone JC. Integration of DAG signaling 
systems mediated by PKC-dependent phosphorylation of RasGRP3. Blood. 
2003;102(4):1414–20.  
 109 
28.  Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, et al. Signal 
transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to 
transcription factors: potential targeting for therapeutic intervention. Leukemia. 2003 
Jul;17(7):1263–93.  
29.  Lin X, O’Mahony A, Mu Y, Geleziunas R, Greene WC. Protein kinase C-theta 
participates in NF-kappaB activation induced by CD3-CD28 costimulation through 
selective activation of IkappaB kinase beta. Mol Cell Biol. 2000;20(8):2933–40.  
30.  Israël A. The IKK complex, a central regulator of NF-kappaB activation. Cold Spring 
Harb Perspect Biol. 2010;2(3).  
31.  Takeda K, Harada Y, Watanabe R, Inutake Y, Ogawa S, Onuki K, et al. CD28 
stimulation triggers NF-kappaB activation through the CARMA1-PKCtheta-
Grb2/Gads axis. Int Immunol. 2008;20(12):1507–15.  
32.  Nunès JA, Collette Y, Truneh A, Olive D, Cantrell DA. The role of p21ras in CD28 
signal transduction: triggering of CD28 with antibodies, but not the ligand B7-1, 
activates p21ras. J Exp Med. 1994;180(3):1067–76.  
33.  Alegre M-L, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. 
Nat Rev Immunol. 2001 Dec;1(3):220–8.  
34.  Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation 
and activation. Nat Rev Immunol. 2003 Apr 25;3(4):317–30.  
35.  Manning BD, Cantley LC. AKT/PKB Signaling: Navigating Downstream. Cell. 2007 
Jun;129(7):1261–74.  
36.  Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB 
activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 
1999;401(6748):82–5.  
37.  Liao W, Lin J-X, Leonard WJ. Interleukin-2 at the Crossroads of Effector Responses, 
Tolerance, and Immunotherapy. Immunity. 2013 Jan;38(1):13–25.  
38.  Sprent J, Surh CD. Normal T cell homeostasis: the conversion of naive cells into 
memory-phenotype cells. Nat Immunol. 2011;12(6):478–84.  
39.  Moses CT, Thorstenson KM, Jameson SC, Khoruts A. Competition for self ligands 
restrains homeostatic proliferation of naive CD4 T cells. Proc Natl Acad Sci U S A. 
2003 Feb 4;100(3):1185–90.  
40.  Troy AE, Shen H. Cutting Edge: Homeostatic Proliferation of Peripheral T 
Lymphocytes Is Regulated by Clonal Competition. J Immunol. 2003 Jan 
15;170(2):672–6.  
41.  Kieper WC, Burghardt JT, Surh CD. A role for TCR affinity in regulating naive T cell 
 110 
homeostasis. J Immunol. 2004 Jan 1;172(1):40–4.  
42.  Hao Y, Legrand N, Freitas AA. The clone size of peripheral CD8 T cells is regulated 
by TCR promiscuity. J Exp Med. 2006 Jul 10;203(7):1643–9.  
43.  Agenès F, Dangy J-P, Kirberg J. T cell receptor contact to restricting MHC molecules 
is a prerequisite for peripheral interclonal T cell competition. J Exp Med. 2008 Nov 
24;205(12):2735–43.  
44.  Newrzela S, Cornils K, Li Z, Baum C, Brugman MH, Hartmann M, et al. Resistance of 
mature T cells to oncogene transformation. Blood. 2008;112(6):2278–86.  
45.  Newrzela S, Al-Ghaili N, Heinrich T, Petkova M, Hartmann S, Rengstl B, et al. T-cell 
receptor diversity prevents T-cell lymphoma development. Leukemia. 2012 Dec 
30;26(12):2499–507.  
46.  Akbar AN, Borthwick NJ, Wickremasinghe RG, Panayoitidis P, Pilling D, Bofill M, et 
al. Interleukin-2 receptor common gamma-chain signaling cytokines regulate activated 
T cell apoptosis in response to growth factor withdrawal: selective induction of anti-
apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xS) gene expression. Eur J 
Immunol. 1996;26(2):294–9.  
47.  Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, Lindsten T, et al. CD28 
costimulation can promote T cell survival by enhancing the expression of Bcl-XL. 
Immunity. 1995;3(1):87–98.  
48.  Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today. 
1995;16(1):39–43.  
49.  Calvo CR, Amsen D, Kruisbeek AM. Cytotoxic T lymphocyte antigen 4 (CTLA-4) 
interferes with extracellular signal-regulated kinase (ERK) and Jun NH2-terminal 
kinase (JNK) activation, but does not affect phosphorylation of T cell receptor zeta and 
ZAP70. J Exp Med. 1997;186(10):1645–53.  
50.  von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol. 
2005;6(4):338–44.  
51.  Van Parijs L, Abbas AK. Homeostasis and self-tolerance in the immune system: 
turning lymphocytes off. Science (80- ). 1998;280(5361):243–8.  
52.  Schluns KS, Kieper WC, Jameson SC, Lefrançois L. Interleukin-7 mediates the 
homeostasis of naïve and memory CD8 T cells in vivo. Nat Immunol. 2000 
Nov;1(5):426–32.  
53.  Kondrack RM, Harbertson J, Tan JT, McBreen ME, Surh CD, Bradley LM. Interleukin 
7 regulates the survival and generation of memory CD4 cells. J Exp Med. 2003 Dec 
15;198(12):1797–806.  
 111 
54.  Goldrath AW, Sivakumar P V, Glaccum M, Kennedy MK, Bevan MJ, Benoist C, et al. 
Cytokine requirements for acute and Basal homeostatic proliferation of naive and 
memory CD8+ T cells. J Exp Med. 2002 Jun 17;195(12):1515–22.  
55.  Swain SL, Hu H, Huston G. Class II-independent generation of CD4 memory T cells 
from effectors. Science (80- ). 1999 Nov 12;286(5443):1381–3.  
56.  Murali-Krishna K, Lau LL, Sambhara S, Lemonnier F, Altman J, Ahmed R. 
Persistence of memory CD8 T cells in MHC class I-deficient mice. Science (80- ). 
1999 Nov 12;286(5443):1377–81.  
57.  Tanchot C, Lemonnier FA, Pérarnau B, Freitas AA, Rocha B. Differential 
requirements for survival and proliferation of CD8 naïve or memory T cells. Science 
(80- ). 1997 Jun 27;276(5321):2057–62.  
58.  Markiewicz MA, Girao C, Opferman JT, Sun J, Hu Q, Agulnik AA, et al. Long-term T 
cell memory requires the surface expression of self-peptide/major histocompatibility 
complex molecules. Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3065–70.  
59.  Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. Tumours of 
Hematopoietic and Lymphoid Tissues. Fourth Edi. World Health Organization 
Classification of Tumours. Lyon, France: IARC Press; 2008.  
60.  Li Z, Woo CJ, Iglesias-Ussel MD, Ronai D, Scharff MD. The generation of antibody 
diversity through somatic hypermutation and class switch recombination. Genes Dev. 
2004;18(1):1–11.  
61.  Küppers R, Dalla-Favera R. Mechanisms of chromosomal translocations in B cell 
lymphomas. Oncogene. 2001 Sep 10;20(40):5580–94.  
62.  Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural 
killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 
2008;26(25):4124–30.  
63.  Savage KJ. Therapies for Peripheral T-Cell Lymphomas. ASH Educ B. 
2011;2011(1):515–24.  
64.  Herling M, Jones D. Mature T-cell Leukemias - Current Challenges in Diagnosis and 
Therapy. Am J Clin Oncol. 2004;10(3):608–17.  
65.  Herling M, Khoury JD, Washington LT, Duvic M, Keating MJ, Jones D. A systematic 
approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO 
categories. Blood. 2004;104(2):328–35.  
66.  Ravandi F, O’Brien S, Jones D, Lerner S, Faderl S, Ferrajoli A, et al. T-cell 
prolymphocytic leukemia: a single-institution experience. Clin Lymphoma Myeloma. 
2005;6(3):234–9.  
 112 
67.  Matutes E, Brito-Babapulle V, Swansbury J, Ellis J, Morilla R, Dearden C, et al. 
Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood. 
1991;78(12):3269–74.  
68.  Grey-Davies E, Dearden C. The T-Cell Leukaemias. In: Foss F, editor. T-Cell 
Lymphomas. New York: Humana Press; 2013. p. 137–53.  
69.  Brito-Babapulle V, Catovsky D. Inversions and tandem translocations involving 
chromosome 14q11 and 14q32 in T-prolymphocytic leukemia and T-cell leukemias in 
patients with ataxia telangiectasia. Cancer Genet Cytogenet. 1991;55(1):1–9.  
70.  Virgilio L, Narducci MG, Isobe M, Billips LG, Cooper MD, Croce CM, et al. 
Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci U 
S A. 1994;91(26):12530–4.  
71.  Hoyer KK, Herling M, Bagrintseva K, Dawson DW, French SW, Renard M, et al. T 
cell leukemia-1 modulates TCR signal strength and IFN-gamma levels through 
phosphatidylinositol 3-kinase and protein kinase C pathway activation. J Immunol. 
2005;175(2):864–73.  
72.  Soulier J, Pierron G, Vecchione D, Garand R, Brizard F, Sigaux F, et al. A complex 
pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia. 
Genes Chromosom Cancer. 2001;31(3):248–54.  
73.  Maljaei SH, Brito-Babapulle V, Hiorns LR, Catovsky D. Abnormalities of 
chromosomes 8, 11, 14, and X in T-prolymphocytic leukemia studied by fluorescence 
in situ hybridization. Cancer Genet Cytogenet. 1998 Jun;103(2):110–6.  
74.  Herling M, Patel KA, Teitell MA, Konopleva M, Ravandi F, Kobayashi R, et al. High 
TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset 
of T-cell prolymphocytic leukemia. Blood. American Society of Hematology; 
2008;111(1):328–37.  
75.  Costa D, Queralt R, Aymerich M, Carrio A, Rozman M, Vallespi T, et al. High levels 
of chromosomal imbalances in typical and small-cell variants of T-cell prolymphocytic 
leukemia. Cancer Genet Cytogenet. 2003;147(1):36–43.  
76.  Stilgenbauer S, Schaffner C, Litterst A, Liebisch P, Gilad S, BarShira A, et al. Biallelic 
mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med. 
1997;3(10):1155–9.  
77.  Warner K, Weit N, Crispatzu G, Admirand J, Jones D, Herling M. T-Cell Receptor 
Signaling in Peripheral T-Cell Lymphoma – A Review of Patterns of Alterations in a 
Central Growth Regulatory Pathway. Curr Hematol Malig Rep. 2013 Sep 27;8(3):163–
72.  
78.  Hodges E, Edwards SE, Howell WM, Smith JL. Polymerase chain reaction 
amplification analyses of clonality in T-cell malignancy including peripheral T-cell 
 113 
lymphoma. Leukemia. 1994;8(2):295–8.  
79.  Tembhare P, Yuan CM, Xi L, Morris JC, Liewehr D, Venzon D, et al. Flow 
Cytometric Immunophenotypic Assessment of T-Cell Clonality by Vβ Repertoire 
Analysis . Am J Clin Pathol. 2011 Jun 1;135 (6 ):890–900.  
80.  Virgilio L, Lazzeri C, Bichi R, Nibu K, Narducci MG, Russo G, et al. Deregulated 
expression of TCL1 causes T cell leukemia in mice. Proc Natl Acad Sci U S A. 
1998;95(7):3885–9.  
81.  Gritti C, Dastot H, Soulier J, Janin A, Daniel MT, Madani A, et al. Transgenic mice 
for MTCP1 develop T-cell prolymphocytic leukemia. Blood. 1998;92(2):368–73.  
82.  Stern MH, Soulier J, Rosenzwajg M, Nakahara K, Canki-Klain N, Aurias A, et al. 
MTCP-1: a novel gene on the human chromosome Xq28 translocated to the T cell 
receptor alpha/delta locus in mature T cell proliferations. Oncogene. 1993;8(9):2475–
83.  
83.  Sugimoto J, Hatakeyama T, Narducci MG, Russo G, Isobe M. Identification of the 
TCL1/MTCP1-like 1 (TML1) gene from the region next to the TCL1 locus. Cancer 
Res. 1999;59(10):2313–7.  
84.  Hallas C, Pekarsky Y, Itoyama T, Varnum J, Bichi R, Rothstein JL, et al. Genomic 
analysis of human and mouse TCL1 loci reveals a complex of tightly clustered genes. 
Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14418–23.  
85.  Croce CM, Isobe M, Palumbo A, Puck J, Ming J, Tweardy D, et al. Gene for alpha-
chain of human T-cell receptor: location on chromosome 14 region involved in T-cell 
neoplasms. Science (80- ). 1985 Mar 1;227(4690):1044–7.  
86.  Fu TB, Virgilio L, Narducci MG, Facchiano A, Russo G, Croce CM. Characterization 
and localization of the TCL-1 oncogene product. Cancer Res. 1994;54(24):6297–301.  
87.  Hoh F, Yang YS, Guignard L, Padilla A, Stern MH, Lhoste JM, et al. Crystal structure 
of p14TCL1, an oncogene product involved in T-cell prolymphocytic leukemia, 
reveals a novel beta-barrel topology. Structure. 1998;6(2):147–55.  
88.  Narducci MG, Virgilio L, Engiles JB, Buchberg AM, Billips L, Facchiano A, et al. 
The murine Tcl1 oncogene: embryonic and lymphoid cell expression. Oncogene. 
1997;15(8):919–26.  
89.  Ivanova N, Dobrin R, Lu R, Kotenko I, Levorse J, DeCoste C, et al. Dissecting self-
renewal in stem cells with RNA interference. Nature. 2006 Aug 3;442(7102):533–8.  
90.  Kang SM, Narducci MG, Lazzeri C, Mongiovi AM, Caprini E, Bresin A, et al. 
Impaired T- and B-cell development in Tcl1-deficient mice. Blood. 2005;105(3):1288–
94.  
 114 
91.  Pekarsky Y, Hallas C, Isobe M, Russo G, Croce CM. Abnormalities at 14q32.1 in T 
cell malignancies involve two oncogenes. Proc Natl Acad Sci U S A. 
1999;96(6):2949–51.  
92.  Seifert M, Sellmann L, Bloehdorn J, Wein F, Stilgenbauer S, Durig J, et al. Cellular 
origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med. 2012 Nov 
19;209(12):2183–98.  
93.  Herling M, Teitell MA, Shen RR, Medeiros LJ, Jones D. TCL1 expression in 
plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of 
skin. Blood. 2003;101(12):5007–9.  
94.  Thick J, Metcalfe JA, Mak YF, Beatty D, Minegishi M, Dyer MJS, et al. Expression of 
either the TCL1 oncogene, or transcripts from its homologue MTCP1/c6.1B, in 
leukaemic and non-leukaemic T cells from ataxia telangiectasia patients. Oncogene. 
1996;12(2):379–86.  
95.  Narducci MG, Fiorenza MT, Kang SM, Bevilacqua A, Di Giacomo M, Remotti D, et 
al. TCL1 participates in early embryonic development and is overexpressed in human 
seminomas. Proc Natl Acad Sci U S A. 2002;99(18):11712–7.  
96.  Roos J, Hennig I, Schwaller J, Zbaren J, Dummer R, Burg G, et al. Expression of 
TCL1 in hematologic disorders. Pathobiology. 2001;69(2):59–66.  
97.  Wang X, Yang S, Zhao X, Guo H, Ling X, Wang L, et al. OCT3 and SOX2 promote 
the transformation of Barrett’s esophagus to adenocarcinoma by regulating the 
formation of tumor stem cells. Oncol Rep. 2014 Apr;31(4):1745–53.  
98.  Hong X, Song R, Song H, Zheng T, Wang J, Liang Y, et al. PTEN antagonises 
Tcl1/hnRNPK-mediated G6PD pre-mRNA splicing which contributes to 
hepatocarcinogenesis. Gut. 2014 Oct;63(10):1635–47.  
99.  Lau SK, Weiss LM, Chu PG. TCL1 protein expression in testicular germ cell tumors. 
Am J Clin Pathol. 2010/04/17 ed. 2010;133(5):762–6.  
100.  Liu A, Cheng L, Du J, Peng Y, Allan RW, Wei L, et al. Diagnostic utility of novel 
stem cell markers SALL4, OCT4, NANOG, SOX2, UTF1, and TCL1 in primary 
mediastinal germ cell tumors. Am J Surg Pathol. 2010/04/23 ed. 2010;34(5):697–706.  
101.  Virgilio L, Isobe M, Narducci MG, Carotenuto P, Camerini B, Kurosawa N, et al. 
Chromosome walking on the TCL1 locus involved in T-cell neoplasia. Proc Natl Acad 
Sci U S A. 1993;90(20):9275–9.  
102.  Pekarsky Y, Hallas C, Croce CM. Molecular basis of mature T-cell leukemia. Jama. 
2001;286(18):2308–14.  
103.  Herling M, Patel KA, Khalili J, Schlette E, Kobayashi R, Medeiros LJ, et al. TCL1 
shows a regulated expression pattern in chronic lymphocytic leukemia that correlates 
 115 
with molecular subtypes and proliferative state. Leukemia. Nature Publishing Group; 
2006;20(2):280–5.  
104.  Fink SR, Paternoster SF, Smoley SA, Flynn HC, Geyer SM, Shanafelt TD, et al. 
Fluorescent-labeled DNA probes applied to novel biological aspects of B-cell chronic 
lymphocytic leukemia. Leuk Res. 2005;29(3):253–62.  
105.  Yuille MR, Condie A, Stone EM, Wilsher J, Bradshaw PS, Brooks L, et al. TCL1 is 
activated by chromosomal rearrangement or by hypomethylation. Genes Chromosom 
Cancer. 2001;30(4):336–41.  
106.  French SW, Malone CS, Shen RR, Renard M, Henson SE, Miner MD, et al. Sp1 
transactivation of the TCL1 oncogene. J Biol Chem. 2003;278(2):948–55.  
107.  Sivina M, Hartmann E, Vasyutina E, Boucas JM, Breuer A, Keating MJ, et al. Stromal 
cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting 
micro-RNAs in chronic lymphocytic leukemia. Leukemia. 2012/03/31 ed. 2012 
Aug;26(8):1812–20.  
108.  Herling M, Patel KA, Hsi ED, Chang KC, Rassidakis GZ, Ford R, et al. TCL1 in B-
cell tumors retains its normal B-cell pattern of regulation and is a marker of 
differentiation stage. Am J Surg Pathol. 2007;31(7):1123–9.  
109.  Vasyutina E, Boucas JM, Bloehdorn J, Aszyk C, Crispatzu G, Stiefelhagen M, et al. 
The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival 
and clinical outcome in CLL. Leukemia. 2015 Oct;29(10):2003–14.  
110.  Hoyer KK, French SW, Turner DE, Nguyen MTN, Renard M, Malone CS, et al. 
Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma. Proc Natl 
Acad Sci U S A. National Academy of Sciences; 2002;99(22):14392–7.  
111.  Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R, et al. Human chronic 
lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl 
Acad Sci U S A. 2002;99(10):6955–60.  
112.  Simonetti G, Bertilaccio MTS, Ghia P, Klein U. Mouse models in the study of chronic 
lymphocytic leukemia pathogenesis and therapy. Blood. 2014 Aug 14;124(7):1010–9.  
113.  Matoba R, Niwa H, Masui S, Ohtsuka S, Carter MG, Sharov AA, et al. Dissecting 
Oct3/4-regulated gene networks in embryonic stem cells by expression profiling. PLoS 
One. 2006;1:e26.  
114.  Ema M, Mori D, Niwa H, Hasegawa Y, Yamanaka Y, Hitoshi S, et al. Krüppel-like 
factor 5 is essential for blastocyst development and the normal self-renewal of mouse 
ESCs. Cell Stem Cell. 2008;3(5):555–67.  
115.  Miyazaki T, Miyazaki S, Ashida M, Tanaka T, Tashiro F, Miyazaki J. Functional 
Analysis of Tcl1 Using Tcl1-Deficient Mouse Embryonic Stem Cells. Wutz A, editor. 
 116 
PLoS One. 2013 Aug 5;8(8):e71645.  
116.  Ragone G, Bresin A, Piermarini F, Lazzeri C, Picchio MC, Remotti D, et al. The Tcl1 
oncogene defines secondary hair germ cells differentiation at catagen-telogen 
transition and affects stem-cell marker CD34 expression. Oncogene. 2009;  
117.  Laine J, Kunstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 is an Akt 
kinase coactivator. Mol Cell. 2000;6(2):395–407.  
118.  French SW, Shen RR, Koh PJ, Malone CS, Mallick P, Teitell MA. A modeled 
hydrophobic domain on the TCL1 oncoprotein mediates association with AKT at the 
cytoplasmic membrane. Biochemistry. 2002;41(20):6376–82.  
119.  Pekarsky Y, Koval A, Hallas C, Bichi R, Tresini M, Malstrom S, et al. Tcl1 enhances 
Akt kinase activity and mediates its nuclear translocation. Proc Natl Acad Sci U S A. 
2000;97(7):3028–33.  
120.  Kunstle G, Laine J, Pierron G, Kagami Si S, Nakajima H, Hoh F, et al. Identification 
of Akt association and oligomerization domains of the Akt kinase coactivator TCL1. 
Mol Cell Biol. 2002;22(5):1513–25.  
121.  Pekarsky Y, Palamarchuk A, Maximov V, Efanov A, Nazaryan N, Santanam U, et al. 
Tcl1 functions as a transcriptional regulator and is directly involved in the 
pathogenesis of CLL. Proc Natl Acad Sci U S A. 2008;105(50):19643–8.  
122.  Colotta F, Polentarutti N, Sironi M, Mantovani A. Expression and involvement of c-
fos and c-jun protooncogenes in programmed cell death induced by growth factor 
deprivation in lymphoid cell lines. J Biol Chem. 1992;267(26):18278–83.  
123.  Gaudio E, Spizzo R, Paduano F, Luo Z, Efanov A, Palamarchuk A, et al. Tcl1 interacts 
with Atm and enhances NF-kappaB activation in hematologic malignancies. Blood. 
2011/11/09 ed. 2012;119(1):180–7.  
124.  Kastan MB, Lim DS. The many substrates and functions of ATM. Nat Rev Mol Cell 
Biol. 2000;1(3):179–86.  
125.  Fan Y, Dutta J, Gupta N, Fan G, Gélinas C. Regulation of programmed cell death by 
NF-kappaB and its role in tumorigenesis and therapy. Adv Exp Med Biol. 
2008;615:223–50.  
126.  Malstrom S, Tili E, Kappes D, Ceci JD, Tsichlis PN. Tumor induction by an Lck-
MyrAkt transgene is delayed by mechanisms controlling the size of the thymus. Proc 
Natl Acad Sci U S A. The National Academy of Sciences; 2001;98(26):14967–72.  
127.  Barlow C, Hirotsune S, Paylor R, Liyanage M, Eckhaus M, Collins F, et al. Atm-
deficient mice: a paradigm of ataxia telangiectasia. Cell. 1996 Jul 12;86(1):159–71.  
 
 117 
128.  Herling M, Patel KA, Weit N, Lilienthal N, Hallek M, Keating MJ, et al. High TCL1 
levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in 
chronic lymphocytic leukemia. Blood. American Society of Hematology; 
2009;114(21):4675–86.  
129.  Despouy G, Joiner M, Le Toriellec E, Weil R, Stern MH. The TCL1 oncoprotein 
inhibits activation-induced cell death by impairing PKC theta and ERK pathways. 
Blood. 2007;110(13):4406–16.  
130.  Soulier J, Madani A, Cacheux V, Rosenzwajg M, Sigaux F, Stern MH. The MTCP-
1/c6.1B gene encodes for a cytoplasmic 8 kD protein overexpressed in T cell leukemia 
bearing a t(X;14) translocation. Oncogene. 1994;9(12):3565–70.  
131.  Madani A, Choukroun V, Soulier J, Cacheux V, Claisse JF, Valensi F, et al. 
Expression of p13MTCP1 is restricted to mature T-cell proliferations with t(X;14) 
translocations. Blood. 1996;87(5):1923–7.  
132.  Auguin D, Barthe P, Royer C, Stern MH, Noguchi M, Arold ST, et al. Structural basis 
for the co-activation of protein kinase B by T-cell leukemia-1 (TCL1) family proto-
oncoproteins. J Biol Chem. 2004;279(34):35890–902.  
133.  Teague TK, Hildeman D, Kedl RM, Mitchell T, Rees W, Schaefer BC, et al. 
Activation changes the spectrum but not the diversity of genes expressed by T cells. 
Proc Natl Acad Sci U S A. 1999;96(22):12691–6.  
134.  Stitz J, Buchholz CJ, Engelstädter M, Uckert W, Bloemer U, Schmitt I, et al. Lentiviral 
vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia 
virus and murine leukemia virus 10A1. Virology. 2000;273(1):16–20.  
135.  Schambach A, Wodrich H, Hildinger M, Bohne J, Kräusslich HG, Baum C. Context 
dependence of different modules for posttranscriptional enhancement of gene 
expression from retroviral vectors. Mol Ther. 2000;2(5):435–45.  
136.  Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free 
retroviruses by transient transfection. Proc Natl Acad Sci U S A. 1993;90(18):8392–6.  
137.  Hartley JW, Rowe WP. Clonal cells lines from a feral mouse embryo which lack host-
range restrictions for murine leukemia viruses. Virology. 1975;65(1):128–34.  
138.  Gillis S, Smith KA. Long term culture of tumour-specific cytotoxic T cells. Nature. 
1977;268(5616):154–6.  
139.  Thomas PD. PANTHER: A Library of Protein Families and Subfamilies Indexed by 
Function. Genome Res. 2003 Sep 1;13(9):2129–41.  
140.  Morse  3rd HC, Anver MR, Fredrickson TN, Haines DC, Harris AW, Harris NL, et al. 
Bethesda proposals for classification of lymphoid neoplasms in mice. Blood. 
2002;100(1):246–58.  
 118 
141.  Noguchi M, Ropars V, Roumestand C, Suizu F. Proto-oncogene TCL1: more than just 
a coactivator for Akt. Faseb J. 2007/03/16 ed. 2007;21(10):2273–84.  
142.  Sanchez-Beato M. Cell cycle deregulation in B-cell lymphomas. Blood. 2003 Feb 
15;101(4):1220–35.  
143.  Tane S, Chibazakura T. Cyclin A overexpression induces chromosomal double-strand 
breaks in mammalian cells. Cell cycle. 2009;8(23):3900–3.  
144.  Sarafan-Vasseur N, Lamy A, Bourguignon J, Le Pessot F, Hieter P, Sesboüé R, et al. 
Overexpression of B-type cyclins alters chromosomal segregation. Oncogene. 
2002;21(13):2051–7.  
145.  Baker DJ, Jeganathan KB, Cameron JD, Thompson M, Juneja S, Kopecka A, et al. 
BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility 
in mice. Nat Genet. 2004;36(7):744–9.  
146.  Dai W, Wang Q, Liu T, Swamy M, Fang Y, Xie S, et al. Slippage of mitotic arrest and 
enhanced tumor development in mice with BubR1 haploinsufficiency. Cancer Res. 
2004;64(2):440–5.  
147.  Xu X, Page JL, Surtees JA, Liu H, Lagedrost S, Lu Y, et al. Broad overexpression of 
ribonucleotide reductase genes in mice specifically induces lung neoplasms. Cancer 
Res. 2008;68(8):2652–60.  
148.  Martelli AM, Tabellini G, Bressanin D, Ognibene A, Goto K, Cocco L, et al. The 
emerging multiple roles of nuclear Akt. Biochim Biophys Acta. 2012 
Dec;1823(12):2168–78.  
149.  Ge Q, Holler PD, Mahajan VS, Nuygen T, Eisen HN, Chen J. Development of CD4+ 
T cells expressing a nominally MHC class I-restricted T cell receptor by two different 
mechanisms. Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1822–7.  
150.  Lui JB, Devarajan P, Teplicki SA, Chen Z. Cross-Differentiation from the CD8 
Lineage to CD4 T Cells in the Gut-Associated Microenvironment with a Nonessential 
Role of Microbiota. Cell Rep. 2015 Feb;10(4):574–85.  
151.  Warner K, Crispatzu G, Al-Ghaili N, Weit N, Florou V, You MJ, et al. Models for 
mature T-cell lymphomas-A critical appraisal of experimental systems and their 
contribution to current T-cell tumorigenic concepts. Crit Rev Oncol Hematol. 
2013;88(3):680–95.  
152.  Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid 
malignancies. Nat Rev Drug Discov. 2013 Mar 1;12(3):229–43.  
153.  Shah A, Mangaonkar A. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic 
Leukemia. Ann Pharmacother. 2015 Oct;49(10):1162–70.  
 119 
154.  Forconi F. Three years of ibrutinib in CLL. Blood. 2015 Apr 16;125(16):2455–6.  
155.  Witzig TE, Reeder C, Han JJ, LaPlant B, Stenson M, Tun HW, et al. The mTORC1 
inhibitor everolimus has antitumor activity in vitro and produces tumor responses in 
patients with relapsed T-cell lymphoma. Blood. 2015 Jul 16;126(3):328–35.  
156.  Dondorf S, Schrader A, Herling M. Interleukin-2-inducible T-cell Kinase (ITK) 
Targeting by BMS-509744 Does Not Affect Cell Viability in T-cell Prolymphocytic 
Leukemia (T-PLL): FIGURE 1. J Biol Chem. 2015 Apr 17;290(16):10568–9.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 120 
5. Appendices 
5.1 Abbreviations 
AICD    Activation-induced cell death 
AITL    Angioimmunoblastic T-cell lymphoma 
APC     Antigen presenting cell 
ALCL   Anaplastic large cell lymphoma 
ATM    Ataxia telangiectasia mutated 
BM    Bone marrow 
BSA     Bovine serum albumin 
CAR     Chimeric antigen receptor 
CCL     Chemokine with C-C motive 
CD     Cluster of differentiation 
CDR    Complementarity determining region 
CLL    Chronic lymphocytic leukemia 
CLP    Common lymphoid progenitor 
CTL    Cytotoxic T-lymphocyte 
DMEM   Dulbecco's modified eagle medium 
DMSO   Dimethyl sulfoxide 
DN    Double negative 
DNA    Deoxyribonucleic acid 
DP      Double positive 
E.coli    Escherichia coli 
EDTA   Ethylenediaminetetraacetic acid 
EGFP    Enhanced green fluorescent protein 
ER    Endoplasmic reticulum 
FACS    Fluorescence activated cell sorting 
FBS     Fetal bovine serum 
FC    Flow cytometry 
FELASA   Federation of European Laboratory Animal Science Associations 
GPCR   G protein–coupled receptor 
HBSS    Hanks balanced salt solution 
HE     Hematoxylin/eosin 
HEPES   Hydroxyethylpiperazineethanesulfonic acid 
HPC    Hematopoietic progenitor cell 
HSC     Hematopoietic stem cell 
ICFC    Intracellular Flow Cytometry 
IFA    Incomplete Freund’s adjuvant 
i.p.     Intraperitoneal 
i.v.     Intravenous 
IFN-γ    Interferon γ 
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Ig     Immunoglobulin 
IL     Interleukin 
ITAM    Immunoreceptor tyrosine-based activation motifs 
IVC     Individually ventilated cages 
LN    Lymph node 
LTR     Long terminal repeats 
M    Molar 
MACS   Magnetic activated cell sorting 
MSA    Mouse Serum Albumin 
MTCP1  Mature T-cell proliferation 1 
MTCL   Mature T-cell leukemias/lymphomas 
MHC     Major histocompatibility complex 
MYC    Myelocytomatosis oncogene 
NK    Natural killer 
OVA    Ovalbumin 
PTCL    Peripheral T-cell leukemias/lymphomas 
RAG     Recombination activating gene 
ROI    Region of interest 
rpm    Rounds per minute 
RPMI    Roswell Park Memorial Institute 
RSD    Relative standard deviation 
SP    Single positive 
spMHC  Self-peptide/Major histocompatibility complex  
STAT    Signal transducer and activator of transcription 
SV40    Simian virus 40 
Th    T-helper cells 
TCL1A  T-cell leukemia/lymphoma 1 
TCR    T-cell receptor 
TGF-β1   Transforming growth factor–β1 
TML1   TCL1A/MTCP1-like 1 
T-PLL   T-cell prolymphocytic leukemia 
v/v   Volume/Volume 
WB   Western Blot 
WBC     White blood count 
WHO    World Health Organization 
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5.2 Plasmid Maps 
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nls-TCL1A. 
* 
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Figure 5-1: Plasmid maps. 
 
 
 
 
 
 
 
 
 
 
 
MP91- 
T-Sapphire- 
Luc 
MP91- 
TCL1A- 
Luc 
 124 
5.3 Lists of differently expressed genes 
Table 5-1: List of pathway genes up-regulated (é) or down-regulated (ê) in at least two of three 
cohorts: TCL1A, myr-TCL1A and nls-TCL1A 
 TCL1A myr-TCL1A nls-TCL1A 
Chemokine 
Signaling 
Pathway 
!  Cxcl2, Gng12 Cxcl2, Gng12 Cxcl2, Gng12 
" Ccr7, Akt3 Ccr7, Akt3 Ccr7, Akt3 
Cell Cycle !  
Bub1b, Bub1, Ccna2, 
Chek1, Ccnb1, Ccnb2, 
Tfdp1, Cdkn1a, Cdc20, 
Mpeg1, Plk1, Cdc25c 
Bub1b, Bub1, Wee1, 
Ccna2, Chek1, Ccnb1, 
Ccnb2, Tfdp1, Cdkn1a, 
Cdc20, Mpeg1, Plk1, 
Cdc25c 
Bub1b, Wee1, Ccna2, 
Ccnb1, Ccnb2, Tfdp1, 
Cdc20, Plk1 
p53 
Signaling 
!  Chek1, Cdkn1a, Ccnb1, Ccnb2, Cdk1, Rrm2 
Chek1, Cdkn1a, Ccnb1, 
Ccnb2, Cdk1, Rrm2 
Ccnb1, Ccnb2, Cdk1, 
Rrm2 
"  - Ddb2 Ddb2 
PI3K-AKT-
mTOR 
Signaling 
Pathway 
!  Gng12, Cdkn1a Gng12, Cdkn1a Gng12 
"  Itgam, Il4ra, Akt3 Itgam, Akt3 Il4ra, Akt3 
miRNA 
regulation of 
DDR 
!  
Cdkn1a, Ccnb1, Chek1, 
Cdk1, Cdc25c, H2afx, 
Ccnb2 
Cdkn1a, Ccnb1, Chek1, 
Cdk1, Cdc25c, H2afx, 
Ccnb2 
Ccnb1, Cdk1, H2afx, 
Ccnb2 
" - Ddb2 Ddb2 
MAPK 
Signaling 
Pathway 
! Stmn1, Hspa5,  Stmn1, Hspa5 - 
" Tgfbr2, Ppp3cc, Akt3 Ppp3cc, Akt3 Tgfbr2, Ppp3cc, Akt3 
Purine 
metabolism 
!  Rrm2 Rrm2, Prps2, Pde8a Rrm2, Pde8a 
" Pde4d, Polr3e Pde4d, Polr3e Polr3e 
Non-odorant 
GPCRs 
! Ccrl2, Lphn2 Ccrl2 Lphn2 
" Ccr7, Gpr174 Ccr7, Gpr174, S1pr1 Ccr7, Gpr174, S1pr1 
TGF-beta 
Receptor 
Signaling 
! Cd44, Atf3, Tfdp1, Cdkn1a, Ccnb2 
Cd44, Atf3, Tfdp1, 
Cdkn1a, Ccnb2 Atf3, Tfdp1, Ccnb2 
" Tgfbr2, Crebbp - Tgfbr2, Crebbp 
Ca2+ 
Regulation 
! Prkar2b, Gng12 Prkar2b, Gng12 Prkar2b, Gng12 
" - Itpr2 Itpr2 
 
 125 
 
Table 5-2: List of pathway genes up-regulated (é) or down-regulated (ê) in at least two of three 
cohorts: TCL1A, myr-TCL1A and nls-TCL1A B cells 
 
 
 
 
 
 TCL1A myr-TCL1A nls-TCL1A 
Cell Cycle !  
Bub1b, Ccna2, 
Gadd45a, Ccnb1, 
Ccnb2, Mpeg1 
Bub1b, Wee1, Ccna2, 
Gadd45a, Ccnb1, Ccnb2 
Ccna2, Gadd45a, 
Ccnb1, Mpeg1 
MAPK 
Signaling 
Pathway 
!  Gadd45a, Gna12, Mapkapk2, Il1a 
Gadd45a, Gna12, 
Mapkapk2 
Gadd45a, Gna12, 
Mapkapk2, Il1a 
"  - Ppm1b Ppm1b 
PI3K-AKT-
mTOR 
Signaling 
Pathway 
!  Creb3l2 Creb3l2 Creb3l2 
"  Itgam, Ppp2r5c Itgam Itgam, Ppp2r5c 
Adipogenesis 
genes !  Pparg, Gadd45a, Ahr  Gadd45a, Ahr Pparg, Gadd45a, Ahr 
Regulation 
of Actin 
Cytoskeleton 
!  Gna12 Gna12, Ssh2 Gna12, Ssh2 
Purine 
metabolism 
!  Rrm2, Entpd1 Rrm1, Rrm2 Entpd1 
"  Pde4d, Nme2 - Pde4d, Nme2 
p53 
Signaling !  
Ccnb1, Ccnb2, 
Gadd45a, Rrm2 
Ccnb1, Ccnb2, 
Gadd45a, Rrm2 Ccnb1, Gadd45a 
mRNA 
processing "  Park7 - Park7 
miRNA 
regulation of 
DDR 
!  Gadd45a, Ccnb1, H2afx, Ccnb2 
Gadd45a, Ccnb1, H2afx, 
Ccnb2 Gadd45a, Ccnb1 
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Table 5-3: List of pathway genes up-regulated (é) or down-regulated (ê) in at least two of three 
cohorts: TCL1A, myr-TCL1A and nls-TCL1A T cells 
 
 
 
 
 
 
 
 
 
 
 
 
 TCL1A myr-TCL1A nls-TCL1A 
Chemokine 
Signaling 
Pathway 
!  Ccr8 Ccr8, Akt1 Ccr8, Akt1 
MAPK 
Signaling 
Pathway 
!  - Gna12, Akt1, Stk3, Mapkapk2  
Gna12, Akt1, Stk3, 
Mapkapk2 
Kit Receptor 
Signaling 
Pathway 
!  Grb7 Grb7, Akt1, Spred1 Grb7, Akt1, Spred1 
Androgen 
Receptor 
Signaling 
Pathway 
!  - Akt1 Akt1 
PI3K-AKT-
mTOR 
Signaling 
Pathway 
!  - Itgax, Akt1, Ppp2r1a Itgax, Akt1, Ppp2r1a 
G1 to S cell 
cycle control !  - Tfdp1, Mcm2, Pola2 Tfdp1, Mcm2, Pola2 
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5.4 Lists of retroviral integration sites  
Tumor Chr Location Type Gene Symbol Distance Start End OR Hit 
TCL1A 
A1 
w/o 
stim 
8 13214233 s Mcf2l 340427 12873806 13020905 F No 
  s Gm15349 -242492 12971826 12972029 R No 
  s Gm15352 192292 13021941 13022210 F No 
  s F7 188199 13026034 13035809 F No 
  s F10 176925 13037308 13056676 F No 
   s Proz 153325 13060908 13075006 F No 
   s Gm17023 138156 13076077 13082740 F No 
   s Pcid2 -109062 13077189 13105459 R No 
   s Gm17022 127716 13086517 13087428 F No 
   s Cul4a 108612 13105621 13147940 F No 
   s Lamp1 55098 13159135 13175338 F No 
   c Grtp1 -13901 13175162 13200620 R Yes 
   s Mir1968 -25423 13189031 13189098 R No 
   s Adprhl1 39641 13235655 13254162 R No 
   s Dcun1d2 73605 13255963 13288126 R No 
   s U6 68693 13283115 13283214 R No 
   s Tmco3 -73780 13288013 13322924 F No 
   s Tfdp1 -124518 13338751 13378395 F No 
   s Atp4b 182257 13386209 13396778 R No 
   s Grk1 -190848 13405081 13421945 F No 
   s Fam70b -221193 13435426 13461452 F No 
 15 76736308 s Cyhr1 -245929 76473825 76490547 R No 
   s Kifc2 245312 76490996 76498625 F No 
   s Foxh1 -236098 76498714 76500378 R No 
   s Ppp1r16a 234263 76502045 76525349 F No 
   s Gpt 209145 76527163 76530104 F No 
   s Mfsd3 204336 76531972 76534669 F No 
   s Recql4 -195513 76533984 76540963 R No 
   s Lrrc14 195255 76541053 76548129 F No 
   s Lrrc24 -183873 76545706 76552603 R No 
   s C030006K11Rik -182201 76551896 76554275 R No 
   s Arhgap39 -87876 76554415 76648600 R No 
   s Gm17271 108548 76627760 76628459 F No 
   s Zfp251 -34611 76682578 76701865 R No 
   s Zfp7 26619 76709689 76722822 F No 
   s Commd5 5968 76730340 76731735 F No 
   c Rpl8 1807 76734501 76736748 F Yes 
   s Zfp647 11964 76741281 76748440 R No 
   s 1110038F14Rik -42661 76778969 76781159 F No 
   s Mb 144624 76845919 76881100 R No 
   s Apol6 -138851 76875159 76887537 F No 
   s U6 -161913 76898221 76898327 F No 
   s Rbfox2 401007 76909420 77137483 R No 
   s 1700109K24Rik -178565 76914873 76926744 F No 
TCL1A 
A2 
w/o 
stim 
1 132948239 s Fcamr 250760 132697479 132711317 F No 
  s Gm15848 -227883 132706554 132720661 R No 
  s Pigr 224978 132723261 132748826 F No 
  s Faim3 185993 132762246 132777367 F No 
   s Il24 -164513 132778651 132784031 R No 
   s Il20 -140671 132803769 132807873 R No 
   s Il19 -111894 132829235 132836650 R No 
   s Il10 31817 132916422 132921551 F No 
   s Mapkapk2 45600 132950281 132994144 R No 
   c U6 21784 132970235 132970328 R Yes 
   s 7SK 50778 132998970 132999322 R No 
   s Dyrk3 86267 133025018 133034811 R No 
   s Eif2d -101519 133049758 133084235 F No 
   s Rassf5 193291 133072987 133141835 R No 
   s Ikbke 227639 133150920 133176183 R No 
   s Srgap2 475394 133181828 133423938 R No 
 14 21036013 s Gng2 -239276 20691781 20796849 R No 
   s 1810063B07Rik -133731 20894868 20902394 R No 
   s Kcnk5 -35121 20959280 21001004 R No 
   c SNORA70 -16791 21019218 21019334 R Yes 
   s Kcnk16 52259 21081978 21088384 R No 
   s Nudt13 -77899 21113912 21136797 F No 
   s Ecd 131218 21139081 21167343 R No 
   s Fam149b -131371 21167384 21202711 F No 
   s Dnajc9 172007 21203860 21208132 R No 
   s Mrps16 176652 21210453 21212777 R No 
   s Ttc18 235323 21213412 21271448 R No 
   s 7330404K18Rik -181568 21217581 21218152 F No 
   s Anxa7 263230 21274483 21299355 R No 
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TCL1A 
A3 
w/o 
stim 
5 108108767 s Ephx4 276978 107831755 107859054 F No 
  s Gm17202 -247838 107833842 107860929 R No 
  s Lpcat2b 248165 107860568 107864058 F No 
  s Btbd8 241717 107867016 107920647 F No 
   s Gm9727 -200668 107907545 107908099 R No 
   s A830010M20Rik 183816 107924917 108009615 F No 
   s 1700028K03Rik 170770 107937963 107980568 F No 
   s Glmn -81860 107977986 108026907 R No 
   s Rpap2 82341 108026392 108090857 F No 
   s A930041C12Rik -45898 108059269 108062869 R No 
   c Gm17717 8267 108088116 108117034 R Yes 
   s Gfi1 46289 108145674 108155056 R No 
   s A430072P03Rik -45444 108154177 108157821 F No 
   s Evi5 195359 108173814 108304126 R No 
   s 1700013N18Rik -150539 108259272 108260361 F No 
   s Gm16007 -164676 108273409 108273694 F No 
   s Rpl5 -220788 108329521 108338024 F No 
   s Snord21 -224841 108333574 108333667 F No 
   s SNORA66 -225463 108334196 108334327 F No 
   s SNORA66 -227631 108336364 108336495 F No 
   s Fam69a 307337 108337072 108416104 R No 
TCL1A 
A4 
w/o 
stim 
3 88255603 s AW047730 251058 88004545 88007403 F No 
  s Gm3764 237196 88018407 88025782 F No 
  s Mir3093 236510 88019093 88019179 F No 
  s AC044864.1 -236407 88019511 88019618 R No 
   s Rhbg -164893 88046796 88091132 R No 
   s Gm17285 174581 88081022 88081376 F No 
   s 1700021C14Rik -155104 88084043 88100921 R No 
   s Cct3 154565 88101038 88125689 F No 
   s 0610031J06Rik 126658 88128945 88135235 F No 
   s Tmem79 -117599 88132577 88138426 R No 
   s Smg5 115421 88140182 88166259 F No 
   s Paqr6 87097 88168506 88172463 F No 
   s Bglap-rs1 -79360 88172538 88176665 R No 
   s Bglap2 -73404 88181658 88182621 R No 
   s Gm6821 70677 88184926 88186733 F No 
   s Bglap -67639 88187423 88188386 R No 
   s Pmf1 -41787 88198061 88214238 R No 
   s Slc25a44 -26964 88214420 88229061 R No 
   c Sema4a 9079 88239881 88265104 R Yes 
   s Lmna 57853 88285070 88313878 R No 
   s Mex3a -80714 88336317 88345318 F No 
   s Mir1905 84279 88340223 88340304 R No 
   s Rab25 96197 88345951 88352222 R No 
   s Lamtor2 100971 88353741 88356996 R No 
   s Ubqln4 -102035 88357638 88373647 F No 
   s Gm10704 125038 88380329 88381063 R No 
   s Ssr2 -127990 88383593 88392319 F No 
   s Arhgef2 -155773 88411376 88451974 F No 
   s RP23-398K14.3.1 168958 88420379 88424983 R No 
   s Rxfp4 201039 88455820 88457064 R No 
   s 2810403A07Rik -234113 88489716 88516855 F No 
   s SCARNA15 -242250 88497853 88497979 F No 
TCL1A 
A5 
w/o 
14 66809027 s Scara3 -236671 66538232 66572581 R No 
  s Clu 221707 66587320 66600385 F No 
  s Gulo -181205 66605624 66628047 R No 
stim   s Adam2 -112682 66646166 66696570 R No 
   s Gm10233 145110 66663917 66664546 F No 
   s Ephx2 -65915 66703214 66743337 R No 
   c Chrna2 49230 66759797 66771785 F No 
   s Ptk2b 90637 66772094 66899889 R Yes 
   s 1700001G11Rik 106714 66914171 66915966 R No 
   s Trim35 -106841 66915868 66930261 F No 
   s Stmn4 -154106 66963133 66980517 F No 
 11 78942302 s Nos2 208013 78734289 78773756 F No 
   s Lgals9 -144319 78776476 78798448 R No 
   c Ksr1 17142 78826942 78959909 R Yes 
   s Gm11201 105203 78837099 78844559 F No 
   s Gm11200 -83996 79026298 79026745 F No 
   s Wsb1 125406 79052874 79068173 R No 
   s Gm9964 167641 79109681 79110408 R No 
   s Nf1 -210893 79153195 79395114 F No 
   s Gm11198 242965 79184759 79185732 R No 
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Table 5-4: List of retroviral integration sites of T-cell tumors induced by TCL1A in unstimulated 
mice 
Tumor: Tumor sample. Chr: Mapped chromosome. Location: Genome location. Type: Closest (c) and 
surrounding (s) genes. Distance: Distance between integration and gene start. Start: Gene start. End: 
Gene end. OR: Relative orientation of integrated vector (F: forward, R: reverse). Hit: Hit in gene.  
 
 
 
 
 
 
 
 
 
 
TCL1A 16 10778487 s Dexi -235823 10530300 10543147 R No 
A6   s Clec16a 233030 10545457 10744971 F No 
w/o   s Gm15558 -95338 10669341 10683632 R No 
stim   c Socs1 6659 10783901 10785629 R No 
   s Tnp2 9778 10788029 10788748 R No 
   s Prm3 12036 10790600 10791006 R No 
   s Prm2 13228 10791476 10792198 R No 
   s Prm1 18009 10796419 10796979 R No 
   s Gm10343 -22975 10801462 10801809 F No 
   s Gm11172 -34521 10813008 10813087 F No 
   s Gm17410 -49533 10828020 10833600 F No 
   s A630055G03Rik -56665 10835152 10886327 F No 
   s Litaf 287280 10959368 11066250 R No 
   s AC164093.1 -187330 10965817 10965942 F No 
   s U1 -215992 10994479 10994662 F No 
   s Gm4262 -230504 11008991 11015279 F No 
 18 35018200 s Brd8 -234020 34758269 34784255 R No 
   s Kif20a 233922 34784278 34792919 F No 
   s Cdc23 -206886 34790605 34811389 R No 
   s n-R5s25 211146 34807054 34807172 F No 
   s Gfra3 -138234 34849557 34880041 R No 
   s Cdc25c -107088 34892651 34911187 R No 
   s Gm3550 121179 34897021 34897665 F No 
   s 2010110K18Rik 106737 34911463 34918339 F No 
   s Fam53c 99640 34918560 34933414 F No 
   s Kdm3b 81538 34936662 34999024 F No 
   s Gm17557 -55137 34956549 34963138 R No 
   s Reep2 17888 35000312 35007106 F No 
   c Egr1 -1277 35019477 35024638 F No 
   s Gm17507 6488 35024439 35024763 R No 
   s Etf1 73382 35062446 35091657 R No 
   s Hspa9 95736 35097068 35114011 R No 
   s SNORD63 82679 35100888 35100954 R No 
   s SNORD63 84092 35102298 35102367 R No 
   s Gm6724 112148 35129314 35130423 R No 
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Tumor Chr Location Type Gene Symbol Distance Start End OR Hit 
TCL1A 
A1 
OVA 
stim 
13 117855843 c Parp8 -41948 117643631 117814323 R Yes 
  s Gm17509 153611 118007508 118009882 R No 
  s Emb -153589 118009432 118062905 F No 
         
 11 103198572 s Plcd3 -236177 102931618 102962972 R No 
   s Acbd4 235576 102962996 102973514 F No 
   s Hexim1 220933 102977639 102981039 F No 
   s Hexim2 204829 102993743 103001190 F No 
   s Fmnl1 166151 103032421 103060215 F No 
   s Gm20511 -144939 103052024 103054210 R No 
   s 1700023F06Rik -129277 103060260 103069872 R No 
   s 4933400C05Rik -119403 103069441 103079746 R No 
   s Map3k14 -70363 103081076 103128786 R No 
   s 1700028N14Rik -70090 103126174 103129059 R No 
   s Arhgap27 25857 103192811 103225006 R No 
   c Gm11648 -7495 103206067 103211438 F Yes 
   s Gm11647 -18443 103217015 103222406 F No 
   s Gm11641 -25955 103224527 103225965 F No 
   s Plekhm1 74829 103226402 103273978 R No 
   s Lrrc37a 166762 103313269 103365911 R No 
   s Gm884 283305 103395891 103482454 R No 
TCL1A 
A2 
OVA 
stim 
5 108176732 s A830010M20Rik 251815 107924917 108009615 F No 
  s 1700028K03Rik 238769 107937963 107980568 F No 
  s Glmn -149886 107977986 108026907 R No 
  s Rpap2 150340 108026392 108090857 F No 
   s A930041C12Rik -113924 108059269 108062869 R No 
   s Gm17717 -59759 108088116 108117034 R No 
   c Gfi1 -21737 108145674 108155056 R No 
   s A430072P03Rik 22555 108154177 108157821 F No 
   s Evi5 127333 108173814 108304126 R Yes 
   s 1700013N18Rik -82540 108259272 108260361 F No 
   s Gm16007 -96677 108273409 108273694 F No 
   s Rpl5 -152789 108329521 108338024 F No 
   s Snord21 -156842 108333574 108333667 F No 
   s SNORA66 -157464 108334196 108334327 F No 
   s SNORA66 -159632 108336364 108336495 F No 
 7 140004122 s Fgfr2 310854 137305965 140315033 R No 
   s Oat -236098 139749158 139768081 R No 
   s Nkx1-2 -212859 139786560 139791320 R No 
   s Gm16764 215052 139789070 139791320 F Yes 
   s Lhpp 201801 139802321 139898103 F No 
   s Gm15582 -152612 139849061 139851567 R No 
   c Fam53b 1390 139903765 140005569 R No 
   s Mettl10 40177 140019140 140044356 R No 
   s Fam175b -46786 140050908 140076794 F No 
   s 1500002F19Rik 118879 140081172 140123058 R No 
   s Zranb1 -118703 140122825 140178074 F No 
   s Gm15718 171056 140171265 140175235 R No 
   s Ctbp2 311858 140179246 140316037 R No 
TCL1A 
A3 
OVA 
stim 
5 3930091 s 4930511M11Rik 244755 116938104 116940269 F No 
  s Ankib1 244302 116938557 116938749 F No 
  s AC022236.1 235709 116947150 116947226 F No 
  s Krit1 -224592 116956262 116958381 R No 
   s 4932412H11Rik 206377 116976482 117020582 F No 
   s Mterf 189055 116993804 116994131 F No 
   c Akap9 186947 116995912 116996359 F No 
   s Cyp51 121884 117060975 117223639 F Yes 
TCL1A 
A4 
OVA 
stim 
7 19888968 s Sympk 279242 19609726 19639967 F No 
  s Rsph6a 248929 19640039 19659796 F No 
  s Dmwd 227370 19661598 19668125 F No 
  s Dmpk 219770 19669198 19679170 F No 
   s Mir3100 216791 19672177 19672241 F No 
   s Six5 209025 19679943 19683898 F No 
   s Gm4969 -185292 19686900 19703717 R No 
   s Fbxo46 183760 19705208 19723610 F No 
   s Qpctl -154464 19725566 19734545 R No 
   s Snrpd2 153897 19735071 19738084 F No 
   s Gipr -137533 19742474 19751476 R No 
   s Eml2 127198 19761770 19791831 F No 
   s Mir330 122154 19766814 19766911 F No 
   s Gpr4 91081 19797887 19809525 F No 
   s Opa3 75285 19813683 19841892 F No 
   s U1 61489 19827479 19827638 F No 
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Table 5-5: List of retroviral integration sites in T-cell tumors induced by TCL1A in stimulated mice 
Tumor: Tumor sample. Chr: Mapped chromosome. Location: Genome location. Type: Closest (c) and 
surrounding (s) genes. Distance: Distance between integration and gene start. Start: Gene start. End: 
Gene end. OR: Relative orientation of integrated vector (F: forward, R: reverse). Hit: Hit in gene.  
 
 
 
 
   s Vasp -31843 19842278 19857166 R No 
   s 1700058P15Rik 45127 19843841 19845088 F No 
   s Ppm1n -23611 19862156 19865398 R No 
   s Rtn2 20957 19868011 19881513 F No 
   c Gm17589 -2890 19883609 19886119 R Yes 
   s Fosb 6385 19888070 19895394 R No 
   s Ercc1 -41159 19930127 19941873 F No 
   s Cd3eap 55823 19942198 19944832 R No 
   s Ppp1r13l -56130 19945098 19963882 F No 
   s Ercc2 -78391 19967359 19981043 F No 
   s Gm17574 89058 19967569 19978067 R No 
   s Mir343 -83024 19971992 19972066 F No 
   s Klc3 100444 19979786 19989453 R No 
   s Ckm -107475 19996443 20006932 F No 
   s Gm17405 -108005 19996973 19997621 F No 
   s A930016O22Rik 117757 20004161 20006766 R No 
 
 
 
  s Mark4 154834 20010816 20043843 R No 
  s U1 157275 20046146 20046284 R No 
  s Exoc3l2 -185437 20074405 20082109 F No 
   s Bloc1s3 204671 20091163 20093680 R No 
   s Trappc6a -205051 20094019 20101494 F No 
   s Nkpd1 -215112 20104080 20110399 F No 
   s Ppp1r37 258738 20116316 20147747 R No 
TCL1A 9 124060503 s Gm4694 223643 123836860 123839608 F No 
A5   s CAAA01010581 -198494 123862202 123862302 R No 
OVA   s Ccr1 -177271 123876959 123883525 R No 
stim   s Ccr1l1 -167555 123891782 123893241 R No 
   s Ccr3 123800 123936703 123946421 F No 
   s Ccr2 43814 124016689 124028296 F No 
   c Ccr5 24221 124036282 124062438 F Yes 
 6 22307449 s A430107O13Rik 371533 21935916 22206404 F No 
   s Wnt16 69222 22238227 22248522 F No 
   c Fam3c -1483 22256520 22306243 R No 
TCL1A 
A6 
OVA 
stim 
11 117182859 s 2810008D09Rik 244755 116938104 116940269 F No 
  s SCARNA16 244302 116938557 116938749 F No 
  s AL627205.1 235709 116947150 116947226 F No 
  s Gm11730 -224592 116956262 116958381 R No 
   s Sec14l1 206377 116976482 117020582 F No 
   s 7SK 189055 116993804 116994131 F No 
   s Gm11745 186947 116995912 116996359 F No 
   s Sept9 121884 117060975 117223639 F Yes 
   c Gm16045 -58222 117118963 117124751 R No 
   s Gm11729 -92844 117275703 117276682 F No 
   s Gm8624 100058 117281951 117283031 R No 
   s Gm11732 -104633 117287492 117300180 F No 
   s Gm11733 -162823 117345682 117350328 F No 
   s Gm11734 -202058 117384917 117393519 F No 
   s AL672228.1 -232278 117415137 117415208 F No 
TCL1A 
A7 
OVA 
stim 
12 5105034 s BC068281 254925 4850109 4863731 F No 
  s Mfsd2b -225000 4869246 4881165 R No 
  s Ubxn2a -191654 4885838 4914511 R No 
  s Atad2b 180824 4924210 5050853 F No 
   c U6 -99991 5006072 5006174 R No 
   s Klhl29 276323 5084278 5382488 R Yes 
 13 37654776 s Ly86 217562 37437214 37510905 F No 
   c Rreb1 -215493 37870269 38043871 F No 
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Tumor Chr Location Type Gene Symbol Distance Start End OR Hit 
myr-
TCL1A 
A1 
w/o 
stim 
7 29166955 s 9530053A07Rik 252470 28914485 28949830 F No 
  s Fbl 212190 28954765 28964288 F No 
  s Dyrk1b 202467 28964488 28972313 F No 
  s Eid2 114055 29052900 29054184 F No 
  s Eid2b 104230 29062725 29065148 F No 
   s BC089491 -90882 29069671 29076205 R No 
   s Dll3 -79830 29076673 29087257 R No 
   s Timm50 -69996 29090535 29097091 R No 
   s Supt5h -43349 29099917 29123738 R No 
   s Rps16 31284 29135671 29137715 F No 
   s SNORA40 30428 29136527 29136651 F No 
   s Plekhg2 -9406 29144623 29157681 R No 
   c Zfp36 -2813 29161803 29164274 R Yes 
   s Med29 10640 29171165 29177727 R No 
   s Paf1 -11015 29177970 29184407 F No 
   s Samd4b 41770 29184568 29208857 R No 
   s Gmfg -55511 29222466 29233252 F No 
   s Lrfn1 -70302 29237257 29252567 F No 
   s Il28a 128387 29293855 29295474 R No 
   s Il28b -140805 29307760 29309366 F No 
   s Sycn -158949 29325904 29327229 F No 
   s Nccrp1 165186 29328615 29332273 R No 
   s Pak4 216117 29343838 29383204 R No 
   s C330005M16Rik 249264 29392653 29416351 R No 
myr- 
TCL1A 
A2 
w/o  
stim 
3 52372036 s Foxo1 299777 52072259 52154031 F No 
  c Gm10293 -44671 52416707 52417938 F Yes 
  s U6 154408 52526571 52526677 R No 
         
         
 6 127103828 s Dyrk4 -232204 126826038 126871857 R No 
  s Rad51ap1 -214456 126873068 126889605 R No 
   s D6Wsu163e 213844 126889984 126925722 F No 
   s Fgf6 138268 126965560 126974736 F No 
   s Fgf23 80908 127022920 127031426 F No 
   s 9630033F20Rik -44493 127035134 127059568 R No 
   s Gm17701 45421 127058407 127060485 F No 
   c Ccnd2 -2995 127075797 127101066 R Yes 
   s 9330179D12Rik 4421 127099407 127162429 F No 
   s Gm4968 -79946 127183774 127184637 F No 
   s Gm7308 128466 127232081 127232527 R No 
myr- 
TCL1A 
A3 
w/o 
stim 
9 123904595 s Ccr9 317038 123587557 123691089 F No 
  s Gm17020 232974 123671621 123671894 F No 
  s Gm17021 -204856 123681303 123700057 R No 
  s Fyco1 -143893 123698628 123761020 R No 
  s Cxcr6 189000 123715595 123720872 F No 
   s Xcr1 -133667 123761436 123771246 R No 
   s Gm4694 67735 123836860 123839608 F No 
   s CAAA01010581 -42611 123862202 123862302 R No 
   s Ccr1 -21388 123876959 123883525 R No 
   c Ccr1l1 -11672 123891782 123893241 R Yes 
   s Ccr3 -32108 123936703 123946421 F No 
   s Ccr2 -112094 124016689 124028296 F No 
   s Ccr5 -131687 124036282 124062438 F No 
 11 4435013 s Gm11958 249550 4185463 4186942 F No 
   s U6 -211076 4224152 4224258 R No 
   s Hormad2 -94226 4245817 4341108 R No 
   s Mtmr3 59532 4380871 4494866 R No 
   c Gm11960 -28642 4463655 4464559 F Yes 
   s Gm11032 -85057 4520070 4521701 F No 
   s Gm11961 94680 4520278 4530014 R No 
   s Ascc2 -102737 4537750 4585702 F No 
   s Uqcr10 169011 4601976 4604345 R No 
   s Zmat5 -169668 4604681 4637672 F No 
   s Cabp7 211447 4636895 4646781 R No 
   s Nf2 314205 4665848 4749539 R No 
myr- 
TCL1A 
A4 
w/o 
7 29166691 s 9530053A07Rik 252206 28914485 28949830 F No  
  s Fbl 211926 28954765 28964288 F No  
  s Dyrk1b 202203 28964488 28972313 F No  
  s Eid2 113791 29052900 29054184 F No  
stim   s Eid2b 103966 29062725 29065148 F No  
   s BC089491 -91114 29069671 29076205 R No  
   s Dll3 -80062 29076673 29087257 R No  
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   s Timm50 -70228 29090535 29097091 R No  
   s Supt5h -43581 29099917 29123738 R No  
   s Rps16 31020 29135671 29137715 F No  
   s SNORA40 30164 29136527 29136651 F No  
   s Plekhg2 -9638 29144623 29157681 R No  
   c Zfp36 -3045 29161803 29164274 R Yes 
   s Med29 10408 29171165 29177727 R No  
   s Paf1 -11279 29177970 29184407 F No  
   s Samd4b 41538 29184568 29208857 R No  
   s Gmfg -55775 29222466 29233252 R No  
   s Lrfn1 -70566 29237257 29252567 F No  
   s Il28a 128155 29293855 29295474 R No  
   s Il28b -141069 29307760 29309366 F No  
   s Sycn -159213 29325904 29327229 F No  
   s Nccrp1 164954 29328615 29332273 R No  
   s Pak4 215885 29343838 29383204 R No  
   s C330005M16Rik 249032 29392653 29416351 R No  
 14 123335721 s Pcca 402175 122933546 123290322 F No 
   s A2ld1 -22810 123215445 123312979 R No 
   s 4930594M22Rik 23469 123312252 123336691 F No 
   s Tmtc4 47468 123318193 123383257 R No 
   c Gm15735 -15620 123351341 123355565 F Yes 
myr-
TCL1A 
A5 
16 24296578 s 1110054M08Rik 96952 24391698 24393674 R No 
  c Lpp -96858 24393436 24992662 F No 
  s U7 109781 24406441 24406503 R No 
w/o          
stim          
 3 94938647 s Psmb4 -247884 94688015 94690883 R No 
   s U6 -214422 94724244 94724345 R No 
   s Selenbp1 201669 94736978 94748680 F No 
   s Rfx5 180650 94757997 94765483 F No 
   s B230398E01Rik -172797 94762956 94765970 R No 
   s Pi4kb 159994 94778653 94810765 F No 
   s A730011C13Rik -137495 94798332 94801272 R No 
   s Gm15265 -129976 94802722 94808791 R No 
   s Zfp687 -119397 94810512 94819370 R No 
   s 4930481B07Rik 119100 94819547 94824060 F No 
   s Psmd4 -92231 94836616 94846536 R No 
   s Pip5k1a -27915 94862452 94910852 R No 
   s SNORD62 -44136 94894547 94894631 R No 
   s U6 35225 94903422 94903528 F No 
   s Vps72 23703 94914944 94926973 F No 
   s Tmod4 10249 94928398 94933131 F No 
   s Scnm1 -833 94933641 94937934 R No 
   c Lysmd1 637 94938010 94943440 F Yes 
   s Tnfaip8l2 7515 94943443 94946282 R No 
   s Sema6c -25732 94964379 94977946 F No 
   s Gabpb2 83097 94985688 95021864 R No 
   s Gm16740 -82732 95021379 95030580 F No 
   s Mllt11 93832 95023057 95032599 R No 
   s Cdc42se1 -94007 95032654 95040331 F No 
   s Gm128 106753 95040842 95045520 R No 
   s Bnipl 116348 95045193 95055115 R No 
   s Prune 147231 95057596 95085998 R No 
   s Fam63a -146620 95085267 95100088 F No 
   s Fam63a -147120 95085767 95088779 F No 
   s Anxa9 172331 95100018 95111098 R No 
   s Gm10691 180272 95111594 95119039 R No 
   s RP24-372P19.1.1 180282 95115298 95119049 R No 
   s Lass2 -180067 95118714 95127510 F No 
   s Setdb1 222357 95127447 95161124 R No 
myr- 11 51686281 s Nhp2 253044 51433237 51437216 F No 
TCL1A   s Rmnd5b -237043 51437173 51449398 R No 
A6   s N4bp3 -222097 51456565 51464344 R No 
w/o   s D930048N14Rik 221825 51464456 51471183 F No 
stim   s 0610009B22Rik -184065 51498888 51502376 R No 
   s Sec24a -109305 51505765 51577136 R No 
   s SNORA48 -135017 51551281 51551424 R No 
   s Sar1b 109092 51577189 51605427 F No 
   c Phf15 -15286 51626957 51671155 R Yes 
   s Gm16953 396575 51763384 52083016 R No 
   s AL669920.1 -91603 51777884 51777991 F No 
   s Cdkn2aipnl -94882 51781163 51790836 F No 
   s Ube2b 127823 51798999 51814264 R No 
   s Gm12204 -128074 51814355 51815413 F No 
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Table 5-6: List of retroviral integration sites in T-cell tumors induced by myr-TCL1A in 
unstimulated mice 
Tumor: Tumor sample. Chr: Mapped chromosome. Location: Genome location. Type: Closest (c) and 
surrounding (s) genes. Distance: Distance between integration and gene start. Start: Gene start. End: 
Gene end. OR: Relative orientation of integrated vector (F: forward, R: reverse). Hit: Hit in gene.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   s Cdkl3 -131442 51817723 51903286 F No 
   s Gm12205 166532 51852352 51852973 R No 
   s Ppp2ca -225902 51912183 51941280 F No 
   s AL935177.1 226214 51912560 51912655 R No 
 7 143105549 s Ptpre 376042 142729507 142877977 F No 
   c Mki67 -198034 142881471 142908062 R Yes 
myr- 7 113380878 s RP23-466I14.1.1 330796 113050082 113236851 F No 
TCL1A   s Gm8979 -159541 113219246 113221378 R No 
A7   c Gvin1 -22065 113300049 113358854 R Yes 
w/o   s Gm8989 87123 113465910 113468042 R No 
stim   s Gm4759 203668 113565064 113584587 R No 
   s SNORA17 -189348 113570226 113570361 F No 
myr- 10 4620468 s Rgs17 196327 4424141 4520878 F No 
TCL1A   s Mtrf1l 97837 4522631 4534654 F No 
A8   s Fbxo5 79527 4540941 4547381 F No 
w/o   c AC162387.1 -38694 4659162 4659257 F Yes 
stim 
  
s 
s 
Vip 
Myct1 
86673 
132163 
4698927 
4739754 
4707323 
4752813 
R 
R 
No 
No 
   s Syne1 -175381 4795849 5326338 F No 
myr- 5 43607358 c Cpeb2 -17344 43624702 43680963 F Yes 
TCL1A   s Gm7854 19052 43626241 43626591 R No 
A9   s U7 -245066 43852424 43852479 F No 
w/o          
stim          
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Tumor Chr Location Type Gene Symbol Distance Start End OR Hit 
myr-
TCL1A 
A1 
OVA 
stim 
17 28393489 s Anks1 347204 28046285 28199545 F No 
  s Gm15598 -248388 28124973 28145377 R No 
  s Tcp11 -176181 28203692 28217584 R No 
  s 4930526A20Rik -180143 28211995 28213622 R No 
  s Scube3 114228 28279261 28311797 F No 
   s Zfp523 79337 28314152 28342831 F No 
   s Def6 48766 28344723 28365553 F No 
   c Ppard 23790 28369699 28438414 F Yes 
   s Fance -56986 28450475 28463513 F No 
   s Rpl10a -71927 28465416 28467977 F No 
   s Tead3 93985 28468616 28487750 R No 
   s Tulp1 108362 28488460 28502127 R No 
   s Fkbp5 260704 28536040 28654469 R No 
   s 7SK -190317 28583806 28584093 F No 
 5 111606075 s Ttc28 297253 111308822 111718800 F No 
   s Mir701 172912 111433163 111433271 F No 
   s Gm15988 -168836 111437499 111437865 R No 
   c Pitpnb -153708 111759783 111817379 F Yes 
   s Mn1 -240307 111846382 111886053 F No 
myr- 
TCL1A 
A2 
OVA 
stim 
7 71302183 s Klf13 -218460 71031237 71083801 R No 
  s U3 -195277 71106787 71106984 R No 
  s RP24-292K9.1.1 99695 71202488 71207844 F No 
  c Trpm1 3462 71298721 71414661 F Yes 
  s AC139849.1 -42059 71344242 71368861 F No 
   s Mir211 -48509 71350692 71350797 F No 
   s Mtmr10 -130356 71432539 71485293 F No 
   s Gm20457 188589 71482436 71490850 R No 
   s Fan1 216720 71491644 71518981 R No 
   s Mphosph10 234893 71521427 71537154 R No 
   s Mcee -235348 71537531 71557007 F No 
myr- 
TCL1A 
A3 
OVA 
stim 
9 45105648 s Mpzl2 255140 44850508 44862098 F No 
  s Mpzl3 242379 44863269 44885519 F No 
  s Amica1 218382 44887266 44916613 F No 
  s Gm10684 -162055 44915259 44943689 R No 
  s Scn2b 179689 44925959 44938153 F No 
   s Scn4b 159128 44946520 44962235 F No 
   c Tmprss4 -93569 44980809 45012175 R No 
   s Gm17099 124568 44981080 44983244 F No 
   s BC049352 115558 44990090 45058103 F No 
   s Il10ra -28512 45061920 45077232 R No 
   s RP24-166B2.4.1 36510 45069138 45069373 F No 
   s 1700003G13Rik 24418 45126348 45130162 R No 
   s Tmprss13 -21535 45127183 45155664 F No 
   s Fxyd6 -72620 45178268 45204241 F No 
   s Fxyd2 -102309 45207957 45218361 F No 
   s 4833428L15Rik 133571 45224709 45239315 R No 
   s Dscaml1 -129640 45235288 45561343 F No 
myr- 
TCL1A 
A4 
OVA 
7 17265909 s Zc3h4 279679 16986230 17023043 F No 
  s Tmem160 227781 17038128 17040838 F No 
  s Npas1 -203988 17041070 17062129 R No 
  s n-R5s151 208747 17057162 17057280 F No 
stim   s Grlf1 -65775 17079822 17200342 R No 
   s U6 -56091 17209924 17210026 R No 
   c Ceacam15 -5063 17256680 17261054 R Yes 
   s AC150681.1 29919 17295966 17296036 R No 
   s Ceacam9 -41369 17307278 17311459 F No 
   s Ap2s1 -57850 17323759 17334643 F No 
   s Slc1a5 -100786 17366695 17383623 F No 
   s Fkrp 134361 17394619 17400478 R No 
   s Strn4 -135329 17401238 17426280 F No 
   s Prkd2 -162374 17428283 17455810 F No 
   s 9330104G04Rik 194118 17456703 17460235 R No 
   s Dact3 -194757 17460666 17472650 F No 
   s Gng8 -211226 17477135 17480784 F No 
   s Ptgir -225930 17491839 17496254 F No 
   s Calm3 243346 17500728 17509463 R No 
 11 51686281 s Nhp2 253044 51433237 51437216 F No 
   s Rmnd5b -237043 51437173 51449398 R No 
   s N4bp3 -222097 51456565 51464344 R No 
   s D930048N14Rik 221825 51464456 51471183 F No 
   s 0610009B22Rik -184065 51498888 51502376 R No 
   s Sec24a -109305 51505765 51577136 R No 
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Table 5-7: List of retroviral integration sites in T-cell tumors induced by myr-TCL1A in stimulated 
mice 
Tumor: Tumor sample. Chr: Mapped chromosome. Location: Genome location. Type: Closest (c) and 
surrounding (s) genes. Distance: Distance between integration and gene start. Start: Gene start. End: 
Gene end. OR: Relative orientation of integrated vector (F: forward, R: reverse). Hit: Hit in gene.  
 
 
 
 
 
 
 
 
 
 
 
 
 
   s SNORA48 -135017 51551281 51551424 R No 
   s Sar1b 109092 51577189 51605427 F No 
   c Phf15 -15286 51626957 51671155 R Yes 
   s Gm16953 396575 51763384 52083016 R No 
   s AL669920.1 -91603 51777884 51777991 F No 
   s Cdkn2aipnl -94882 51781163 51790836 F No 
   s Ube2b 127823 51798999 51814264 R No 
   s Gm12204 -128074 51814355 51815413 F No 
   s Cdkl3 -131442 51817723 51903286 F No 
   s Gm12205 166532 51852352 51852973 R No 
   s Ppp2ca -225902 51912183 51941280 F No 
   s AL935177.1 226214 51912560 51912655 R No 
myr-
TCL1A 
A5  
OVA 
15 96539134 s Scaf11 -247925 96242129 96291274 R No 
  s Slc38a1 -65855 96401849 96473344 R No 
  s U6 36910 96502224 96502331 F No 
  c Slc38a2 -9070 96517825 96530129 R Yes 
stim          
 X 103210461 s Fgf16 250843 102959618 102970278 F No 
   s Atrx -85836 102992954 103124736 R No 
   s U2 195239 103015222 103015404 F No 
   s Gm14853 -170220 103039804 103040352 R No 
   s U6 141298 103069163 103069274 F No 
   s Magt1 -3327 103163423 103207245 R No 
   c Cox7b -578 103211039 103217789 F Yes 
   s Atp7a -12154 103222615 103320265 F No 
   s Tlr13 -128082 103338543 103355832 F No 
   s Gm14856 -161192 103371653 103372265 F No 
   s Pgk1 -171978 103382439 103399038 F No 
   s Taf9b 205925 103402222 103416497 R No 
   s Fnd3c2 240143 103430585 103450715 R No 
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Tumor Chr Location Type Gene Symbol Distance Start End OR Hit 
nls-
TCL1A 
A1 
w/o 
stim 
3 105733705 s Ddx20 -243414 105481178 105490492 R No 
  s 6530418L21Rik 226188 105507517 105523760 F No 
  s Rap1a -129658 105530185 105604248 R No 
  s Adora3 59929 105673776 105711846 F No 
  s Adora3 59880 105673825 105726954 F No 
   c I830077J02Rik 1676 105728809 105735582 R Yes 
   s Atp5f1 29111 105745616 105763017 R No 
   s Wdr77 -28582 105762287 105787518 F No 
   s Ovgp1 -42924 105776629 105790341 F No 
   s 1700027A23Rik 83617 105799875 105817523 R No 
   s Chi3l7 101907 105819837 105835813 R No 
   s Gm4540 -103923 105837628 105837921 F No 
   s Chia -182442 105916147 105935038 F No 
   s Chi3l3 288519 105950472 106022425 R No 
 1 87501588 s Gm2666 -120162 87380827 87381717 R No 
   s Gm16092 -78143 87407708 87423736 R No 
   s Gm7592 78413 87423175 87465775 F No 
   s Sp110 -6487 87473474 87495392 R No 
   s Gm16094 5727 87495861 87496414 F No 
   c Sp140 4635 87496953 87541612 F Yes 
   s Gm10552 6592 87500660 87508471 R Yes 
   s Gm17017 45281 87537797 87547160 R No 
   s Sp100 -44975 87546563 87606573 F No 
   s n-R5s215 -69869 87571457 87571560 F No 
   s A630001G21Rik 173339 87613658 87675218 R No 
   s AC161342.1 -158781 87660369 87660446 F No 
   s AC161342.2 -179700 87681288 87681535 F No 
   s Cab39 -188428 87690016 87748151 F No 
nls- 
TCL1A 
A2 
w/o  
stim 
11 86287134 s 4632419I22Rik 272262 86014872 86117945 F No 
  s Ints2 -216233 86024183 86071077 R No 
  s Med13 -116206 86080535 86171104 R No 
  s U3 156366 86130768 86130989 F No 
  s Y_RNA 140426 86146708 86146810 F No 
   s 5S_rRNA 64806 86222328 86222447 F No 
  s U6 -36393 86250812 86250917 R No 
   c Rnft1 -11025 86298159 86312527 F No 
   s Rps6kb1 70997 86312373 86358307 R No 
   s Tubd1 -71359 86358493 86380862 F No 
   s Vmp1 210028 86397367 86497338 R No 
   s Mir21 110350 86397569 86397660 R No 
   s Gm11478 157218 86443930 86444528 R No 
   s Ptrh2 -210353 86497487 86505959 F No 
   s Cltc 283757 86507853 86571067 R No 
 16 14082962 s Ntan1 263618 13819344 13835544 F No 
   s Pdxdc1 -179783 13833241 13903224 R No 
   s Mpv17l 179708 13903254 13949712 F No 
   s Gm15950 -161515 13919520 13921492 R No 
   s 5S_rRNA -113457 13969441 13969550 R No 
   s Ifitm7 -96059 13981795 13986948 R No 
   s 2900011O08Rik 96265 13986697 14101593 F Yes 
   s Gm15806 -71198 14010855 14011809 R No 
   s Gm15807 -44053 14037829 14038954 R No 
   c Gm15808 15466 14067496 14068099 F No 
   s 4921513D23Rik 76360 14110626 14159367 R No 
   s Mir484 -76757 14159719 14159785 F No 
   s Nde1 -80406 14163368 14193021 F No 
   s Myh11 208494 14194620 14291501 R No 
   s 0610037P05Rik 234461 14299337 14317468 R No 
   s Gm15868 -228972 14311934 14314107 F No 
   s Gm15869 234371 14316167 14317378 R No 
nls- 
TCL1A 
A3 
w/o 
stim 
10 120926106 s Tbc1d30 -178193 120700880 120748245 R No 
  s Gm4478 145778 120780328 120780714 F No 
  s Gns 123960 120802146 120834301 F No 
  c Rassf3 -13132 120847406 120913306 R No 
  s Tbk1 97412 120983511 121023850 R No 
   s Xpot 136934 121024436 121063372 R No 
   s AC124992.1 129161 121055524 121055599 R No 
   s D930020B18Rik -152538 121078644 121130940 F No 
nls- 
TCL1A 
A4 
w/o 
14 26299776 s Gm17716 -101942 26175287 26198121 R No 
  c D930049A15Rik -19449 26275223 26280614 R No  
  s Zmiz1 21105 26278671 26486229 F Yes  
  s Mir3075 -54149 26353925 26354009 F No  
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Table 5-8: List of retroviral integration sites in T-cell tumors induced by nls-TCL1A in 
unstimulated mice 
Tumor: Tumor sample. Chr: Mapped chromosome. Location: Genome location. Type: Closest (c) and 
surrounding (s) genes. Distance: Distance between integration and gene start. Start: Gene start. End: 
Gene end. OR: Relative orientation of integrated vector (F: forward, R: reverse). Hit: Hit in gene.  
 
 
 
 
 
 
   s Gm10397 -184743 26484519 26486217 F No  
   s Ppif -213864 26513640 26519954 F No  
   s 1700054O19Rik 226498 26525992 26526561 R No  
   s Zcchc24 288279 26531126 26588342 R No  
nls-
TCL1A 
A5 
10 79494181 s Fstl3 254164 79240017 79245375 F No 
  s Prss57 -240822 79244219 79253706 R No 
  s Palm 237864 79256317 79283641 F No 
w/o   s 9130017N09Rik 210415 79283766 79293197 F No 
stim   s E130317F20Rik -176827 79314126 79317701 R No 
   s Ptbp1 177009 79317172 79327516 F No 
   s BC005764 -157149 79323220 79337379 R No 
   s Gm17134 -167349 79326682 79327179 R No 
   s Prtn3 156960 79337221 79345919 F No 
   s Elane 145124 79349057 79350961 F No 
   s Cfd 140583 79353598 79355401 F No 
   s Med16 -122845 79357452 79371683 R No 
   s U6 122241 79371940 79372046 F No 
   s C030046I01Rik -114777 79372798 79379751 R No 
   s Kiss1r 114465 79379716 79385018 F No 
   s Arid3a 104393 79389788 79417763 F No 
   s Wdr18 71284 79422897 79431991 F No 
   s Grin3b 60721 79433460 79439935 F No 
   s ORF61 -47453 79437693 79447075 R No 
   s U6 45930 79448251 79448357 F No 
   s Cnn2 42852 79451329 79458807 F No 
   s Abca7 34942 79459239 79478317 F No 
   s Hmha1 14783 79479398 79494217 F Yes 
   c Polr2e 8012 79498694 79502540 R No 
   s Gpx4 -15730 79509911 79519184 F No 
   s Sbno2 70915 79520161 79565443 R No 
   s Stk11 -84367 79578548 79593427 F No 
   s Dos 109052 79593196 79603580 R No 
   s Atp5d -107196 79601377 79608563 F No 
   s Midn -116836 79611017 79621113 F No 
   s Cirbp -134549 79628730 79635531 F No 
   s 1600002K03Rik -141508 79635689 79637891 F No 
   s Efna2 -148046 79642227 79652755 F No 
   s Mum1 -194998 79689179 79706648 F No 
   s Ndufs7 -217685 79711866 79719539 F No 
   s Gamt 229229 79720896 79723757 R No 
   s Dazap1 -230050 79724231 79751153 F No 
nls- 15 97107287 s Slc38a4 -221110 96825254 96886387 R No 
TCL1A   s Amigo2 -29779 97074505 97077718 R No 
A6   c Fam113b 29749 97077538 97216120 F Yes 
w/o          
stim          
 10 53759381 c Man1a 35771 53624594 53795602 R Yes 
   s Gm16998 -36347 53795728 53800887 F No 
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Tumor Chr Location Type Gene Symbol Distance Start End OR Hit 
nls-
TCL1A 
A1 
OVA 
stim 
5 123096660 s Arpc3 254773 122841887 122856188 F No 
  s Anapc7 224958 122871702 122894921 F No 
  s Gm15846 -208089 122888605 122888924 R No 
  s Atp2a2 -144830 122903531 122952183 R No 
  s U6 139862 122956798 122956898 F No 
   s Ift81 -32486 123000213 123064527 R No 
   c P2rx7 2740 123093920 123141441 F Yes 
   s Gm10064 50599 123147205 123147612 R No 
   s P2rx4 -60933 123157593 123179747 F No 
   s Camkk2 132378 123183213 123229391 R No 
   s Anapc5 174335 123237478 123271348 R No 
   s Rnf34 -203537 123300197 123318954 F No 
   s Kdm2b 368076 123320677 123465089 R No 
 1 182947910 s H3f3a -204488 182730963 182744074 R No 
   s Gm17275 215211 182732699 182739614 F No 
   s Gm16067 204003 182743907 182746990 F No 
   s U6 185010 182762900 182763007 F No 
   s BC031781 166628 182781282 182798228 F No 
   s Lefty2 124671 182823239 182829234 F No 
   s Pycr2 113505 182834405 182838218 F No 
   s Lefty1 82757 182865153 182868531 F No 
   s Tmem63a 75435 182872475 182905243 F No 
   s 2210411M09Rik -60282 182882195 182888280 R No 
   c Ephx1 2473 182906286 182951035 R Yes 
   s 9130409I23Rik -33458 182981368 182990798 F No 
   s Nvl 125726 183023554 183074288 R No 
   s Cnih4 -133152 183081062 183099125 F No 
   s Wdr26 193547 183103359 183142109 R No 
   s A430110L20Rik -208297 183156207 183158621 F No 
   s Rpl35a-ps2 223936 183172076 183172498 R No 
nls- 
TCL1A 
A2 
OVA 
stim 
3 89193350 s Pklr 253286 88940064 88950706 F No 
  s Hcn3 -229638 88949996 88964118 R No 
  s Clk2 224633 88968717 88980843 F No 
  s Scamp3 211955 88981395 88986687 F Yes 
  s Gm16069 -207541 88984677 88986215 R No 
   s Fam189b 206285 88987065 88993217 F No 
   s U6 -188561 89005089 89005195 R No 
   s Gba 186500 89006850 89012603 F No 
   s Mtx1 -162746 89013003 89031010 R No 
   s Thbs3 174248 89019102 89030759 F No 
   s Mir92b -162636 89031038 89031120 R No 
 
 
  s Muc1 160371 89032979 89037303 F No 
  s Trim46 -143525 89038099 89050231 R No 
  s Krtcap2 143462 89049888 89053644 F No 
  s Dpm3 130070 89063280 89071001 F No 
  s Slc50a1 -119264 89072168 89074492 R No 
   s Efna1 -108692 89075655 89085064 R No 
   s AC132327.1 86946 89106404 89106651 F No 
   s Efna3 -66869 89117821 89126887 R No 
   s Gm15998 73989 89119361 89122829 F No 
   s Efna4 -51806 89137312 89141950 R No 
   s 4731419I09Rik 51578 89141772 89151753 F No 
   s Adam15 -39824 89142464 89153932 R No 
   s Dcst1 -24581 89154141 89169175 R No 
   s Gm10702 35799 89157551 89158820 F No 
   s Zbtb7b 4942 89181566 89198698 R No 
   c Gm15417 -2422 89195772 89202701 F No 
   s Lenep 12959 89204910 89206715 R No 
 
  s Flad1 22036 89204926 89215792 R No 
  s Cks1b 28549 89219394 89222305 R No 
  s Shc1 -29015 89222365 89233937 F No 
  s Pygo2 -40786 89234136 89239050 F No 
   s Pbxip1 -47278 89240628 89254874 F No 
   s Pmvk -69690 89263040 89272935 F No 
   s Kcnn3 -130736 89324086 89471683 F Yes 
nls- 11 60399450 s Tom1l2 -233104 60040216 60166407 R No 
TCL1A   s Gm12266 242703 60156747 60157708 F No 
A3   s Lrrc48 232623 60166827 60207843 F No 
OVA   s Atpaf2 -167552 60214128 60231959 R No 
stim   s 4933439F18Rik 168803 60230647 60264429 F No 
   s Gm12268 139205 60260245 60260686 F No 
   s Gm12267 -136039 60262712 60263472 R No 
   s Drg2 131357 60268093 60282256 F No 
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Table 5-9: List of retroviral integration sites induced by nls-TCL1A in stimulated mice 
Tumor: Tumor sample. Chr: Mapped chromosome. Location: Genome location. Type: Closest (c) and 
surrounding (s) genes. Distance: Distance between integration and gene start. Start: Gene start. End: 
Gene end. OR: Relative orientation of integrated vector (F: forward, R: reverse). Hit: Hit in gene.  
 
 
 
 
 
 
 
 
 
 
 
 
   s Myo15 116609 60282841 60341871 F No 
   s Alkbh5 49567 60349883 60372014 F No 
   s Gm12622 -24704 60374426 60374807 R No 
   s Gm12628 -13799 60385125 60385712 R No 
   s Gm17423 12421 60387029 60446615 F No 
   s Gm12623 -10460 60387069 60389051 R No 
   c Gm12621 6093 60405223 60405604 R Yes 
   s Gm12627 15299 60414429 60414810 R No 
   s Gm12613 24508 60423638 60424019 R No 
   s Gm12614 33718 60432848 60433229 R No 
   s Gm12615 42954 60442084 60442465 R No 
   s Gm12626 47020 60444549 60446531 R No 
   s Gm12625 56233 60455363 60455744 R No 
   s Gm12619 71848 60464572 60471359 R No 
   s Gm12624 81056 60480186 60480567 R No 
   s Gm12612 85116 60482425 60484627 R No 
   s Gm12616 94079 60493209 60493590 R No 
   s Gm12620 98155 60495681 60497666 R No 
   s Gm12617 107066 60506197 60506577 R No 
   s Llgl1 -113775 60513225 60527688 F No 
   s Flii 141254 60527625 60540765 R No 
   s Smcr7 -142450 60541900 60546453 F No 
   s Mir5100 -142715 60542165 60542228 F No 
   s U6 -149913 60549363 60549459 F No 
   s Top3a 191356 60553560 60590867 R No 
   s Smcr8 -191577 60591027 60601789 F No 
   s Shmt1 225709 60601606 60625220 R No 
   s SNORA25 -218630 60618080 60618205 F No 
   s Gm12611 -230465 60629915 60631249 F No 
   s Gm12618 233269 60632298 60632780 R No 
   s Dhrs7b -244683 60644133 60673697 F No 
 2 98507281 s Gm13806 66094 98441187 98441511 F No 
   s Gm10801 4887 98502394 98504240 F No 
   c Gm10800 15 98506704 98507458 R Yes 
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